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ABSTRACT 
 
YUAN LU: Design of Nitric Oxide-Releasing Macromolecular Scaffolds for 
Antimicrobial Applications 
(Under the direction of Professor Mark H. Schoenfisch) 
 
Nitric oxide (NO)-releasing materials have attracted much attention for antimicrobial 
applications due to the physiological roles of NO in immune defense. Prior study showed 
enhanced bactericidal efficacy of NO-releasing silica particles compared to small 
molecule NO donors, attributable to the efficient NO delivery into the interior of the 
bacteria. Unfortunately, these silica particles elicited significant toxicity towards 
mammalian cells at the concentrations for biofilm eradication. To address this limitation, 
my research has focused on the design of NO-releasing macromolecular scaffolds with 
enhanced bactericidal efficacy and reduced toxicity against mammalian cells. Herein, the 
synthesis of NO-releasing silica particles, dendrimers, and chitosan oligosaccharides with 
tunable NO-release kinetics, chemical structures (exterior hyrophobicity, ionic 
characteristics) and physical properties (size, morphology, molecular weight) were 
presented. The bactericidal efficacy of these NO-releasing scaffolds was evaluated 
against both planktonic bacteria and biofilms. Nitric oxide-releasing dendrimers with 
intermediate hydrophobicity and NO-releasing chitosan oligosaccharides exhibited 
enhanced antibacterial activities and proved effective at eradicating biofilms at the 
concentrations eliciting no toxicity against mammalian cells.  
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Chapter 1 
       Macromolecular Nitric Oxide Delivery Systems 
 
1.1 Introduction 
Nitric oxide (NO) is a diatomic free radical produced endogenously by various nitric 
oxide synthase (NOS) enzymes that catalyze the conversion of L-arginine to L-citrulline 
and NO.1-2  Several bioregulatory processes are mediated by NO including vasodilation, 
angiogenesis, neurotransmission, macrophage destruction of foreign pathogens, 
gastrointestinal motility, muscle contractility, etc.3-12 Due to NO’s integral role in human 
physiology, deficiencies in NO biosynthesis or the overproduction of NO have been 
linked to a number of diseases including Parkinson’s disease and cancer.13-15 As such, the 
development of NO-based therapies have become a major target in drug discovery.  
Small molecule NO donors have been widely implemented to unravel some of the 
mysteries of NO in physiology, and proposed as potential therapeutics for diseases 
requiring NO therapy.16-25 Numerous reports have demonstrated the therapeutic role of 
NO in anti-cancer, antimicrobial, cardioprotective and anti-thrombotic applications.16-25 
Despite the promising therapeutic potential of small molecule NO donors, low NO 
payloads and the lack of targeted NO release to a specific site have hindered the clinical 
development of NO-releasing therapeutics. In response, macromolecular NO-releasing 
scaffolds have been designed to target NO delivery and enhance therapeutic utility (e.g., 
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antimicrobial efficacy).26-27 In this introduction chapter, I will set the stage for my thesis 
research by reviewing recent developments in the design and applications of NO-
releasing macromolecular scaffolds. In particular I will focus on the bactericidal efficacy 
of macromolecular NO-releasing scaffolds as a function of NO-release kinetics, chemical 
structures and scaffold sizes. 
1.2 N-Diazeniumdiolate Functionalized Macromolecules 
1.2.1 N-Diazeniumdiolate Formation and Nitric Oxide Release Characteristics 
Perhaps the most widely studied NO donor class, are N-diazeniumdiolates formed via 
the reaction of amines with high pressures of NO (5 atm).28 As shown in Scheme 1.1, a 
nucleophilic amine substrate attacks the electrophilic nitrogen atom of NO. In the 
subsequent step, the resulting radical species reacts rapidly with an additional molecule 
of NO forming a zwitterionic intermediate. Upon addition of a strong base (e.g., sodium 
methoxide), the intermediate is deprotonated and results in the formation of a stable N-
diazeniumdiolate. Efficient formation of N-diazeniumdiolate NO donors requires both 
appropriate precursor structures (e.g., secondary amines) and the presence of a base (e.g., 
sodium methoxide). Although primary and secondary amine adducts both can be used to 
form N-diazeniumdiolates formation, secondary amine adducts are typically 
characterized by a greater diazeniumdiolate conversion efficiency due to the increased 
basicity.29-30 Moreover, the nitrosamine byproduct formed on primary amine-modified 
scaffolds upon NO liberation may be problematic for biomedical applications due to its 
carcinogenic nature.31 
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N-diazeniumdiolate structures are particularly attractive for biomedical applications 
because they decompose spontaneously in physiological milieu to yield two moles of NO 
per mole of amine precursor.30 For small molecule alkyl secondary amine species, the 
proton-initiated decomposition of the diazeniumdiolate follows first-order decay kinetics 
with rates governed by the pH of the solution.30 More rapid N-diazeniumdiolate 
decomposition is often observed at low pH. Another factor that influences NO-release 
kinetics is the chemical structure of the amine precursor.30 For example, hydrophobic 
polyamines often have extended NO release due to slower hydration. N-
diazeniumdiolates may also be stabilized by free primary amines whereby a cyclic ring is 
formed, resulting in slower decomposition of the NO donor due to the enhanced 
stability.32 Compared to small molecule N-diazeniumdiolate NO donors, macromolecular 
scaffolds generally exhibit more controllable NO-release kinetics as both the 
hydrophobicity and local pH within the scaffold may be tuned. As such, a number of 
macromolecular scaffolds have been developed to store and release NO.27, 29, 33-36 
1.2.2 N-Diazeniumdiolate-Modified Polymers 
Although the majority of NO-releasing materials reported in the literature have been 
utilized as coatings for medical devices, my thesis is uniquely focused on the study of 
water soluble polymers and nanomaterials as NO-delivery vehicles. Such scaffolds may 
prove useful for a number of administration routes including topical, pulmonary, oral, 
ocular, and injection delivery.26, 35, 37-38 Zhou et al. reported the first water soluble 
macromolecular NO-releasing scaffolds. Water soluble N-diazeniumdiolate-
functionalized poly(ethylenimine) (PEI) was synthesized.37 The PEI scaffolds exhibited a 
large NO storage capacity (i.e., ~3.84 µmol/mg) and slow NO-release kinetics  
4 
 
 
 
 
 
 
 
Scheme 1.1 Formation of N-diazeniumdiolate in the presence of NaOMe. 
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(i.e., half-life ~192 min) due to the inherently large precursor content and basic local pH, 
respectively. 
To achieve more rapid NO release, carboxylated PEI and Proline-incorporated PEI 
were synthesized.37 As expected, the carboxylic groups on the PEI scaffolds accelerated 
the decomposition of N-diazeniumdiolates (half life ~59 min) by lowering the local pH 
near the N-diazeniumdiolate species. The proline-incorporated PEI also exhibited faster 
NO release (~24 min) due to the rapid decomposition kinetics of PROLI/NO.37  Despite 
the large NO storage and tunable NO release, the PEI scaffold was inherently toxic 
raising safety concerns for biomedical application of these materials. To synthesize 
scaffolds with reduced toxicity, West et al. reported the synthesis of amino-acid lysine-
poly(ethylene glycol) (PEG) dendrimers for NO storage by conjugating NO on the lysine 
residues.35 Briefly, dendrimers are synthetic, highly branched macromolecules of 
nanometer dimensions, for which bonds radiate out from a central core in a regular 
branching pattern.39 With respect to their application as NO-releasing scaffolds, the 
multivalency of the dendrimers allows for facile modification with NO to allow large NO 
payloads. However, the PEG-lysine dendrimers were characterized by low NO storage 
due to the low diazeniumdiolate conversion efficiency characteristic of primary amines 
on lysine residues. In addition, the lack of control over the NO-release kinetics limited 
the application of the lysine-PEG dendrimers. To increase the total NO storage, the 
Schoenfisch lab has synthesized secondary amine-functionalized polypropylenimine (PPI) 
dendrimers with significantly enhanced NO storage capacity (up to 5.6 µmol NO/mg).29 
Varied NO-release kinetics was furthered by tuning the exterior hydrophobicity of the 
dendrimer. Compared to dendrimers with short hydrocarbon chains (C1) on their exterior 
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(i.e., half-life ~28 min), the long hydrocarbon chains (C7)-modified dendrimers exhibited 
extended NO release (i.e., half life of 86 min) as a result of the delayed water 
uptake/hydration.  The multivalent exterior of dendritic NO-releasing scaffolds also 
enables the combination of NO donors with other functionalities, including those 
necessary for imaging and targeting.29 To fully explore the effects of size and exterior 
modifications on NO release properties and antibacterial activity, more structural diverse 
NO-releasing dendrimers must first be synthesized. 
1.2.3 N-Diazeniundiolate-Functionalized Micro- and Nanoparticles 
 Micro- and nanoparticles have been widely employed for drug delivery due to their 
potential to elicit controlled release of an active compound at a desired site.40 Many 
methods exist for preparing such materials. For an example related to NO, Pulfer et al. 
synthesized epoxide-crosslinked polyethyleneimine microspheres using a water-in-oil 
emulsion method.41 Conversion of interior amines to NO-releasing diazeniumdiolates 
resulted in particles with long NO-release half-lives due to the basicity of the local NO 
donor environment (t1/2 = 66 h). These particles were doped into the pores of Gore-tex 
vascular grafts with a yield of 10 nmol NO/mg graft materials.41 Analogous to water 
soluble PEIs, however, the crosslinked PEI particles present toxicity risks inherent to the 
PEI scaffolds. To fabricate biocompaticle NO-releasing micro-particles, Jeh et al. 
reported the encapsulation of N-diazeniumdiolate-modified proline (PROLI/NO) within 
biodegradable polyethylene oxide-co-lactic acid (PELA) or poly-lactic-co-glycolic acid 
(PLGA) microparticles by a double emulsion method.42 Both particles were capable of 
releasing ~120 nmol NO/mg with a half life of ~4.0 min.   
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Figure 1.1 Secondary-amine functionalized polyethylenimine (PPI) dendrimers. 
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The size of the PELA particles (~2 µm) may allow for subsequent inhalation therapy 
whereas the much larger PLGA particle (23.5 µm) are less useful as stand-alone 
therapeutics.43 Although these biodegradable NO-releasing particles are anticipated to 
show reduced toxicity (this was not studied), their low NO storage and inability to control 
NO release have limited their use as therapeutics.  
Over recent years, a number of N-diazeniumdiolate NO donor-modified 
nanoscaffolds have been created to make use of the drug delivery advantages of 
nanomaterials and better harness the power of NO. For example, NO-releasing gold 
nanoparticles were synthesized by conjugating polyamine ligands onto the surface of 
gold nanoparticles and then functionalization with NO.34 These materials exhibited a NO 
storage capacity of 0.386 µmol/mg with durations exceeding 16 h.34 Although the 
particles exhibited desirable properties (e.g., water solubility and multivalency) for 
pharmacological applications,34 the cost of the gold and necessary solvents greatly 
hindered their further development as NO-based therapeutics (primarily due to scale up 
concerns). To prepare low cost NO-releasing nanoparticles, silica-based materials have 
been extensively studied. Zhang et al. reported the synthesis of N-diazeniumdiolate NO 
donor-modified fumed silica particles (200 to 300 nm) by grafting aminosilanes onto the 
particle surface and then functionalizing the secondary amines with NO.44 The NO 
donor-grafted particles released ~0.56 µmol NO/mg with a half-life of 43 min under 
physiological conditions.44  The low NO storage was a result of the limited number of 
silanol groups on the particle surface to modify with aminosilanes. To enhance NO 
storage, Shin et al. has synthesized aminosilane/tetraethoxysilane (TEOS) hybrid 
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particles by co-condensation of aminosilanes with TEOS.45 In contrast to surface grafted 
particles, the hybrid particles contained amines (aminosilanes) throughout the silica 
scaffold, resulting in significantly larger NO storage (~1.8 µmol/mg). Furthermore, the 
total NO storage (i.e., 0.056–1.8 µmol/mg) and kinetics (i.e., half life 0.5–12 h) proved 
tunable by varying the amount and types of aminosilanes, respectively.45 To further 
control the size of NO-releasing silica particles, a reverse microemulsion technique was 
used to synthesize NO-releasing silica particles with distinct sizes (i.e., 50, 100, 200 nm) 
by controlling the organic solvents and reaction time.27 In a reverse microemulsion 
strategy, smaller organic solvent molecules can penetrate deeper into the surfactant layer, 
decreasing the overall size of the water droplet and ensuing particles.27 As such, high 
molecular weight organic solvents (i.e., heptanes) were used to yield 100 and 200 nm 
sized particles in 3 and 18 h reactions, respectively. In contrast, low molecular weight 
organic solvent (i.e., pentane) resulted in smaller particles (i.e., 50 nm).27 Collectively, 
NO-releasing silica particles have shown varied NO-release kinetics and sizes, 
facilitating studies on the influence of NO-release kinetics and scaffold size on biological 
effects (i.e., biocidal activity). To date, particle shape has been neglected despite its role 
in drug delivery efficiency.46-47  
1.3 S-Nitrosothiol Functionalized Macromolecules 
1.3.1 S-Nitrosothiol Formation and NO-Release Characteristics 
In contrast to N-diazeniumdiolate NO donors, S-nitrosothiols (RSNO) are the 
endogenous transporters of NO in the body and form the basis of a number of NO 
signaling cascades.48 For example, S-nitrosoglutathione (GSNO) is an endogenous S-
nitrosothiol (SNO) that plays a critical role in NO signaling.48 S-nitrosothiols are formed 
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either via the reaction of thiols (e.g., glutathione) with dinitrogen trioxide or through a 
host of redox mechanisms involving metabolites of NO and transition metal centers.49  
Nitric oxide stored in this way also regulates several biological processes including 
vasodilation, platelet activation, neurotransmission, and tissue inflammation.49 Nitrosated 
cysteine on albumin and other serum proteins account for a large portion of the ~1.8 µM 
nitrosothiol concentration in blood.50 In the lab, nitrosothiols can be synthesized by the 
reaction of free thiols in acidified sodium nitrite solution.51 Small molecule RSNOs (e.g., 
GSNO, S-nitroso-N-acetyl-D,L-penicillamine (SNAP)) synthesized via this method have 
been employed as NO sources to better understand the many roles of NO in regulatory 
biology.52 
Compared to N-diazeniumdiolate NO donors, S-nitrosothiols decompose through a 
multitude of pathways.53-54 Photo and thermal irradiation of RSNOs result in homolytic 
cleavage of the S-N bond, yielding NO and the thiyl radical. The thiyl radical may 
subsequently react with an RSNO to generate a disulfide and an additional equivalent of 
NO.53-54  Dicks et al. have shown that Cu(I), resulting from the reduction of Cu(II) via 
trace thiolate ions, is active in a catalytic RSNO decomposition mechanism.55 
Transnitrosation between a thiol and an RSNO may also occur, resulting in the transfer of 
the nitroso functionality and the formation of a new RSNO species that may decompose 
via the aforementioned pathways.53-54 As opposed to the proton-induced N-
diazeniumdiolate NO donors breakdown, the multiple decomposition pathways of S-
nitrosothiols, especially light irradiation, represents an alternative trigger for spatial and 
temporal control over NO release.51 Although small molecule S-nitrosothiols have 
demonstrated great antiplatelet, antimicrobial, and vasodilatory activities,  
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Scheme 1.2 Decomposition pathways of S-nitrosothiol.  
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both the inability to target the NO to a specific site and the rapid systemic clearance in 
vivo have hindered their clinical development.56 As such, recent research has focused on 
the synthesis of macromolecular NO-releasing vehicles via S-nitrosothiol NO donors.  
1.3.2 S-Nitrosothiol Silica Particles 
Analogous to the N-diazeniumdiolate-grafted fumed silica mentioned previously, 
Frost et al. reported the synthesis of surface grafted S-nitrosothiol-modified silica 
particles by anchoring S-nitrosothols onto the particle surface.57 In a typical synthesis, 
thiolated silanes were tethered to the surface of fumed silica particles, and then converted 
to the corresponding S-nitrosothiol form by reaction with tert-butylnitrite. The NO 
storage for the S-nitrosothiol-modified silica particles was roughly 0.138 µmol NO/mg 
with release of NO readily controlled by the duration and intensity of heat or light to 
initiate NO release. The low NO storage of these particles was attributed to the limited 
surface area for the grafting of S-nitrosothiols. To increase NO storage capacity, Riccio et 
al. synthesized thiol-modified silica particles by co-condensation of a thiolated silane and 
tetraethoxysilane. Enhanced NO storage was anticipated due to the incorporation of 
thiolated silanes throughout the particles. The nitrosation of the thiol-modified particles 
resulted in significantly increased NO storage (up to ׽4.40 μmol NO/mg) and tunable 
sizes (241-718 nm).58 However, the duration of NO release in PBS shielded from light at 
37 oC was only ~24 h due to the instability of primary S-nitrosothiols.58 More extended 
NO release is desired to enable better understanding of the effects of larger NO exposure 
to bacteria, cells, and tissue. 
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1.3.3 S-Nitrosothiol Poly(amidoamine) (PAMAM) Dendrimers 
The size of a drug delivery scaffold greatly influences the delivery efficiency and 
related therapeutic performance.27 While NO-releasing silica particles range in size from 
~50 to 1000 nm, dendrimers can be synthesized at sizes less than 10 nm.45, 58-59 While 
maintaining high drug payloads per unit of drug carrier.60 Indeed, previous work on N-
diazeniumdiolate-modified polypropylenimine dendrimers revealed a greater NO storage 
capacity (~5.6 µmol/mg) compared to other types of macromolecular scaffolds.29 The 
multivalent exterior of dendrimers also enables the attachment of additional 
functionalities on a single scaffold, making them extremely useful for drug targeting to a 
specific tissue type.39 Stasko et al. synthesized S-nitrosothiol PAMAM dendrimers by 
modifying the exterior primary amines with either N-acetyl-D,L-penicillamine (NAP) or 
N-acetyl-L-cysteine (NACys), followed by the nitrosation of the dendritic thiols.59 
Chemiluminescent NO detection was used to demonstrate that the dendrimers stored ׽2 
μmol NO/mg.59  The kinetics of NO release was found to be highly dependent on the 
structure of the nitrosothiol (i.e., tertiary vs. primary). Primary nitrosothiol-functionalized 
dendrimers exhibited slower NO-release kinetics due to the “cage effect”, causing 
recombination of NO and thiyl radical, resulting in S-nitrosothiol reformation. Despite 
the greater NO storage of these dendrimers, the NO release in PBS at 37 oC was 
negligible for both primary and tertiary S-nitrosothiol-modified dendrimers when 
shielded from light, hindering the utility of these materials in applications where light 
triggered NO release is not feasible. S-nitrosothiol-modfied dendrimers capable of 
releasing large amounts of NO under physiological conditions (dark, 37 oC) remains an 
important opportunity for study.  
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Figure 1.2 Chemical structure of generation 3 poly(amidoamine) (PAMAM) dendrimers. 
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Figure 1.3  Generation 4 PAMAM dendrimers with a completely modified exterior (64 
thiols) of S-nitroso-N-acetyl-D,L-penicillamine (G4-SNAP) or S-nitroso-N-acetylcysteine 
(G4-NACysNO). 
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1.4 Antibacterial properties of Nitric Oxide  
Bacteria in nature exist in two states – free-floating planktonic bacteria and bacterial 
biofilms.61 Medically relevant infections such as those associated with medical implants, 
diabetes mellitus, and cystic fibrosis are often caused by bacterial biofilms.61-63 Biofilms 
are communities of microorganisms adhered to a surface and embedded within a self-
produced exopolysaccharides (EPS) matrix, which anchors and protects the encapsulated 
bacteria from immune cells and antibiotics.64 Along with protective EPS inhibiting the 
penetration of antibiotics, biofilms exhibited other defense mechanisms such as 
overexpression of stress-responsive genes, oxygen gradients within the biofilm matrix, 
and differentiation of a subpopulation of biofilm bacteria into resistant dormant 
species.65-68 Collectively, this results in greater resistance to antimicrobial action of 
agents/drugs compared to planktonic bacteria. As such, antimicrobial agents capable of 
eradicating biofilms are urgently needed.69-77 
Fortunately, NO plays a key role in the natural immune response to pathogens.1, 78 
Both NO and its reactive byproducts (e.g., peroxynitrite and dinitrogen trioxide) exert 
significant oxidative and nitrosative stress on bacteria to facilitate killing. Nitrosative 
stress occurs when thiols on proteins and DNA are nitrosated, impairing normal function. 
Oxidative stress is mostly observed through lipid peroxidation that readily destroys the 
bacterial membrane integrity.1, 78 As such, gaseous NO and NO-releasing scaffolds have 
been used as antimicrobial agents against planktonic bacteria and biofilms. In this section, 
recent development of NO gas, small molecule NO donors, and NO-releasing 
macromolecular scaffolds as antibacterial agents are reviewed. 
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Figure 1.4 Proposed mechanisms by which NO acts as an antibacterial agent26  
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1.4.1 Gaseous NO (gNO) 
Gaseous NO (gNO) is an FDA-approved therapy and has been clinically used in the 
U.S. to treat pulmonary hypertension.79 Due to the established protocol of administration, 
gaseous NO has also been studied as a strategy to treat bacterial infection. Gahaffari et al. 
reported on the use of gaseous NO (gNO) to eradicate clinical isolates of Staphylococcus 
aureus, methicillin-resistant S. aureus (MRSA), Escherichia coli, Group B Streptococcus, 
Pseudomonas aeruginosa, and Candida albicans.80 Medical grade gNO was delivered to 
bacteria cultures using a horizontal-flow delivery system. Exposure to gNO at 200 ppm 
for ~4.1 h completely inhibited bacterial growth. Additionally, the authors reported that 
the NO exposure did not elicit cytotoxicity against human fibroblast cells for up to 48 h. 
Despite the bactericidal efficacy and low cytotoxicity of gNO, the cumbersome delivery 
system and safety concerns of possible nitrogen dioxide formation by the oxidation of 
gNO warranted more efficient NO-delivery systems.81  
1.4.2 Small Molecule Nitric Oxide Donors as Antibacterial Agents 
N-diazeniumdiolate and S-nitrosothiol NO donors enable nearly instantaneous release 
of NO under physiological conditions, allowing for a wide range of biomedical 
applications including as antimicrobial agents.  Indeed, small molecule NO donors have 
been used to demonstrate antibacterial action.82-84 Examples of readily available small 
molecule NO donors include 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate 
(PROLI/NO), N- diazeniumdiolated diethyltriamine (DETA/NO), S-nitroso-N-
acetylcysteine (SNAC), and S-nitrosoglutathione (GSNO) (Scheme 1.3). In some of the 
earliest work, Dukelow et al. reported the utility of N-diazeniumdiolated diethyltriamine 
(DETA/NO) for the treatment of acute Pseudomonas aeruginosa (P. aerguginosa) 
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pneumonia in a mouse model.82 Pneumonia was induced by intratracheal instillation of P. 
aeruginosa (3 × 107 CFU/mL). Mice were treated with nebulized DETA/NO (12.5 or  
125 µmol) at 4 and 12 h or continuous gaseous NO (10 or 40 ppm) before being 
sacrificed. Nebulized DETA/NO was shown to decrease the pulmonary bacterial load in 
mice with pneumonia by ~65% whereas inhaled NO gas had no significant effect on 
bacterial viability. Despite the enhanced bactericidal efficacy of DETA/NO, its use as an 
NO therapy is hindered due to the substantial toxicity observed.82  In contrast, S-
nitrosothiol NO donors such as GSNO and SNAC are endogenous transporters of NO.48 
The NO-mediated antimicrobial activity of GSNO and SNAC has been studied using 
several pathogens associated with infectious eye diseases.84-86 For example, Cariello et al. 
evaluated the antimicrobial activity of GSNO and SNAC against clinical isolates 
Pseudononas aeruginosa, Staphylococus aureus, Serratia marcescenes, Enterobacter 
aerogenes from patients with infectious keratitis.84 Both NO-release scaffolds proved 
effective at inhibiting and killing all bacterial strains. SNAC showed greater 
antimicrobial activity than GSNO against all bacteria, with Gram-positive bacteria being 
more susceptible to the NO-releasing S-nitrosothiols.84  
Although the NO-mediated antimicrobial activity of small molecule NO donors 
demonstrates the potential of NO-releasing scaffolds as antimicrobial agents, the low NO 
payloads and inability to target the NO delivery limits their therapeutic usefulness. A 
recent review has highlighted the benefits of macromolecular scaffolds for drug delivery 
over small molecule NO-releasing systems.87  
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Scheme 1.3 Structure of small molecule NO donors. A) 1-[2-(carboxylato)pyrrolidin-1-
yl]diazen-1-ium-1,2-diolate (PROLI/NO); B) N- diazeniumdiolated diethyltriamine 
(DETA/NO); C) S-nitroso-N-acetylcysteine (SNAC); D) S-nitrosoglutathione (GSNO). 
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Indeed, work by former group members in the Schoenfisch lab has shown enhanced 
bacterial killing and reduced cytotoxicity of NO-releasing silica particles compared to 
small molecule NO donors.26 A wide range of NO-releasing macromolecular scaffolds 
have been synthesized to date including particle and dendrimer scaffolds modified with 
nitrite, N-diazeniumdiolates, and S-nitrosothiols. In contrast to S-nitrosothiol-modified 
macromolecular scaffolds, nitrite-containing and N-diazeniumdiolate-modified materials 
have exhibited larger NO payloads under physiological conditions (dark, 37 oC), and thus 
represent more suitable systems as antibacterial therapeutics.  
1.4.3 Nitrite-Containing NO-releasing Macromolecular Scaffolds 
When exposed to low pH or reducing agent, nitrites are able to generate exogenous 
NO and have been used to treat skin infections.88 Nitrite has also been incorporated into 
macromolecular scaffolds for NO release. For example, Friedman et al. reported the 
synthesis of nitrite-containing hydrogel/glass nanoparticles by lyophilizing a gel formed 
from the mixture of tetramethyl orthosilicate, polyethylene glycol, chitosan, glucose, and 
sodium nitrite in a 0.5 mM sodium phosphate buffer.89 The encapsulated sodium nitrite 
was reduced to NO within the matrix with thermally generated electrons from glucose. 
The NO-release profile at 37 oC of the resulting particles showed an initial burst of NO at 
20 pmol NO/mg particle followed by a steady state of NO at 8 pmol NO/mg particle. To 
evaluate the susceptibility of clinical MRSA strains to these NO-releasing hydrogel/glass 
nanoparticles, 107 colony forming unit (CFU)/mL MRSA suspensions were incubated 
with the particles at concentrations ranging from 313 to 5000 µg/mL.90 The minimum 
inhibitory concentration (MIC) for the NO-releasing hydrogel/glass nanoparticle against 
11 clinical isolated MRSA ranged from 313 to 2500 µg/mL.90 Additionally, the efficacy 
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of the hydrogel/glass nanoparticle in killing MRSA was studied in mice.90 Full thickness 
excision wounds of 5 mm diameter were infected by inoculation using 107 CFU MRSA 
in phosphate buffered saline (PBS). The wounds were then treated with 5 mg NO-
releasing hydrogel/glass particles at 1 and 72 h. On day 7, MRSA growth was inhibited 
by 5-logs for mice treated with NO-releasing hydrogel/glass nanoparticles compared to 
untreated wounds.90 
Although the nitrite-containing nanoparticles exhibited an inhibitory effect on 
bacterial growth, their ability to kill bacteria was not evaluated. The poor control over 
NO release and particle morphologies along with the carcigenic risk of nitrite clearly 
limit their application as antimicrobial therapeutics.91 To prepare less toxic NO-releasing 
scaffolds, recent research has focused on the development of N-diazeniumdiolate NO 
donor-modified macromolecular scaffolds as antimicrobial agents. 
1.4.4 N-Diazeniumdiolate-Functionalized Silica Nanoparticles 
Silica nanoparticles have been studied extensively as scaffolds for drug delivery due 
to their relatively low toxicity and tunable size.92 Most recently, the ability to store NO 
onto silica scaffolds have has also been demonstrated.27, 45 For example, Hetrick et al. 
reported the synthesis of aminosilane/tetraethoxysilane (TEOS) hybrid particles with 
tunable NO-release kinetics and sizes, allowing for study of how size and NO-release 
kinetics affect antibacterial activity. Among the particles synthesized, the utility of 
TEOS/N-(6- Aminohexyl)aminopropyltrimethoxysilane (AHAP3) hybrid silica particles 
as novel antibacterial agents was demonstrated against Pseudomonas aeruginosa.26 
Comparison of the bactericidal efficacy of the NO-releasing nanoparticles to small 
molecule 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO) 
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demonstrated enhanced bactericidal efficacy for the particles-derived NO due to particle-
bacteria association and more efficient NO delivery.93 The bactericidal NO dose from the 
NO-releasing silica particles (i.e., 0.6 µmol/mL) was also much lower than that required 
from small molecule NO donors PROLI/NO (i.e., 4.5 µmol/mL). The NO-releasing silica 
particles also elicited less toxicity to mammalian cells at the minimum bactericidal 
concentration (MBC) compared to small molecule NO donors PROLI/NO, indicating the 
improved therapeutic potential of these macromolecular scaffolds.26 To study how 
scaffold size affects bactericidal efficacy, NO-releasing AHAP/TEOS hybrid silica 
particles of three distinct sizes (e.g., 50, 100, 200 nm) were synthesized by reverse 
microemulsion.27 The similar NO storage (~1 µmol/mg) and NO-release kinetics (tm=0.6 
min) allowed for a study of size-dependent bacterial killing against P. aeruginosa. Briefly, 
the bactericidal eﬃcacy of the NO-releasing nanoparticles against P. aeruginosa 
increased with decreasing particle size as a result of improved particle-bacteria 
association.27  
The ability of nitric oxide (NO)-releasing silica nanoparticles to kill biofilm bacteria 
was reported by Hetrick et al.38 Replicative viability experiments revealed that > 99% of 
bacteria from Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, 
Staphylococcus epidermidis, and Candida albicans biofilms were killed via NO release, 
with the greatest efficacy (>99.999% killing) against Gram-negative P. aeruginosa and E. 
coli biofilms.38 Unfortunately, the NO-releasing silica particles exhibited significant 
toxicity to mammalian cells (~80% cell viability reduction) at concentrations required to 
eradicate biofilms, necessitating the design of NO-releasing silica particles with enhanced 
biocidal activity and reduced toxicity to mammalian cells.  
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1.4.5 N-Diazeniumdiolate-NO donors-Modified Dendrimers 
Based on the silica size study, the use of dendrimers as NO-delivery vehicles were 
expected to exhibit more enhanced antibacterial activity. Sun et al. evaluated the 
antibacterial activity of a series of NO-releasing poly(propylene imine) (PPI) dendrimers 
against both Gram-positive and Gram-negative planktonic bacteria, including methicillin-
resistant Staphylococcus aureus.94 The bactericidal efficacy of the NO-releasing 
dendrimers was highly dependent on their exterior functionality with hydrophobic 
functionalization exhibiting enhanced bactericidal efficacy due to facilitating greater 
association with bacteria and allowing for more efficient intracellular NO delivery. In 
contrast to the control dendrimers (non-NO-releasing), the NO-releasing dendrimers also 
showed less cytotoxicity to L929 mouse fibroblast cells due to the lower dose of material 
required.94 However, dendrimers with hydrophobic exteriors proved toxic (>80% 
viability reduction) at 2x minimum bactericidal concentrations (~30 µg/mL), a potential 
concern when used to eradicate biofilms where larger doses of material are required. As 
such, dendrimers with tunable exterior hydrophobicity should be evaluated to study the 
impact of such functionalization on the bactericidal efficacy and cytotoxicity to 
mammalian cells. 
1.5 Impact of Particle Morphologies on Drug Delivery Efficiency 
Recent work on particle design for drug delivery to mammalian cells indicates the 
importance of particle shape on particle-cell adhesion strength, internalization rate, 
biodistribution, cytotoxicity, phagocytosis and circulation time.95-109 In particular, rod-
like nanoparticles have been shown to influence mammalian cell internalization and 
circulation time compared to their spherical or cubic counterparts.101-105 For example, 
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rod-like PEG hydrogel, mesoporous silica and needle-shaped poly(lactide-co-glycotide) 
(PLGA) particles with high aspect ratios (e.g., aspect ratio of 3) were found to be 
internalized in a faster rate compared to their spherical or cubic counterparts. 47, 99, 102-103 
PLGA needles also exhibited substantially larger cytoplasmic delivery of drug.47 In 
contrast, gold nanorods with high aspect ratio were less internalized by human breast 
adenocarcinoma cell line (MCF-7),110 indicating that the interaction between particles 
and cells depends on both particle properties (e.g., morphology, surface chemistry) and 
cell type. Likewise, particle shape may play an important role in particle phagocytosis 
and circulation time in the blood stream.46 Filomicelles with high aspect ratios were 
reported to exhibit reduced rates of phagocytosis and long circulation half-lives (e.g., ~5 
days) in comparison to spherical micelles.108 Although the influence of particle shape on 
particle interactions with mammalian cells and macrophages has been noted in prior 
reports, the effect of particle shape on antibacterial efficacy has not been evaluated 
carefully to date.  
1.6 Mesoporous Silica Particles for Drug Delivery 
Mesoporous silica materials were first developed by Mobil Oil Corporation using 
surfactant molecules as templates for silicate polymerization.111 To date, both acidic112-
113and alkaline111, 114-115synthetic strategies have been used to prepare mesoporous silica 
materials.116-120 According to a mechanism proposed by Stucky and coworkers,112-113, 121 
mesophase formation arises from the multidentate binding of silicate species to surfactant 
micelle interfaces via electrostatic interactions. The resulting liquid crystal phases self-
assemble by charge density matching across the interface, and continuously grow end-to-
end or side-to-side through accretion into well-formed particles.122 Mesoporous particles 
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with unique porous structures have been widely used as drug delivery systems for tissue 
engineering123, diabetes, 124inflammation,125 and cancer92 due to their tailorable pore 
structure, high specific surface area, and large pore volume, allowing for the 
encapsulation of therapeutic agents. The size and morphology of the resulting particles 
are easily tuned in a scalable, cost-effective, and controllable manner.126 Control over the 
aspect ratio of micron-sized mesoporous silica rods under acidic condition was reported 
by Naik et al by adjusting silane concentration and pH.122 As shown in Figure 1.5, the 
large surface area of mesoporous silica particles may result in larger NO storage by 
anchoring larger amount of aminosilanes on the particle surface. 
1.7 Chitosans for Nitric Oxide Release 
Although silica particles and dendrimers with controlled NO release and size can be 
synthesized, certain applications may require scaffolds capable of degradation after the 
NO release expires. For example, NO-induced eradication of the biofilms in the lungs of 
cystic fibrosis might benefit more from NO-releasing scaffolds that degrade over time. 
Chitosan, the second most abundant natural biopolymer, has been widely used for a 
number of applications including tissue engineering, drug delivery, and antimicrobial 
agents, due to its biocompatibility, biodegradability and cationic composition.127-130 The 
development of chitosan derivatives as NO-releasing scaffolds has also been explored 
due to the high concentration of amine precursors necessary for N-diazeniumdiolate NO 
donor formation.131-133 
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Figure 1.5 Synthesis of mesoporous silica particles by A) surfactant-templated routes and 
representative transmission electron microscopy images of particles with different 
morphologies. B) particles with high aspect ratio; C) particles with low aspect ratio. 
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To date, the N-diazeniumdiolate NO donor-functionalized chitosan polysaccharides 
(~60 to 220 kD) have been characterized by low N-diazeniumdiolate conversion 
efficiency and NO storage (~0.2 µmol/mg), likely the result of chitosan’s insolubility 
under the basic conditions required for N-diazeniumdiolate formation (Scheme 1.4).131-133 
The potential bactericidal efficacy of such scaffolds would clearly be limited due to their 
insolubility under physiological conditions and low NO payloads.134,135 In this regard, 
chitosan oligosaccharides (< 20 kD) may prove more useful as NO-releasing scaffolds 
due to their solubility under basic conditions. Multiple strategies have been reported for 
degrading chitosan into oligomer derivatives, including direct oxidative and enzymatic 
degradation.136-137 Compared to enzymatic degradation where enzymes (e.g., chitosanase) 
are required, oxidative degradation by hydrogen peroxide represents a more facile and 
economic approach. The molecular weight (Mw) of the product can be controlled by 
varying the oxidation conditions (e.g., concentration of hydrogen peroxide and 
temperature) and determined by the classic Mark-Houwink equation.138  
1.8 Impact of NO-Release Kinetics 
Although NO has been shown to be an important mediator of wound healing, the 
foreign body response and bactericidal efficacy, the exact effects of NO-release kinetics 
remains unclear.139 Nichols et al. designed NO-releasing polyurethane-coated wires that 
were implanted into porcine subcutaneous tissue to evaluate the foreign body response as 
a function of NO release. The NO-release kinetics of the polyurethane coating were 
controlled by the type of NO-releasing silica particle dopants (e.g., N-diazeniumdiolate- 
and S-nitrosothiol-modified silica particles) and polyurethane. 
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Scheme 1.4 Synthesis of A) secondary amine-; and B) N-diazeniumdiolate-modified 
chitosan polysaccharides; and, C) oxidative degradation of chitosan polysaccharides. 
R=CH(CH3)CH2CH2COO-Na+, CH2CH2COO-Na+, CH2CH2COOCH3, CH2COO-Na+, 
CH2CH2CH3. 
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The most prolonged NO release was achieved using S-nitrosothiol silica particle-doped 
polyurethane, with a duration of 14 d. Histological analysis revealed that materials with 
longer release durations (i.e., 14 d) and greater NO payloads more significantly reduced 
the collagen encapsulation at 3 and 6 weeks relative to faster, more finite NO-releasing 
coatings.139 Analogously, the bactericidal efficacy of NO-releasing materials may also 
depend on the amount of NO released and the NO-release kinetics. Prior work by Hetrick 
et al. demonstrated that the rapid NO release (e.g., half life ~18 min) from N-
Methylaminopropyltrimethoxysilane (MAP3)/TEOS hybrid NO-releasing silica particles 
exhibited 1000-fold improvement in biofilm eradication compared to AHAP/TEOS (e.g., 
half life ~6 min).38 Further systematic investigation is clearly necessary. 
1.9 Overview of Dissertation Research 
Prior work in the Schoenfisch lab have focused mainly on the development of 
macromolecular scaffolds (e.g., silica particles, dendrimers) with tunable NO-release 
kinetics and sizes. The bactericidal efficacy of N-diazeniumdiolate NO donor-modified 
silica particles and dendrimers is highly dependent on the NO-release kinetics, exterior 
hydrophobicity, and scaffold size.26, 94 Nitric oxide-releasing silica particles and 
dendrimers proved effective at killing planktonic bacteria with minimal toxicity against 
mammalian cells. Unfortunately, the cytotoxicity (~80% viability reduction) of the 
particles remains a concern, and warrants further improvement in the design of NO-
releasing scaffolds.38 To improve the biocidal efficacy of NO release, my research has 
focused on the synthesis of NO-releasing macromolecular scaffolds (e.g., silica particles, 
dendrimers, and chitosan oligosaccharides) with tunable NO-release kinetics, 
sizes/molecular weights, shapes, and exterior functionalities to control hydrophobicity. 
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The NO-delivery efficiency and ensuing bactericidal efficacy of these materials were 
carefully evaluated against both planktonic bacteria and biofilms as a function of their 
physical and chemical properties mentioned above. 
The specific aims of my research included: 
1) the synthesis of N-diazeniumdiolate-functionalized dendrimers with controlled 
NO release for studying of the structure/property relationships of these materials 
on NO-release kinetics; 
2) the design of N-diazeniumdiolate NO donor-functionalized dendrimers with 
unique exterior hydrophobicities to study how the exterior of the dendrimer 
impacts bactericidal efficacy against bacteria biofilms and cytotoxicity to 
mammalian cells; 
3) the synthesis of N-diazeniumdiolate-NO donor-functionalized silica rods with 
different aspect ratios to enable the study of the shape- and NO release-dependent 
bactericidal efficacy against both Gram-positive and -negative bacteria; 
4) the synthesis of N-diazeniumdiolate-functionalized chitosan oligosaccharides as 
new, biodegradable NO-releasing vehicles. 
The research in this thesis presents the synthesis of various NO-releasing scaffolds 
with tunable NO-release properties, exterior functionality, and morphologies. The NO 
delivery efficiency and bactericidal efficacy as a functional of these chemical and 
physical properties were systematically studied, facilitating the future development of 
NO-releasing materials as antimicrobial therapeutics. 
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Chapter 2 
     Structurally Diverse Nitric Oxide-Releasing Poly(propylene imine) Dendrimers 
 
2.1 Introduction 
Dendrimers are a family of hyperbranched macromolecules with multivalent surfaces 
that enable the design of targeted therapeutics agent delivery vehicles.1-4 For example, 
polyamidoamines,5 polyamines,6 polypeptides,7 polyesters8 and polyethers9 dendrimers 
have been utilized for a range of biomedical applications, including drug and gene 
delivery,10-22 biological imaging,23-29 and tissue engineering.30-33 Bactericidal dendrimers 
have been prepared by encapsulating antibacterial agents (e.g., sulfomethoxazole34) 
within the dendrimer or at its periphery (e.g., quaternary ammonium groups35). Anionic 
amphiphilic dendrimers were also reported to possess antibacterial efficacy against 
Gram-positive bacteria.36  
Nitric oxide is an endogenously produced diatomic free radical that mediates multiple 
processes in mammalian physiology. Due to NO’s pharmacological potential, the 
synthesis of prodrugs capable of controlled exogeneous NO production is important in 
further understanding NO’s role in physiology and developing NO-based therapeutics. 
The therapeutic effectiveness of such donors depends on the target (e.g., cell type and 
condition), concentration and rate of NO release.37, 38 For example, Chakrapani and 
coworkers synthesized O2-(2,4-dinitro-5-(4-(N-methylamino)benzoyloxy)phenyl)-1-
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(N,N-dimethylamino)diazen-1-ium-1,2-diolate (PABA/NO) as an anti-cancer NO 
prodrug with efficacy against human leukemia and A2780 human ovarian cancer 
xenografts.39 Both the NO payload and release kinetics were shown to influence the 
anticancer activity. The study of how chemical structure impacts the rate of NO release 
from small molecule NO donors has been an active area of research, particularly with 
respect to biological activity.40-45 Generally, stabilization of the N-diazeniumdiolate NO 
donor correlates directly with extended NO release.46 
To enhance NO storage and release levels relative to small molecule NO donors, we 
previously reported the synthesis of N-diazeniumdiolate-functionalized poly(propylene 
imine) (PPI) dendrimer conjugates as macromolecular NO donors capable of storing up 
to ~5 μmol NO/mg with NO release kinetics dependent on the dendrimer structure.47 
Although we alluded to the multivalent exterior benefit on NO storage/release and further 
functionalization for imaging, controlled toxicity, and/or active targeting, for example, 
the study of structure/nitric oxide release relationships was not systematically pursued. In 
subsequent work, Stasko et al. reported the synthesis of S-nitrosothiol-modified 
polyamidoamine (PAMAM) dendrimers with alternative decomposition mechanisms for 
controlled NO release.48 While capable of storing ~2 μmol NO/mg, the kinetics of NO 
release were found to be highly dependent on the structure of the nitrosothiol and NO 
release trigger (e.g., light, copper, temperature).  Collectively, the dendritic effects 
exerted on NO donor stability and reactivity, and the benefits of multi-functionalization 
with imaging beacons and/or active targeting agents, highlight the tremendous potential 
of dendrimers as NO release therapeutics. 
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Herein, we describe the synthesis of N-diazeniumdiolate-functionalized PPI 
dendrimers using select exterior functionalities to diversify both the NO release kinetics 
and potential applications for which such materials may prove useful. In addition to 
assessing the roles of molecular weight (e.g., generation or size of dendrimer) and 
exterior chemical structure on NO release, we demonstrate the ability to tune NO release 
kinetics using multiple NO donor functionalization. 
2.2 Experimental Section 
2.2.1 Materials and General Considerations.  
Ethylenediamine (EDA), acrylonitrile (ACN), propylene oxide (PO), styrene oxide 
(SO), poly(ethylene glycol) methyl ether acrylate (average Mn = 480) (PEG), and 1,2-
epoxy-9-decene (ED) were purchased from Aldrich Chemical Company (Milwaukee, 
WI). 1,6-Hexanediamine (HDA) and sodium methoxide (5.4 M solution in methanol) was 
purchased from Acros Organics (Geel, Belgium). Sponge cobalt catalyst (A-8B46) was 
purchased from Johson Matthey Catalysts (London, UK). Common laboratory salts and 
solvents were purchased from Fisher Scientific (Pittsburgh, PA). All other materials were 
used as received without further purification unless otherwise noted. 1H nuclear magnetic 
resonance (NMR) spectra were recorded on Bruker (400 MHz) and Varian (600 MHz) 
spectrometers. Hydrogenation reactions used for the synthesis of PPI-NH2 (e.g., from G2 
to G5) were carried out in a stainless steel high-pressure reactor purchased from Parr 
Instrument Company (Moline, IL). Agitation was provided by a Teflon-coated magnetic 
stirring bar. Heating was provided using a heating fabric wrapped around the reactor, and 
temperature was controlled using a temperature controller via a thermal coupler. Nitric 
oxide release was measured using Sievers 280i Chemiluminesce Nitric Oxide Analyzer 
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(Boulder, CO) as described previously.47 The chemiluminescence analyzer was calibrated 
with NO gas (26.9 ppm). A parameter for converting the instrument response (ppb) to 
moles of NO was obtained using the conversion of nitrite standards to NO in a 0.1 M 
KOH/H2SO4 solution (1.31  10-13 moles NO/ppb). 
2.2.2 Synthesis of [G-0.5]-PPI-CN to [G-4.5]-PPI-CN.  
The synthetic approach reported here builds upon studies described previously. For 
the synthesis of [G-0.5]-PPI-CN, ethylenediamine (EDA, 25.0 mL, 0.374 mol) and 
deionized water (263 mL) were placed in a 1000 mL round-bottomed flask. Acrylonitrile 
(ACN, 140 mL) was added in portions of 20 mL with stirring for 15 minutes. The 
resulting mixture was refluxed for 2 hrs, and then cooled to room temperature overnight. 
ACN was removed in vacuo at 40 °C. [G-0.5]-PPI-CN was crystallized from the mixture 
and isolated by vacuum filtration. The crude product was recrystallized from 
THF/methanol as a white power. Representative 1HNMR data: (300 MHz, CDCl3):  
(ppm) 2.55 (8H, -NCH2CH2CN), 2.77 (4H, -NCH2CH2N-), 2.96 (t, 8H, -NCH2CH2CN). 
Synthesis of higher generation PPI-CN (e.g., from [G-1.5] to [G-4.5]) was not 
significantly different from the synthesis of PPI-[G-0.5]-CN as described above, with the 
exception that PPI-CN (e.g., from [G-1.5] to [G-4.5]) are usually viscous liquid and their 
purification processes would normally require the use of preparative-scale 
chromatography. As a result, the synthesis of higher generation PPI-CN was conducted in 
a slightly different manner. Higher generation PPI-CN (10.0 g) (e.g., from [G-1.5] to [G-
4.5]) was dissolved in deionized water (50 mL) and THF (100 mL). To this solution was 
added ACN (50 mL). If phase separation of the resulting solution occurs, an additional 
amount of THF was added.  The reaction mixture was stirred at room temperature for 3 
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days and a small amount was removed for analysis by 1H NMR spectroscopy to 
determine the extent of reaction.  If the reaction is not complete, an additional amount of 
ACN (25 mL) was added and the reaction was stirred for two to three extra days.  
2.2.3 Synthesis of [G-1]-PPI-NH2 to [G-5]-PPI-NH2.  
The synthetic approach reported here is similar to those reported in past studies. For 
the synthesis of [G-1]-PPI-NH2, sponge cobalt catalyst (5.0–6.0 g) was washed with 10% 
KOH solution for 10 minutes, three times with de-ionized water, and twice with methanol 
prior to use. [G-0.5]-PPI-CN (10.0 g) was placed in a glass reactor sleeve and dissolved 
in THF (70 mL) and methanol (30 mL). To this solution, the sponge cobalt catalyst 
prepared as described above (5.0–6.0 g) was added using a pipet and the reactor sleeve 
was placed in the hydrogenation chamber with proper stirring. The reactor was purged 
with house nitrogen (60 PSI) for five times, and then with hydrogen (400 PSI) for two 
times. The reactor was charged with hydrogen to a pressure of 800 PSI, and heated to 
100°C. The hydrogen gas pressure was maintained at 1000 PSI throughout the reaction. 
After 3 hours, the reaction mixture was allowed to cool down to room temperature. 
Hydrogen remained in the reactor was slowly removed, and the reaction chamber was 
purged once with house nitrogen.  The resulting reaction mixture was then filtered to 
remove the cobalt catalyst, and solvent was removed in vacuo. The final product was 
dried under vacuum overnight to yield [G-1]-PPI-NH2 as a colorless liquid. 
Representative 1HNMR data: (300 MHz, CDCl3):  (ppm) 1.52 (q, 8H, 
NH2CH2CH2CH2N-), 2.40 (t, 8H, NH2CH2CH2CH2N-), 2.44 (s, 4H, -NCH2CH2N-), 2.64 
(t, 8H, NH2CH2CH2CH2N-). The approach to synthesis of higher generation PPI-NH2 
(e.g., from [G-2] to [G-5]) was similar to that of [G-1]-PPI-NH2 with the exception that a 
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mixture of EDA and THF (50:50, v/v) was used as a solvent and was removed after 
reaction in vacuo using 1-butanol as an azeotropic agent to assist the removal of high 
boiling point solvent (e.g., EDA). The resulting higher generation PPI-NH2 (e.g., from 
[G-2] to [G-5]) was dried under vacuum overnight to yield as a light yellow liquid. 
2.2.4 Synthesis of Secondary Amine-Functionalized PPI Dendrimers.  
100 mg PPI-NH2 (e.g., from G2 to G5) was dissolved in 2 ml methanol in a 10ml vial. 
One equivalent of acrylonitrile (ACN), poly(ethylene glycol) methyl ether acrylate 
(average Mn = 480) (PEG), propylene oxide (PO), styrene oxide (SO), or 1,2-epoxy-9-
decene (ED) (e.g., with respect to molar amount of primary amine functionality) was then 
added to the 10 mL vial. The solution was stirred at room temperature for 4 d. Solvent 
was removed under reduced pressure. Dendrimers were dissolved in water followed by 
dialysis against water and lyophilization. 
Representative 1HNMR data of secondary amine-functionalized G5-PPI conjugate 
formed via the reactions of G5-PPI-NH2 with ACN, PEG, PO, SO, and ED (referred to 
hereafter as G5-PPI-ACN a-64, G5-PPI-PEG b-64, G5-PPI-PO c-64, G5-PPI-SO d-64, 
G5-PPI-ED e-64) are as follows: G5-PPI-ACN a-64: 1H NMR (400 MHz, CD3OD, δ): 
2.87 (NHCH2CH2CN), 2.82 (NHCH2CH2CN), 2.60 (NCH2CH2CH2NH), 2.40 
(NCH2CH2CH2NH), 1.60 (NCH2CH2CH2NH). 13C NMR (400 MHz, CD3OD, δ): 117, 
52.4, 51.8, 44.5, 33.3, 26.1, 23.6, 16.9. G5-PPI-PEG b-64: 1H NMR (400 MHz, CD3OD, 
δ): 2.60 (NCH2CH2CH2NH), 2.40 (NCH2CH2CH2NH), 1.60 (NCH2CH2CH2NH), 3.40–
3.70 (OCH2CH2O), 2.80 (CH2NHCH2CHCOOPEG), 2.65 (CH2NHCH2CHCOOPEG), 
2.42 (CH2NHCH2CHCOOPEG). 13C NMR (400 MHz, CD3OD, δ): 172, 71.6, 70.85, 69.3, 
60.1, 57.0, 51.4, 43.9, 39.1, 22.9. G5-PPI-PO c-64: 1H NMR (400 MHz, CD3OD, δ): 3.70 
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(CH2CH(OH)CH3), 2.60–2.62 (CH2CH(OH)CH3, NCH2CH2CH2NH), 2.40 
(NCH2CH2CH2NH), 1.60 (NCH2CH2CH2NH), 1.00 (CH2CH(OH)CH3). 13C NMR (400 
MHz, CD3OD, δ): 66.9, 58.2, 53.7, 52.8, 41.2, 30.8, 27.6, 24.9, 21.8. G5-PPI-SO d-64: 
1H NMR (400 MHz, CD3OD, δ): 7.50–7.20 (CH2CH(OH)Ph), 3.70 (CH2CH(OH)Ph), 
2.72 (CH2CH(OH)Ph), 2.60 (NCH2CH2CH2NH), 2.40 (NCH2CH2CH2NH), 1.60 
(NCH2CH2CH2NH). 13C NMR (400 MHz, CD3OD, δ): 140.6, 128.2, 127.5, 127.3, 125.8, 
71.9, 57.1, 52.4, 45.6, 39.8, 26.3, 23.6. G5-PPI-ED e-64: 1H NMR (400 MHz, CD3OD, δ): 
5.74 (CH2CH=CH2), 4.88 (CH2CH=CH2), 3.58 (NHCH2CH(OH)CH2), 2.60 
(NCH2CH2CH2NH), 2.40 (NCH2CH2CH2NH), 1.98 (CH2CH=CH2), 1.60 
(NCH2CH2CH2NH), 1.2–1.4 ((CH2)5CH2CH=CH2 ). 13C NMR (400 MHz, CD3OD, δ): 
140.0, 116.1, 70.5, 56.5, 52.4, 47.2, 39.2, 33.9, 30.2, 25.6, 24.9.  
2.2.5 Synthesis of Diazeniumdiolate-Functionalized PPI Dendrimers.  
One equivalent of 5.4 M sodium methoxide solution in methanol (e.g., with respect to 
the molar amount of primary amine functionalities in PPI-NH2 used to synthesize these 
secondary amine-functionalized PPI) was added to a vial containing G1 to G5 secondary 
amine-functionalized PPI dendrimers in methanol (2 mL), The resulting reaction solution 
was charged with 10 atm of NO while stirring in a stainless steel reactor. Prior to 
charging with NO, the reactor was flushed three times with argon followed by a series of 
three longer charge/discharge cycles with argon (3  10 min) to remove oxygen from the 
stirring solutions. The reactor was then filled with 10 atm of NO (purified over KOH 
pellets for 30 min to remove trace NO degradation products) at ambient temperature. 
After 3 days, the NO was expunged using the same charge/discharge procedures 
described above with argon to remove unreacted NO from the reaction solution. 
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2.2.6 Characterization of NO Storage and Release.  
Aliquots (~10–25 L) of diazeniumdiolate-functionalized PPI as a solution in 
methanol (e.g., ~7–200 mM) were added to 30 mL deoxygenated phosphate buffered 
saline (PBS) (10 mM, pH = 7.4) at 37 °C to initiate NO release. Nitrogen was flowed 
through the solution at a flow rate of 70 mL/min to carry the liberated NO to the analyzer. 
Additional nitrogen flow was supplied to the flask to match the collection rate of the 
instrument at 200 mL/min. Nitric oxide analysis was terminated when levels decreased to 
10 ppb NO/mg dendrimer. Chemiluminescence data for the NO-releasing dendrimers 
were represented as: i) total amount of NO release (t[NO], µmol NO/mg and µmol 
NO/µmol of secondary amine-functionalized dendrimers); ii) maximum flux of NO 
release ([NO]max, ppb/mg of secondary amine-functionalized dendrimers); iii) half-life 
(t1/2) of NO release; and, iv) conversion efficiency defined as percentages of amine 
functionalities in PPI (e.g., from G1 to G5) converted to diazeniumdiolate functionality 
(e.g., total moles of NO release divided by twice the molar amount of primary amine 
functionalities in PPI-NH2 used initially to synthesize secondary amine-functionalized 
dendrimer conjugates).  
2.3 Results and Discussion 
2.3.1 Synthesis and Characterization of Secondary Amine-Functionalized PPI 
Dendrimers 
 
Stasko et al. previously reported an approach whereby secondary amine-
functionalized PPI conjugates were reacted with NO at high pressure to form NO-
releasing dendritic scaffolds with large NO storage capacity47. Analogously, primary 
amine-functionalized PPI dendrimers were characterized by significantly less NO storage 
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and shorter NO release durations. These results suggest that the structural features of the 
dendrimer are critical in the design of diazeniumdiolate-functionalized scaffolds. Since 
chemical reaction of primary amine functionalities with organic compounds represents a 
simple approach for designing secondary amine-functionalized PPI conjugates, we 
targeted the synthesis of secondary amine-functionalized dendrimers using ring-opening 
and conjugate-addition reactions of PPI-NH2 with PO, SO, ED, ACN, and PEG (Scheme 
2.1) to fully unlock a series of dendrimer scaffolds with diverse exterior properties (e.g., 
aromatic, hydrophilic, hydrophobic). Indeed, the epoxides, acrylated and acrylonitrile 
selected for conjugation were based on sterics, hydrophobicity, and biocompatibility. Of 
note, it is also possible to yield tertiary amine adducts. In addition, we carried out a series 
of model kinetic studies using NMR spectroscopy for conjugate-addition reactions of first 
generation G1-PPI-NH2 with ACN and ring-opening reactions of HDA with PO to 
determine the suitability of conjugate-addition and ring-opening reactions for the 
synthesis of secondary amine-functionalized PPI dendrimers. 
The results of these studies revealed large differences in the rates of reactions of G1-
PPI-NH2 with ACN (i.e., k1=1.75 M-1 s-1, k2=0.009 M-1 s-1), and HDA with PO (i.e., 
k1=0.13 M-1 s-1, k2=0.065 M-1 s-1). The rate constants of the first conjugate-addition or 
ring-opening reaction (k1) were substantially larger than those of the second reactions (k2), 
providing strong support for the use of such reactions (e.g., over a period of four days, in 
a dilute solution, and at one equivalent of ACN, epoxides, or acrylates with respect to 
molar amount of PPI-NH2) to yield secondary amine-functionalized products suitable for 
subsequent NO release studies. 
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Scheme 2.1 Synthesis of secondary amine- and diazeniumdiolate-functionalized PPI 
conjugates for which n represents the number of primary amines on the periphery of PPI 
dendrimers (n = 8, 16, 32, 64). 
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2.3.2 Influence of Exterior Functionality on Nitric Oxide Release 
The approach described above is based on dendrimer functionalization at their 
exterior to yield secondary amine-functionalized PPI dendrimers. Two practical 
advantages of this approach include that the synthesis is simple and the resulting 
structurally diverse exteriors greatly expand the potential applications for which these 
materials may find utility. Reactions of secondary amine-functionalized PPI (e.g., from 
G2 to G5) with NO under basic conditions (e.g., sodium methoxide) yielded N-
diazeniumdiolate NO donor-functionalized dendrimers with diverse NO release 
characteristics.  
Chemiluminescence was used to characterize the NO storage and release properties 
(e.g., in PBS, pH = 7.4, 37 °C) for the N-diazenuimdiolate-modified PPI dendrimers. 
Representative NO release profiles for these dendrimers are shown in Figure 2.1. The 
workup of specific NO release parameters (e.g., total NO release, maximum flux, half-
life, and conversion efficiency) are provided in Table 2.1. In general, the NO release 
results reveal high NO storage capabilities (e.g., 0.9–3.8 µmol NO/mg) and a broad range 
of release kinetics (e.g., NO release half-life from 0.3–4.9 h). Further inspection of these 
data reveals that the conversion efficiencies (e.g., 10–40%) of the dendrimers varied 
substantially based on the chemical modification. As shown in Table 2.1,  
G2 to G5-PPI-SO (d-NO) were characterized by lower NO donor formation (e.g., 
~10–15%) versus the other PPI dendrimers (e.g., ~14–40%). The lower conversion 
efficiencies for PPI-SO (d-NO) may be attributed to a more sterically-hindered 
environment around the NO donor precursors (i.e., secondary amines), resulting in lower 
NO and base accessibility to the amines during the NO charging process. 
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The exterior modification also influenced the NO release kinetics. For example, both 
PPI-PO (c-NO) and PPI-PEG (b-NO) released NO rapidly (Table 2.1 and Figure 2.1). 
Such rapid NO release kinetics might be expected since the isopropyl and PEG groups 
are hydrophilic and facilitate water solvation favorable to diazeniumdiolate NO donor 
degradation. The data also indicate that the NO release half-lives for G2-G5 PPI-SO (d-
NO) and PPI-ED (e-NO) are slightly longer than PPI-PO (c-NO) and PPI-PEG (b-NO). 
The longer NO release for PPI-SO (d-NO) and PPI-ED (e-NO) correlates well with the 
increased hydrophobic structure at the exteriors of these dendrimers.  
The ACN modification for PPI dendrimer (a-NO) exhibited large NO storage (e.g., 
~1.7–3.6 µmol NO/mg) and conversion efficiency (e.g., ~14–26%)  (Table 2.1). Of note, 
past studies have indicated that the reaction of cyano-containing compounds with NO at 
high-pressures under basic conditions may yield C-diazeniumdiolate-functionalized 
products. Both NO and nitrous oxide (N2O) may be release from C-diazeniumdiolates in 
aqueous environments at low pH.49-51 In this context, it may be possible that the high 
conversion efficiencies for PPI-ACN (a-NO) arise from the contribution of NO released 
from C-diazeniumdiolate-functionalized products. 
A series of experiments were thus carried out to probe the nature of the NO release 
from PPI-ACN (a-NO) using G0.5-PPI, a cyano-containing compound without the 
capacity to form N-diazeniumdiolate due to the absence of secondary amines. The NO 
release from G0.5-PPI was ~4.5×10-3 µmol NO/mg, providing strong support that the 
high NO storage and conversion efficiency for the ACN-modified dendrimers are indeed 
the result of N-diazeniumdiolate functionalization. The PPI-ACN (a-NO) analogues were 
also characterized as having the longest NO release half-lives (e.g., ~5 h).  
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Table 2.1 Nitric oxide release characteristics for PPI dendrimers in PBS (pH = 7.4) at 
37 °C. 
Dendrimer t[NO] (μmol NO/mg)a 
t[NO] 
(µmol NO/µmol)b 
[NO]max 
(ppb/mg)c 
[NO]max 
(ppb/mol)d 
t½ 
(h) 
Conversion 
(%) 
 G2-PPI-ACN-NO 3.57 4.18 1529 1788 4.81 26.1 
 G3-PPI-ACN-NO 3.33 8.35 1100 2758 4.84 26.1 
 G4-PPI-ACN-NO 2.45 12.7 1547 7977 4.82 19.9 
 G5-PPI-ACN-NO 1.68 17.7 881 9282 4.88 13.8 
 G2-PPI-PEG-NO 1.11 5.10 3771 17291 0.67 31.9 
 G3-PPI-PEG-NO 1.08 10.1 2309 21564 1.11 31.6 
 G4-PPI-PEG-NO 1.37 25.8 4088 77035 0.84 40.3 
 G5-PPI-PEG-NO 1.17 44.3 1886 71403 1.22 34.6 
 G2-PPI-PO-NO 2.99 3.63 17130 20725 0.30 22.7 
 G3-PPI-PO-NO 3.22 8.38 9617 24888 0.62 26.2 
 G4-PPI-PO-NO 3.27 17.5 7762 41481 0.78 27.3 
 G5-PPI-PO-NO 3.78 41.1 6839 74250 1.06 32.1 
 G2-PPI-SO-NO 1.14 1.95 8495 14496 1.47 12.2 
 G3-PPI-SO-NO 0.91 3.30 2363 8462 0.97 10.3 
 G4-PPI-SO-NO 1.18 8.70 1720 12609 1.43 13.6 
 G5-PPI-SO-NO 1.25 18.5 2215 32843 1.62 14.5 
 G2-PPI-ED-NO 1.95 3.87 5648 11178 0.81 24.2 
 G3-PPI-ED-NO 1.64 6.75 2733 11279 1.71 21.1 
 G4-PPI-ED-NO 1.51 12.8 2401 20217 1.34 19.9 
 G5-PPI-ED-NO 1.86 31.6 3190 54262 1.88 24.7 
 
a total amount of NO release (μmol) per milligram of secondary amine-functionalized PPI. b total amount of 
NO release (μmol) per micromole of secondary amine-functionalized PPI. c maximum flux of NO release 
(ppb) per milligram of secondary amine-functionalized PPI. d maximum flux of NO release (ppb) per 
micromole of secondary amine-functionalized PPI. 
 
 
 
 
 
56 
 
 
 
  
Figure 2.1 (A) Real time NO release profile for NO-releasing G4-PPI dendrimer 
conjugates; and (B) plot of t[NO] vs time for NO-releasing PPI dendrimer conjugates. 
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Given the hydrophilic nature of the cyano functionality, the extended NO release is 
not attributable to water uptake. For example, the long half-lives of N-diazeniumdiolate-
functionalized small molecule derivatives (e.g., dipropylenetriamine or DPTA-NO) have 
previously been attributed to diazeniumdiolate stabilization by neighboring cationic 
ammonium functionalities as depicted in Figure 2.2A.45,52,53 In this manner, the presence 
of neighboring cationic functionalities (e.g., protonated imidates) for PPI-ACN (a-NO) 
dendrimers may provide additional stabilization to the diazeniumdiolate functionality 
(Figure 2.2B). Since sodium methoxide was used as the base for the reaction of PPI-ACN 
(a) with NO (to yield diazeniumdiloate-functionalized products), the methoxide anion 
may also serve as a nucleophile to react with the cyano group in PPI-ACN (a) and yield 
imidate adducts.54 The transfer of proton from solvent (e.g., methanol) to the relatively 
basic nitrogen atom in the resulting imidates might thus lead to protonated-imidate 
functionality (Figure 2.2B) that is similar to cationic ammonium functionality in DPTA-
NO (Figure 2.2A).  
As shown in Table 2.1, both the NO storage and maximum NO flux per dendrimer 
molecule increased as a function of dendrimer size (i.e., generation). For example, the 
NO payload from G5-PPI-PO-NO (c-64-NO) was 41.1 μmol/μmol dendrimer, much 
greater than G2-PPI-PO-NO (c-8-NO) (e.g., 3.63 μmol/μmol dendrimer). A similar trend 
is observed for maximum NO flux. These results reveal the capability of larger NO-
releasing PPI dendrimers to deliver significant concentrations of NO, a potentially 
beneficial attribute for therapeutic anti-microbial and anti-cancer applications. 
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Figure 2.2 Proposed structures for stabilization of (A) diazeniumdiolate-functionalized 
DPTA by neighboring cationic ammonium functionality, and (B) PPI-ACN (a-NO) by 
neighboring cationic protonated-imidate functionality. 
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2.3.3 Effect of Solvent for NO Conjugation 
As synthesized, the amphiphilic secondary amine-functionalized dendrimers (e.g., 
PPI-SO, PPI-ED) possess a hydrophilic PPI core and hydrophobic periphery of aromatic 
rings or long alkyl chains. Different from PPI-ACN, PPI-PO and PPI-PEG, these 
amphiphilic dendrimers may have more packed exterior in the charging solvent due to the 
poor compatibility of the aromatic rings or long alkyl chains with polar solvent (e.g., 
methanol). We thus sought to investigate the role of charging solvent on NO donor 
formation efficiency using mixtures of methanol with less polar solvent (e.g., 
methanol/THF (9:1, v/v), methanol/toluene (9:1, v/v) and methanol/toluene (1:1, v/v)). 
As shown in Figure 2.3, the NO release data reveals an adverse effect of toluene and THF 
on NO conjugation to PPI-SO dendrimers. Compared to toluene, use of THF 
compromised the NO storage to a larger extent. The lower NO conjugation efficiency 
may be the result of the PPI dendrimer core collapsing in the mixture of methanol and 
less polar solvents (e.g., toluene and THF). Indeed, this hypothesis is supported by 
dynamic light scattering data (data not shown). In turn, the dendrimer backbone collapse 
likely contributes to a greater steric hindrance around the secondary amines and 
concomitant lower NO conjugation efficiency. 
2.3.4 Characterization of PPI Conjugates Synthesized from Defined Mixtures of PO 
and ACN 
 
To evaluate the ability to define NO release, we designed multi-functionalized N-
diazeniumdiolate-functionalized dendrimer conjugates using G5-PPI-NH2 and defined 
ratios of PO and/or ACN during the functionalization step. Specifically, G5-PPI-NH2 was 
reacted with either PO exclusively (e.g., c-64), ACN exclusively (e.g., a-64), or three  
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Figure 2.3 (A) Real time NO release profile and (B) plot of t[NO] vs time for G4-PPI-
SO-NO synthesized in different NO conjugation solvents. 
 
 
A
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
0
200
400
600
800
1000
1200
1400
1600
1800
2000
N
O
 r
el
ea
se
 (p
pb
/m
g)
 Methanol
 Methanol/Toluene (9:1)
 Methanol/Toluene (1:1)
 Methanol/THF (9:1)
Time (h)
B
0 5 10 15 20 25 30
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
To
ta
l N
O
 r
el
ea
se
 (
m
ol
/m
g)
Time (h)
 Methanol
 Methanol/Toluene (9:1)
 Methanol/Toluene (1:1)
 Methanol/THF (9:1)
61 
 
different mixtures comprised of PO and ACN at molar ratios of 3:7, 5:5, and 7:3, 
respectively; the PO, ACN, or defined mixtures of PO and ACN were one equivalent 
with respect to molar amount of primary amine functionalities in G5-PPI-NH2. A series 
of 1H NMR experiments were carried out on the products of these reactions to determine 
the actual compositions of PO and ACN conjugated to the G5-PPI-NH2 (Figure 2.4). A 
distinct resonance at 1.10 ppm was apparent corresponding to the methyl protons in the 
isopropyl group of the products. The chemical shift of this peak was noted in the products 
for reactions with PO exclusively (e.g., c-64) and those with different mixtures of PO and 
ACN. Further inspection of these data indicates the presence of a second distinct peak at 
2.80 ppm, formed upon G5-PPI-NH2 dendrimer reaction with either ACN exclusively 
(e.g., a-64) or defined mixtures of PO and ACN; this peak corresponds to the methylene 
protons one carbon away from the cyano group of the products. The compositions of PO 
and ACN incorporated in the products were 27/73 (c/a (27/73)), 40/60 (c/a (40/60)), and 
60/40 (c/a (60/40)), and indicate that the ACN was incorporated at ratios greater than that 
in the reaction mixtures likely due to more rapid reaction of G5-PPI-NH2 with ACN 
versus PO.  
The NO release from the G5-PPI-PO/ACN conjugates at PO/ACN molar ratios of 
27/73, 40/60, and 60/40, respectively, were intermediate to those synthesized based upon 
G5-PPI-NH2 reactions with either PO (e.g., c-64) or ACN (e.g., a-64) alone. Furthermore, 
the NO release profiles were influenced by the molar ratio of PO/ACN composition. For 
instance, the NO release was prolonged for the PPI conjugates modified with lower molar 
ratio of PO/ACN (half-lives of 2.90, 1.57, and 1.10 h for 27/73, 40/60, and 60/40, 
respectively) (Figure 2.5). A mathematical model was developed to predict the NO 
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release from hybrid G5-PPI-PO/ACN conjugates using the NO release data from the 
single G5-PPI-PO (c-64) and G5-PPI-ACN (a-64) systems. In Equation 2.1, a:b is the 
molar ratio of the PO and ACN modification in the hybrid G5-PPI-PO/ACN conjugate as 
determined by NMR spectroscopy, while yPO and yACN represent the normalized NO 
release profiles of the G5-PPI-PO (c-64) and G5-PPI-ACN (a-64) systems, respectively. 
Simulated NO release from a hybrid G5-PPI-PO/ACN conjugate (ya:b) was thus derived 
by averaging the normalized NO release from G5-PPI-PO (c-64) (yPO) and G5-PPI-ACN 
(a-64) (yACN) weighted with respect to the mole percentages of PO (i.e., [a/(a+b)]  
100%) and ACN (i.e., [b/(a+b)]  100%) modification in the hybrid G5-PPI-PO/ACN 
conjugate.  
                                                             Eq.2.1 
As shown in Figure 2.5, the simulated NO release from G5-PPI-PO/ACN conjugates 
were comparable with the experimental data, even though the experimental hybrid PPI 
conjugates were characterized by slightly faster NO release (e.g., NO release half-lives of 
3.13, 2.42, and 1.65 h for c/a (27/73), c/a (40/60), and c/a (60/40), respectively). 
Nevertheless, the developed mathematical model appears to be well suited for simulating 
dual NO release kinetics using NO release data from single NO donor systems. For 
dendrimers, these results demonstrate that functionalization of PPI-NH2 with a defined 
mixture of PO and ACN allows for precise NO release selection with access to NO 
release kinetics that are intermediate to those formed upon reactions with one NO donor 
type exclusively.  
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Figure 2.4 1H NMR spectra of G5-PPI-PO (c-64) (A), G5-PPI-ACN (a-64) (E), G5-PPI-
PO/ACN at molar ratios of 7:3 (B), 5:5 (C), and 3:7 (D). The actual compositions of PO 
and ACN incorporated into these three PPI conjugates are at molar ratios of 27/73 (B), 
40/60 (C), and 60/40 (D), respectively, as determined by integrating two chemical shifts 
at 1.10 and 2.80 ppm. 
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Figure 2.5 (A) Experimental plot of percent total NO released in PBS (pH = 7.4) at 37 ºC 
as a function of time for G5-PPI-PO (c-NO), G5-PPI-ACN (a-NO), and G5-PPI-PO/ACN 
conjugates; (B) Simulated plot of percent total NO released for G5-PPI-PO/ACN 
conjugates. 
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2.4 Conclusions 
To expand the utility of macromolecular NO-release scaffolds as stand-alone 
therapeutics, dopants for biomedical polymers, or general NO-release sources, we 
synthesized a series of diverse NO-releasing PPI dendrimers by straightforward chemical 
modification of the core dendrimer using conjugation addition (ACN and PEG) or ring 
opening (PO, ED, and SO) reactions. The NO release from these resulting dendrimers 
demonstrated that size (i.e., generation number or molecular weight) and exterior 
structures (e.g., steric environment, hydrophobicity, etc.) play important roles in NO 
release kinetics. Furthermore, the use of select NO donors with unique NO release 
kinetics and overall payloads may be exploited by multi-NO donor/dendrimer 
functionalization. The combination of structural diversity and achievable NO release (i.e., 
up to 3.8 μmol NO/mg with half-lives from 0.3–4.9 h) should prove useful in the further 
study and utilization of these NO release materials for a broad range of fundamental and 
applied applications including pharmacological agents.  
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Chapter 3 
     Nitric Oxide-Releasing Amphiphilic Poly(amidoamine) (PAMAM)  Dendrimers 
as Anti-biofilm Agents 
 
3.1 Introduction 
Bacteria in nature exist in two states – free-floating planktonic bacteria and 
bacterial biofilms.1 While many antimicrobial agents have proven effective against 
planktonic bacteria, medically relevant infections including those associated with medical 
implants, diabetes mellitus, and cystic fibrosis are often caused by bacterial biofilms.1-3 In 
contrast to planktonic bacteria, biofilms are communities of microorganisms adhered to a 
surface and protected by a self-secreted exopolysaccharides (EPS) matrix.4 Along with 
inhibiting the penetration of antibiotics, biofilms exhibit several other defense 
mechanisms such as overexpression of stress-responsive genes, oxygen gradients within 
the biofilm matrix, and differentiation of a subpopulation of biofilm bacteria into resistant 
dormant species.4 Collectively, these effects result in greater resistance of bacteria within 
biofilms to antimicrobial agents compared to their planktonic counterparts.  It has been 
shown that killing bacteria in biofilms may require up to 1000 times the antibiotic dose 
necessary for killing planktonic bacteria.1 As such, new antimicrobial agents capable of 
eradicating mature biofilms are urgently needed. 
Dendrimers, a family of macromolecular scaffolds with hyper-branched 
architectures and multivalent surfaces,5-13 have exhibited antibacterial activity against 
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both planktonic bacteria14-18 and biofilms.19-21 For example, quaternary ammonium-
functionalized poly(propylenimine) (PPI) dendrimers15 and primary amine-functionalized 
poly(amidoamine) (PAMAM) dendrimers14 were shown to be biocidal against planktonic 
Pseudomonas aerugionsa and Staphylococcus aureus. Unfortunately, the inherent 
toxicity of these materials to eukaryotic (e.g., mammalian) cells has slowed their 
development as therapeutics.22 To reduce overall toxicity to mammalian cells, Grinstaff 
et al. synthesized anionic amphiphilic polyester dendrimers that were potent against 
Gram-positive Bacillus subtilis but not human umbilical vein endothelial cells 
(HUVECs).16 Likewise, hydroxyl-, carboxyl-, and poly(ethylene glycol) (PEG)-
functionalized PAMAM dendrimers have been designed to minimize toxicity towards 
mammalian cells while retaining their antibacterial efficacy against bacterial species.17, 23 
Although most work to date has focused on the planktonic antibacterial activity of 
dendrimers, the efficacy of dendritic scaffolds against more challenging systems, 
including antibiotic-resistant bacteria and biofilms, has become an important focus in the 
design of antimicrobial dendrimers.  Several studies have demonstrated the dispersion 
and inhibition of Pseudomonas aeruginosa and Escherichia coli biofilms by amphiphilic 
dendritic glycopeptides.19-21, 23 As opposed to linear antimicrobial peptides, these 
dendritic peptides exhibited enhanced inhibition of biofilm growth.19 However, additional 
work is required to elucidate the potential of dendrimers as effective agents for both 
inhibiting biofilm growth and eradicating mature biofilms.  
Nitric oxide (NO), an endogenously-produced diatomic free radical, plays a key role 
in the natural immune response to pathogens.24-26 Both NO and its reactive byproducts 
(e.g., peroxynitrite and dinitrogen trioxide) exert significant oxidative and nitrosative 
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stress on bacterial cells to facilitate killing. Nitrosative stress occurs when thiols on 
proteins and DNA are nitrosated, impairing normal function. Oxidative stress is mostly 
observed through lipid peroxidation, which destroys the bacterial membrane integrity.26 
Nitric oxide exhibited broad-spectrum antimicrobial efficacy and its short-lived nature 
allows for local bactericidal action.26 As such, macromolecular vehicles (e.g., gold 
nanoparticles, silica nanoparticles, and dendrimers) have been developed to store and 
controllably release NO.27-31 These materials have proven highly effective against both 
Gram–positive and –negative bacteria.32-35 Nitric oxide-releasing dendrimes in particular 
have exhibited highly promising bactericidal action due to large NO payloads and 
dendrimer–bacteria association.33 The biocidal activity of NO-releasing dendrimers was 
found to be highly dependent on both the size (i.e., generation) and the exterior 
functionality with hydrophobic functionalizations (e.g., via  styrene oxide modification of 
primary amines) proving most effective against Gram-positive and –negative bacteria.33 
Unfortunately, the utility of these dendrimers for eradicating established biofilms 
presents toxicity concerns due to the larger concentration required (vs. planktonic assays) 
membrane disrupting properties of the hydrophobic exterior.36 Herein, we report the 
synthesis of NO-releasing amphiphilic dendrimers with varied exterior hydrophobicity as 
a new class of anti-biofilm agents capable of eradicating bacterial biofilms with reduced 
toxicity to mammalian cells. 
3.2 Experimental Section 
3.2.1 Materials.  
Phenazine methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), trypsin, 
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phosphate buffered saline (PBS), penicillin streptomycin (PS), rhodamine B 
isothiocyanate (RITC), Dulbecco's modified Eagle's medium (DMEM), and propidium 
iodide (PI) were purchased from Sigma-Aldrich (St. Loius, MO). Sodium methoxide (5.4 
M solution in methanol), propylene oxide (PO), and 1,2-epoxy-9-decene (ED) were 
obtained from Acros Organics (Geel, Belgium). Tryptic soy broth (TSB) and tryptic soy 
agar (TSA) were obtained from Becton, Dickison and Company (Franklin Lakes, NJ). 
Spectra/Por Float-A-Lyzers for dialysis of the dendrimers were purchased from Spectrum 
Laboratories, Inc. (Rancho Dominguez, CA). 4,5-Diaminofluorescein diacetate (DAF-2 
DA) was purchased from Calbiochem (San Diego, CA). Syto 9 green fluorescent nucleic 
acid stain was purchased from Life Technologies (Grand Island, NY). Glass bottom 
microscopy dishes were received from MatTek Corporation (Ashland, MA). Common 
laboratory salts and solvents were purchased from Fisher Scientific (Pittsburgh, PA). 
Unless noted otherwise, these and other materials were used as received without further 
purification. 
3.2.2 Synthesis of Secondary Amine- and N-Diazeniumdiolate-Functionalized 
PAMAM Dendrimers.  
Secondary amine-functionalized PAMAM dendrimers (generation 1 or G1 and 
generation 3 or G3) were synthesized as described previously.27 Briefly, primary amine-
functionalized G1-PAMAM dendrimer (100 mg) was dissolved in methanol (2 mL). One 
molar equivalent of PO, ED, or a mixture of PO and ED relative to the primary amines 
was then added to the G1-PAMAM-NH2 solution under constant stirring at room 
temperature for 4 d to yield the secondary amine-functionalized G1-PAMAM conjugates. 
Similarly, secondary amine-functionalized G3-PAMAM conjugates were formed via the 
reaction of G3-PAMAM-NH2 with PO, ED, or a mixture of PO and ED, respectively. 
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Following 3 d of reaction, solvent was removed under reduced pressure. The dendrimers 
were then washed with ethanol, followed by dialysis against water and lyophilization. 
The resulting secondary amine-functionalized dendrimers (G1 and G3) were 
characterized by nuclear magnetic resonance (NMR) spectroscopy in deuterated 
methanol. 
Representative 1H NMR data of secondary amine-functionalized G1-PAMAM 
conjugates formed via the reactions of G1-PAMAM-NH2 with PO, ED and PO/ED 
mixtures yielded the following peaks: G1-PAMAM-PO: 1H NMR (400 MHz, CD3OD, 
δ): 3.82 (CH2NHCH2CH(OH)CH3), 3.10–3.20 (CONHCH2CH2), 2.75 
(CH2N(CH2CH2CO)2), 2.60 (CH2NHCH2CH(OH)CH3), 2.55 (CH2N(CH2CH2CO)2), 2.37 
(CH2N(CH2CH2CO)2), 1.00 (CH2NHCH2CH(OH)CH3). G1-PAMAM-ED: 1H NMR 
(400 MHz, CD3OD, δ): 5.80 (CH2CH=CH2), 4.88 (CH2CH=CH2),  3.58 
(NHCH2CH(OH)CH2), 3.10–3.20 (CONHCH2CH2),  2.73 (CH2N(CH2CH2CO)2),  2.67 
(NH(CH2)2), 2.55 (CH2N(CH2CH2CO)2),  2.36 (CH2N(CH2CH2CO)2), 1.98 
(CH2CH=CH2), 1.2–1.4 (CH2)5CH2CH=CH2). G1-PAMAM-PO/ED: 1H NMR (400 
MHz, CD3OD, δ): 5.80 (CH2CH=CH2), 4.88 (CH2CH=CH2), 3.82 
(CH2NHCH2CH(OH)CH3), 3.58 (NHCH2CH(OH)CH2), 3.10–3.20 (CONHCH2CH2), 
2.75 (CH2N(CH2CH2CO)2), 2.60 (CH2NHCH2CH(OH)CH3), 2.55 (CH2N(CH2CH2CO)2), 
2.37 (CH2N(CH2CH2CO)2), 1.98 (CH2CH=CH2), 1.2–1.4 (CH2)5CH2CH=CH2), 1.00 
(CH2NHCH2CH(OH)CH3).  
N-diazeniumdiolate-functionalized PAMAM dendrimers were synthesized by adding 
one equivalent of 5.4 M sodium methoxide solution in methanol (with respect to the 
molar amount of primary amine functionality in PAMAM-NH2 used to synthesize 
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dendrimers) to a vial containing dendrimers (100 mg) in methanol (1 mL). The glass vials 
were then inserted in a stainless steel reactor, and the headspace in the reactor was 
subsequently flushed with argon three times followed by three longer purges with argon 
(3  10 min) to remove oxygen from the stirred solution. The reactor was then filled with 
NO (purified over KOH pellets for 30 min to remove trace NO degradation products) to 
10 atm for 3 d. Unreacted NO was then removed using the same argon flushing procedure 
described above to obtain the N-diazeniumdiolate-modified PAMAM dendrimers. 
3.2.3 Characterization of NO Storage and Release.  
Nitric oxide release was measured using a Sievers 280i Chemiluminesce Nitric Oxide 
Analyzer (Boulder, CO) by adding NO-releasing dendrimers (1 mg) to a sample 
containing deoxygenated PBS (30 mL) (pH = 7.4, 37 oC).  Nitrogen was purged through 
the sample vessel solution to carry liberated NO to the analyzer at a flow rate of 70 
mL/min. Additional nitrogen flow was supplied to the vessel to match the collection rate 
of the analyzer (200 mL/min). Nitric oxide release was measured in real time, thus 
allowing for the determination of NO release total (t[NO]), half-life (t1/2), and maximum 
NO flux ([NO]max). The analysis was terminated when the NO release levels fell to below 
10 ppb NO/mg dendrimer.  
3.2.4 Planktonic Bactericidal Assays Under Static Conditions.  
Bacterial cultures were grown from a frozen (-80 oC) stock overnight in TSB at 37 oC. 
A 500 μL aliquot of the resulting suspension was added to fresh TSB (50 mL) and 
incubated at 37 oC for ~2 h until the concentration reached 1×108 colony forming units 
(CFU)/mL, as confirmed by the OD600. A working bacterial stock was generated by 
plating the bacterial suspension on TSA and incubating at 37 oC overnight. Subsequent 
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TSA bacterial stocks were prepared weekly and stored at 4 oC. For bactericidal assays, 
colonies of P. aeruginosa were taken from the TSA plate, dispersed in TSB (3 mL), and 
then incubated at 37 oC overnight. A 500 μL aliquot of culture was added to fresh TSB 
(50 mL) and incubated to a concentration of ~1×108 CFU/mL. The bacteria was then 
collected by centrifugation (3645  g for 10 min), resuspended in PBS, and diluted 100-
fold to obtain a final concentration of 1×106 CFU/mL. The bactericidal efficacy of NO-
releasing dendrimers against the bacteria was evaluated by incubating the bacteria 
suspension with NO-releasing dendrimers over a range of concentrations in PBS at 37 oC. 
At 4 h, 100 μL aliquots of the bacteria suspensions were removed, diluted 10-fold in PBS, 
plated on TSA, and incubated overnight at 37 oC. The minimum concentration of NO-
releasing dendrimers that resulted in a 3-log reduction in bacterial viability was defined 
as the planktonic minimum bactericidal concentration (MBC). 
3.2.5 Growth of P. aeruginosa Biofilms.  
A standard US centers for disease control (CDC) bioreactor (Biosurface Technologies, 
Bozeman, MT) was used to grow P. aeruginosa biofilms over a 48 h period. Briefly, 
medical grade silicone rubber substrates were mounted in coupon holders prior to 
assembling the reactor. The assembled reactor was then autoclaved. The reactor effluent 
line was clamped and 1% (v/v) sterile TSB (500 mL) was added aseptically. 
Subsequently, the reactor was inoculated with an aliquot (1 mL) of P. aeruginosa (108 
CFU/mL in TSB) to achieve a final concentration ~2 × 105 CFU/mL. The reactor was 
then incubated at 37 °C for 24 h with stirring (150 rpm). Following this “batch phase” 
growth, the reactor media was refreshed continuously with 0.33% (v/v) TSB at 6 mL/min 
for another 24 h.    
78 
 
3.2.6 Treatment of P. aeruginosa Biofilms with NO-releasing Dendrimers.  
P. aeruginosa biofilms grown on silicone rubber substrates were exposed to 
dendrimers in PBS with slight agitation (37 °C, 24 h) to determine the minimum 
bactericidal concentration (MBC) necessary to elicit a 5-log reduction in viability of the 
biofilm-based bacteria. At 24 h, samples were sonicated and vortexed to disrupt the 
biofilm. Aliquots (100 µL) of the cell/dendrimer suspensions were diluted and plated on 
TSA and incubated overnight. Bacterial viability was determined by counting observed 
colonies. Of note, the limit of detection for this selected plate counting method is 2.5 × 
103 CFU/mL. As such, biofilm growth conditions were selected to accurately represent a 
5-log reduction in viability. 
3.2.7 In vitro Cytotoxicity.  
L929 mouse fibroblasts were grown in DMEM supplemented with 10% (v/v) fetal 
bovine serum (FBS) and 1 wt% penicillin/streptomycin, and incubated in 5% (v/v) CO2 
under humidified conditions at 37 oC. After reaching confluency (80%), the cells were 
trypsinized, seeded onto tissue-culture treated polystyrene 96-well plates at a density of 
3×104 cells/mL, and incubated at 37 oC for 48 h. The supernatant was then aspirated prior 
to adding 200 μL fresh DMEM and 50 μL of NO-releasing dendrimers in PBS to each 
well. After incubation at 37 oC for 24 h, the supernatant was aspirated and a 120 μL 
mixture of DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well. The absorbance 
of the resulting colored solution after 1.5 h incubation at 37 oC was quantified using a 
Thermoscientific Multiskan EX plate reader at 490 nm. The mixture of 
DMEM/MTS/PMS and untreated cells were used as a blank and control, respectively. 
Cell viability was calculated as follows (Eq. 3.1): 
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Cell Viability ൌ  ሺ Absorbance୲୰ୣୟ୲ୣୢ ୡୣ୪୪ െ Absorbanceୠ୪ୟ୬୩ሻሺ Absorbance୳୬୲୰ୣୟ୲ୣୢ ୡୣ୪୪ െ Absorbanceୠ୪ୟ୬୩ሻ                  Eq. 3.1 
3.2.8 Confocal Microscopy for Association of Dendrimers with Bacteria Cells.  
Fluorescently-labeled control and NO-releasing dendrimers were prepared following 
a previously reported procedure.33 Briefly, G1-PAMAM-NH2 (100 mg) and rhodamine B 
isothiocyanate (RITC) (3 mg) were dissolved in 2 mL methanol. The solution was stirred 
for 3 d in the dark. The product solution was dialyzed against 0.1 M NaCl (2 L) for 24 h, 
and ultrapure Milli-Q water for 3 d (3 × 2 L). Subsequent lyophilization yielded RITC-
labeled G1-PAMAM-NH2. The fluorescently-labeled G1-PAMAM-NH2 dendrimers were 
modified with one molar equivalent of PO or ED alone, or a PO/ED mixture, and further 
reacted with NO at 10 atm under basic conditions as described above to yield NO-
releasing G1-PAMAM dendrimers. P. aeruginosa was cultured in TSB to a concentration 
of 1 × 108 CFU/mL, collected via centrifugation (3645  g for 10 min), resuspended in 
sterile PBS, and adjusted to 1 × 106 CFU/mL. Aliquots of the bacteria solution were 
incubated in a glass bottom confocal dish for 2 h at 37 °C. A Zeiss 510 Meta inverted 
laser scanning confocal microscope with a 543 nm HeNe excitation laser and a LP 585 
nm filter was used to obtain fluorescence images of the RITC-modified dendrimers. The 
bright field and fluorescence images were collected using a N.A. 1.2 C-apochromat water 
immersion lens with a 20× objective. Solutions of RITC-labeled NO-releasing (400 
μg/mL) dendrimers in PBS (1.5 mL) were added to the bacteria solution (1.5 mL) in the 
glass confocal dish to achieve a final concentration of 200 μg/mL. Images were collected 
at 2 h incubation to characterize the association, if any, of the dendrimers with P. 
aerugionsa. Dendrimer–bacteria association within biofilms was also characterized using 
confocal microscopy. Established biofilms stained with Syto 9 (10 µM) were incubated 
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with RITC-labeled NO-releasing dendrimers (50 µg/mL) for 1 h before imaging. A 488 
nm Ar excitation laser with BP 505-530 nm filter was used to image Syto 9 fluorescence. 
The bright field and fluorescence images were collected simultaneously using a N.A. 1.2 
C-apochromat water immersion lens with a 10× objective. 
3.2.9 Confocal Microscopy for the Detection of Intracellular NO and Cell Death.  
The efficiency of NO delivery and resulting bacteria death were evaluated as a 
function of dendrimer exterior hydrophobicity using confocal microscopy. Bacteria (P. 
aeruginosa) were cultured in TSB to a concentration of 1 × 108 CFU/mL, collected via 
centrifugation (3645  g for 10 min), resuspended in sterile PBS, and adjusted to 1 × 106 
CFU/mL in PBS supplemented with 10 μM DAF-2 DA and 30 μM PI. The bacteria 
solution (2.5 mL) was incubated in a glass bottom confocal dish for 45 min at 37 °C. A 
Zeiss 510 Meta inverted laser scanning confocal microscope with a 488 nm Ar excitation 
laser and a BP 505–530 nm filter was used to obtain DAF-2 (green) fluorescence images. 
Red fluorescence images for PI were obtained using a 543 nm HeNe excitation laser with 
a BP 560–615 nm filter. The bright field and fluorescence images were collected by a 
N.A. 1.2 C-apochromat water immersion lens with a 40× objective. An aliquot (1.5 mL) 
of NO-releasing dendrimers (10 µg/mL) in PBS (supplemented with 10 μM DAF-2 DA 
and 30 μM PI) was added to the bacteria solution (1.5 mL) in the glass confocal dish. 
Images were collected every 5 min to observe intracellular NO concentrations (green 
fluorescence) and compromised bacteria membrane (red fluorescence) temporally. The 
efficiency of NO delivery to bacteria within biofilms was also evaluated as a function of 
dendrimer composition by incubating the P. aeruginosa biofilm with NO-releasing 
dendrimers (20 µg/mL) in PBS supplemented with 10 μM DAF-2 DA and 30 μM PI for 1 
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h. Bright field and fluorescence images were collected using a N.A. 1.2 C-apochromat 
water immersion lens with a 20× objective. 
3.3 Results and Discussion 
Sun et al. previously reported on the planktonic bactericidal activity of NO-releasing 
dendrimers as a function of exterior functionality.33 Functionalization with hydrophobic 
groups at the dendrimer exterior improved bactericidal efficacy but also resulted in 
significant toxicity towards mammalian cells. Indeed, even low concentration (~34 
µg/mL) of hydrophobic dendrimer resulted in ~80% killing of L929 mouse fibroblast 
cells.33 We thus sought to synthesize NO-releasing dendrimers with tunable exterior 
hydrophobicity in order to evaluate the impact of surface energy 
(hydrophobicity/hydrophilicity) on both bactericidal action and cytotoxicity.  
3.3.1 Synthesis of Nitric Oxide Donor-Modified PAMAM Dendrimers.  
We prviously has reported the synthesis of secondary amine-functionalized 
dendrimers with diverse exterior functionalities using the ring opening of epoxides to the 
primary amines on the dendrimer exterior.27 N-diazeniumdiolate NO donors were formed 
by the reaction of the resulting secondary amines with NO gas under basic conditions.27  
   
Scheme 3.1 Synthesis of secondary amine- and N-diazeniumdiolate-functionalized 
PAMAM conjugates for which n represents the number of primary amines on the 
periphery of PAMAM dendrimers (n = 8, 32). 
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To synthesize secondary amine-functionalized dendrimer with varied exterior 
hydrophobicicty, poly(amidoamine) (PAMAM) dendrimers were modified by a similar 
ring opening reaction with either hydrophilic PO exclusively, hydrophobic ED 
exclusively, or varying molar ratios of PO and ED (Scheme 3.1). The PO, ED, and 
PO/ED mixtures were added in a total of one equivalent with respect to the molar 
concentration of PAMAM primary amine functionality. The actual ratio of PO and ED 
conjugated to the PAMAM dendrimers was determined using 1H NMR spectroscopy. As 
shown in Figure 3.1, a distinct resonance at 3.82 ppm corresponded to the methyne 
protons adjacent to the hydroxyl group of the product. This chemical shift was observed 
in the products of dendrimer reacting with PO exclusively, as well as those with the 
PO/ED mixture. Further inspection of the NMR spectra reveals the presence of a second 
distinct peak at 5.80 ppm, formed upon reaction of the dendrimer with either ED 
exclusively or the PO/ED mixtures. The 5.80 ppm peak corresponds to the methyne 
protons of the unsaturated ED double bond. The integration of the 3.82 and 5.80 ppm 
peaks allowed for the determination of the molar ratio of PO and ED. For PO/ED 
bifunctionalized dendrimers, the feed molar ratio of PO and ED was tuned to yield 
PO/ED ratios of 7:3 (i.e., G1-PE 73, G3-PE 73), 5:5 (i.e., G1-PE 55), and 3:7 (i.e., G1-
PE 37). In this manner, we were able to study the effects of hydrophobicity on 
bactericidal activity and cytotoxicity (Table 3.1). In addition, recent research suggests 
that dendrimer size (i.e., dendrimer generation) plays an important role in the bactericidal 
efficacy of NO-releasing dendrimers, with higher generation (i.e., larger) NO-releasing 
dendrimers being more effective at killing bacteria due to the delivery of greater NO 
payloads.33 Multivalent dendrimer-bound NO donors with 8 (G1) and 32 (G3) terminal  
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Figure 3.1 1H NMR spectra of A) G1-PAMAM-ED, B) G1-PAMAM-PE 37, C) G1-
PAMAM-PE 55, D) G1-PAMAM-PE 73, and E) G1-PAMAM-PO. The actual 
composition of ED and PO was determined by the integration of peaks at 5.80 (-CH=CH2) 
and 3.82 (-CH(OH)CH3) ppm. 
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functional groups were thus synthesized to understand the influence of dendrimer size on 
the anti-biofilm efficacy against P. aeruginosa biofilms.  
Subsequent reaction of the secondary amine-functionalized dendrimers (e.g., PO, ED, 
PE) with NO at 10 atm under basic conditions (Scheme 3.1) produced N-
diazeniumdiolate-functionalized dendritic scaffolds (e.g., PO-NO, ED-NO, PE-NO). 
The dendrimers exhibited similar NO storage (~1 µmol/mg) and NO-release kinetics 
(i.e., half life ~1 h) regardless of modification (Table 3.1). Of note, similar total NO 
storage and NO-release kinetics for the PO/ED (PE)-functionalized dendrimers was 
expected since both 100% PO or ED-functionalized dendrimers exhibited a total NO 
storage of ~1 µmol/mg and a half-life of ~1 h. These NO-release properties facilitate the 
evaluation of how surface hydrophobicity (via the PO to ED ratio) and dendrimer 
generation impact NO delivery and bacteria killing. 
3.3.2 Bactericidal studies: Planktonic Bacteria.  
 
Planktonic Gram-negative P. aeruginosa were exposed to control and NO-releasing 
dendrimers to evaluate the effects of the PO/ED ratio on bacterial killing. Bacterial 
viability assays were conducted over a 4-h period under static conditions to quantify the 
concentration of dendrimer required to reduce bacteria viability by 3-logs. This 
concentration is hereafter referred to as the planktonic minimum bactericidal 
concentration or MBC. The bactericidal NO dose for the NO-releasing dendrimers was 
also determined by multiplying total NO dose over 4 h (i.e., t[NO]a) and the 
corresponding MBC (Table 3.2). As expected, the amphiphilic control dendrimers 
functionalized with ED exclusively or a PO/ED mixture (e.g., G1-ED, G1-PE 37, G1-PE  
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Table 3.1 Nitric oxide-release properties for G1 and G3 PAMAM dendrimers in PBS (pH 
= 7.4 at 37 °C) as measured by a chemiluminescence NO analyzer. 
 Feed molar ratio (PO/ED) 
t[NO]a 
 (μmol/mg) 
t[NO]b  
(μmol/mg) 
[NO]max 
(ppb/mg) 
t1/2 
 (h) 
G1-ED  0:1  0.71  1.23  3295  0.94  
G1-PE 37  5:5  0.93 1.10  5666  0.87 
G1-PE 55  7:3  1.10  1.23  5000  0.95  
G1-PE 73  9:1  0.88  1.04  3000  1.01  
G1-PO  1:0  0.92  1.03  3800  0.75  
G3-PE 73 9:1 0.89 1.06 2400 1.02 
a the NO released over 4 h (μmol per milligram of secondary amine-functionalized dendrimers). 
b the NO released over 24 h (μmol per milligram of secondary amine-functionalized dendrimers). 
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Table 3.2 Comparison of the minimum bactericidal concentration (MBC) and        
bactericidal NO doses of control and NO-releasing dendrimers against 
planktonic Gram-negative P. aeruginosa after 4 h exposure for 3-log 
reduction in bacterial viability. 
Dendrimers MBC
a 
(µg/mL) 
MBCb 
(µg/mL) 
Bactericidal NO Doses 
(nmol/mL) 
G1-ED  8  5  3.55  
G1-PE 37  5 4 3.72 
G1-PE 55  10  7  7.70  
G1-PE 73  30  20  17.6  
G1-PO  3000  200  182  
G3-PE 73 20  15  13.4  
    
 
 
 
 
 
aconcentration of control dendrimer required to reduce bacterial viability by 3-logs.  
bconcentration of NO-releasing dendrimer required to reduce bacterial viability by 3-logs. 
Each parameter was analyzed with multiple replicates (n=3). 
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55, G1-PE 73) exhibited enhanced biocidal activity against planktonic P. aeruginosa 
compared to the hydrophilic control dendrimer (G1-PO). This behavior can in part be 
attributed to the enhanced perturbation and disruption of the bacteria membrane by the 
amphiphilic structures.37 For example, functionalizing 30% of the dendrimer primary 
amines with ED (i.e., G1-PE 73) improved the biocidal action of the dendrimer scaffold 
by 99% (i.e., the MBC for G1-PE 73 and G1-PO was 30 and 3000 µg/mL, respectively) 
compared to dendrimers functionalized solely with PO (i.e., G1-PO).  
Further inspection of the results revealed lower MBCs for NO-releasing dendrimers 
compared to their non-NO-releasing counterpart, indicating enhanced bactericidal 
activity with NO. This increase in bactericidal efficacy is attributed to the oxidative and 
nitrosative stresses resulting from NO byproducts (e.g., peroxynitrite and dinitrogen 
trioxide).26 As shown in Table 3.2, the bactericidal NO dose required to elicit the 3-log 
reduction in bacterial viability decreased with increasing dendrimer hydrophobicity (i.e., 
ED content), suggesting enhanced bacterial killing. For example, the bactericidal NO 
doses for G1-ED-NO and G1-PO-NO were 3.55 and 182 nmol/mL, respectively. Since 
dendrimer association with the outer surface (i.e., membrane) of bacteria followed by 
penetration through the bacteria membrane has been identified previously as important 
killing mechanisms,18 we hypothesized that increasing the ED (hydrophobic) content of 
the dendrimer exterior would improved dendrimer association with the bacteria and 
facilitate more efficient NO delivery. Confocal microscopy was thus used to characterize 
the association of RITC-labeled G1-PE 73-NO, G1-PE 55-NO, G1-PE 37-NO, and G3-
PE 73-NO with planktonic P. aeruginosa (Figure 3.2). (Dendrimers were labeled with 
RITC following a previous report.33) The impact of the RITC label on the dendrimer–
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bacteria association was minimized by using a low amount of RITC (i.e., 1:100 molar 
ratio to total primary amines). As expected, based on hydrophobicity, the red 
fluorescence intensity was the greatest from RITC-labeled G1-PE 55-NO and G1-PE 37-
NO indicating more rapid association of these dendrimers with P. aeruginosa than G1-
PE 73-NO. However, the association of G1-PE 37-NO and G1-PE 55-NO with P. 
aeruginosa were similar, illustrating that the improvement of dendrimer association due 
to hydrophobicity plateaus at ~50% ED functionality (G1-PE-55-NO). Additional ED 
modification had negligible influence on the dendrimer-bacteria association kinetics. 
Furthermore, the association of the larger dendrimer (G3-PE 73-NO) was similar to that 
of G1-PE 73-NO, indicating that the hydrophobicity of the dendritic scaffolds plays a 
greater role in bacteria association than size, at least for G1 vs. G3 dendrimers. Other 
sizes and bacteria may result in altered behavior in dendrimer–bacteria association. 
Based on enhanced dendrimer–bacteria association for dendrimers with greater ED 
character, we predicted more effective NO delivery and greater bacteria damage (i.e., 
membrane disruption). Fluorescence from DAF-2 (green) and PI (red) molecular probes 
were employed to study the intracellular NO levels and ensuing membrane disruption, 
respectively, using confocal microscopy. Green fluorescence (DAF-2) was nearly always 
observed first, indicating a buildup of intracellular NO. Red fluorescence (PI) followed as 
the bacteria membrane became compromised, with concomitant diminished green 
fluorescence. The buildup of measurable intracellular NO for bacteria incubated with G1-
PE 37-NO, G1-PE 55-NO, and G3-PE 73-NO was observed at 35 min (Figure 3.3), 
significantly earlier than bacteria incubated with G1-PE 73-NO (60 min). The more rapid 
association (G1-PE 37-NO and G1-PE 55-NO) with bacteria and greater localized NO  
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Figure 3.2 Bright field/fluorescent overlay and fluorescent images of RITC-label NO-
releasing dendrimers association with P. aeruginosa. A) G1-PE 73; B) G1-PE 55; C) 
G1-PE 37; D) G3-PE 73. Scale bar 5 µm. 
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Figure 3.3. Intracellular DAF-2 (green) and PI (red) fluorescence from P. aeruginosa 
exposed to NO-releasing dendrimers G1-PE 37-NO (at A-35, B-50, C-55, D-65, E-105, 
F-110 min), G1-PE 55-NO (at A-35, B-60, C-75, D-85, E-115, F-150 min), G1-PE 73-
NO (at A-60, B-85, C-125, D-135, E-140, F-150 min), and G3-PE 73-NO (at A-35, B-50, 
C-65, D-70, E-100, F-130 min). Intracellular NO is indicated by the DAF-2 green 
fluorescence, whereas PI red fluorescence points to compromised membranes. Scale bar: 
2 µm. 
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Figure 3.4. Intracellular DAF-2 (green) and PI (red) fluorescence from P. aeruginosa 
exposed to NO-releasing dendrimers at 135 min incubation A) G1-PE 37-NO; B) G1-PE 
55-NO; C) G1-PE 73-NO; and D) G3-PE 73-NO. Scale bar: 5 µm. 
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release (G3-PE 73-NO) allowed for faster NO localization and biocidal action. Indeed, 
red fluorescence (PI) was observed at 55, 75, 135, and 70 min for G1-PE 37-NO, G1-PE 
55-NO, G1-PE 73-NO, and G3-PE 73-NO, respectively. The confocal images of 
bacteria incubated with G1-PE 37-NO, G1-PE 55-NO, G1-PE 73-NO, and G3-PE 73-
NO at 135 min were also used to compare the bactericidal activity of the dendrimers. As 
shown in Figure 3.4, bacteria incubated with G1-PE 37-NO, G1-PE 55-NO, and G3-PE 
73-NO generally exhibited compromised membranes. Conversely, bacteria incubated 
with G1-PE 73-NO exhibited DAF-2 fluorescence, but without a compromise in 
membrane integrity (i.e., low PI fluorescence), confirming the enhanced bactericidal 
activity of larger generation dendrimers and those with greater exterior hydrophobicity. 
3.3.3 Bactericidal Studies: Biofilm Eradication.  
 
Although planktonic killing assays are helpful in determining a drug or antibacterial 
agent’s potential biomedical utility, most bacteria establish biofilms as a protective 
mechanism against therapeutics.1 To evaluate the effects of PO/ED ratio and dendrimer 
size on the anti-biofilm activity of NO-releasing amphiphilic dendrimers, P. aeruginosa 
biofilms were exposed to a range of NO-releasing dendrimer concentrations (10–800 
µg/mL) for 24 h (Table 3.3). Following treatment, the biofilm was forced off of the 
substrate and dispersed by vortexing and sonication to enable viability quantification. 
Control experiments were performed to confirm both the growth of P. aeruginosa 
biofilms under the selected conditions and the negligible effect of vortexing/sonication on 
bacteria viability when incubated only in PBS. The viability of bacteria embedded in 
biofilms was ~2×108 CFU per biofilm. Considering the detection limit of 2,500 CFU/mL 
for this selected plate counting method, a maximum of 5-log reduction in bacterial 
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viability can be achieved. The lowest concentration for a 5-log reduction in bacterial 
viability (minimum bactericidal concentration or MBC) was then used to characterize the 
antibacterial efficacy of amphiphilic dendrimers. The bactericidal NO dose for each of 
the NO-releasing dendrimers was also derived by multiplying total NO release over 24 h 
(t[NO]b) and  the corresponding MBCs (Table 3.3).   
Analogous to the inherent bacterial killing observed for planktonic P. aeruginosa, the 
amphiphilic control dendrimers (G1-PE 73, G1-PE 55, G1-PE 37, and G1-ED) proved 
more effective at killing bacterial biofilms than the hydrophilic dendrimer (G1-PO) due 
to the membrane disruption properties by amphiphilic structures. Indeed, the dendrimer 
MBCs for biofilm eradication (5-log killing) were 10000, 150, 30, 15, and 25 µg/mL for 
G1-PO, G1-PE 73, G1-PE 55, G1-PE 37, and G1-ED, respectively. As expected, NO 
release improved the bactericidal activity of the dendrimers with reduced MBCs (i.e., 800, 
80, 20, 10, and 15 µg/mL for G1-PO-NO, G1-PE 73-NO, G1-PE 55-NO, G1-PE 37-
NO, and G1-ED-NO, respectively). Of the dendrimer systems studied, G1-PE 37-NO 
exhibited the greatest anti-biofilm efficacy indicated by the lowest MBC (10 µg/mL) and 
corresponding bactericidal NO dose (11 nmol/mL). To evaluate the enhanced bactericidal 
activity of G1-PE 37-NO and whether it could be attributed to more rapid association 
with bacteria embedded within the biofilms, the association of G1-PE 73-NO, G1-PE 
37-NO, and G1-ED-NO with bacteria in P. aeruginosa biofilms was characterized using 
confocal microscopy. As shown in Figure 3.5, a greater number of bacteria in the 
biofilms exhibited red fluorescence upon incubation with RITC-labeled G1-PE 37-NO 
compared to G1-PE 73-NO. As for planktonic bacteria, the enhanced hydrophobic 
interaction between the dendrimer and bacteria membrane likely facilitates more efficient  
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Table 3.3. Comparison of the minimum bactericidal concentration and 
bactericidal NO doses of control and NO-releasing dendrimers required to 
achieve 5-log reduction in bacteria viability of Gram-negative P. aeruginosa 
biofilms after 24 h exposure. 
 MBC
a 
(µg/mL) 
MBCb 
(µg/mL) 
Bactericidal NO Doses 
(nmol/mL) 
G1-ED  25  15  18.5  
G1-PE 37  15  10  11.0  
G1-PE 55  30  20  24.6 
G1-PE 73  150 80  83.2 
G1-PO  10000 800  824 
G3-PE 73 150 60  63.6 
 
 
 
 
 
 
 
a concentration of control dendrimer required to reduce bacterial viability by 5-logs.  
b concentration of NO-releasing dendrimer required to reduce bacterial viability by 5-logs. 
Each parameter was analyzed with multiple replicates (n=3). 
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Figure 3.5. Three dimentional scanning confocal microscopy images of P. aeruginosa 
biofilms exposed to A) G1-PE-37-NO; B) G1-ED-NO; C) G1-PE 73-NO; and D) G3-
PE 73-NO RITC-labeled NO-releasing dendrimers for 1 h incubation. Greater red 
fluorescence indicates more efficient dendrimer–bacteria association. Scale bar: 300 µm. 
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NO delivery and killing bacteria (e.g., membrane disruption). However, less dendrimer–
bacteria association was noted for G1-ED-NO compared to G1-PE 37-NO despite the 
greater hydrophobicity of G1-ED-NO. At this stage, we associate this result to less 
efficient EPS penetration due to the greater hydrophobicity of G1-ED-NO.38 Indeed, 
Wicke et al. reported the inhibited diffusion of hydrophobic organic molecules within 
microbial biofilms compared to hydrophilic derivatives.38 G1-PE 37-NO proved to be the 
most effective dendrimer construct for eradicating the biofilm bacteria because of its 
rapid penetration into the biofilm and association with embedded bacteria. 
Perhaps unexpectedly, dendrimer size (i.e., dendrimer generation) only slightly 
impacted the association with bacteria in the P. aeruginosa biofilms. Although G3-PE 
73-NO exhibited similar association with bacteria in P. aeruginosa biofilms compared to 
G1-PE 73-NO, the DAF-2 fluorescence from biofilms incubated with the larger (G3) 
dendrimer indicated greater intracellular NO delivery. The increased NO payload and 
delivery from the larger generation dendrimer (G3-PE 73-NO) proved more bactericidal, 
as noted by the lower required dose to eradicate the bacteria.  
3.3.4 Toxicity of NO-Releasing Dendrimers against L929 Mouse Fibroblast Cells.  
Although effective at eradicating biofilms, Sun et al. previously reported that 
amphiphilic NO-releasing dendrimers were toxic to mammalian cells.33 For example, 
polypropylenimine dendrimers modified with styrene oxide elicited substantial toxicity 
(i.e., >80% reduction in viability at >34 µg/mL) towards L929 mouse fibroblast cells, 
whereas dendrimers modified with hydrophilic PO elicited no toxicity at concentrations 
up to 500 µg/mL. Based on these results, we hypothesize that the ratio of hydrophobic  
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Figure 3.6. Three dimensional intracellular DAF-2 fluorescence images of P. aeruginosa 
biofilms incubated with A) G1- and B) G3-PE 73-NO for 1 h. Scale bar: 20 µm. Green 
fluorescence indicates the intracellular NO levels. 
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(ED)/hydrophilic (PO) functionalization likely influences the cytotoxicity of the 
amphiphilic NO-releasing dendrimers reported herein. Cytotoxicity to L929 mouse 
fibroblast cells was thus evaluated at the dendrimer concentrations necessary for 3- and 
5-log reductions in bacteria viability against planktonic and biofilm P. aeruginosa 
bacteria, respectively, using the MTS assay (24 h incubation). 
Normalized L929 mouse fibroblast cell viabilities of NO-releasing and control 
dendrimers at the planktonic and biofilm bacteria MBCs are shown in Figure 3.7A and 
7B, respectively. In general, the NO-releasing dendrimers were less toxic than their 
control counterparts due to the lower concentration of NO-releasing dendrimers required 
for planktonic killing and biofilm eradication. As expected, dendrimers with increased 
hydrophobic character (e.g., G1-ED-NO and G1-PE 37-NO) exhibited greater toxicity 
(i.e., ~70% cell viability reduction) after 24 h incubation at the MBCs against P. 
aeruginosa biofilms, likely resulting from membrane disruption by the large density of 
hydrophobic chains on the dendrimer periphery. The most hydrophilic dendrimer, G1-
PO-NO, was also toxic at its corresponding MBC (800 µg/mL) as a result of the large 
concentration required to eradicate the biofilm-embedded bacteria. Dendrimers with 
intermediate ratios of PO/ED (e.g., G1-PE 55-NO and G1-PE 73-NO) exhibited 
significantly lower toxicity to the mammalian cells at the MBCs required to kill the 
biofilm bacteria. The reduced toxicity is clearly the result of the lower concentrations of 
dendrimers required to deliver sufficient levels of NO and the lower ED content on the 
dendrimer exterior compared to G1-ED-NO and G1-PE 37-NO. Clearly, the PO/ED 
ratio at the dendrimer exterior had a significant impact on overall cytotoxity.  
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Figure 3.7. Cytotoxicity of NO-releasing dendrimers to L929 fibroblast cells at the MBCs 
against A) planktonic and B) biofilm-based P. aeruginosa. 
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Despite the enhanced biocidal activity against biofilms, G1-PE 37-NO and G1-ED-
NO also elicited toxicity towards L929 cells as a result of the ED-induced membrane 
disruption properties. The larger dendrimer constructs (e.g., G3-PE 73-NO) were found 
to be slightly more toxic (~10% reduction in cell viability) to the L929 mouse fibroblast 
cells compared to G1-PE 73-NO at their respective MBCs, corroborating results by Sun 
et al. who reported similar generation dependent-cytotoxicity of NO-releasing dendrimers 
to L929 cells (larger generation being more toxic).33 The favorable toxicity of the 
antibacterial G1-PE 55-NO, G1-PE 73-NO, and G3-PE 73-NO dendrimers over 
previously reported hydrophobic polypropylenimine dendrimers33 indicate the advantage 
of using amphiphilic NO-releasing vehicles with intermediate exterior hydrophobicity 
(e.g., G1-PE 55-NO, G1-PE 73-NO) to maximize bacteria killing while minimizing 
toxicity to mammalian cells. 
3.4 Conclusions 
The utility of amphiphilic NO-releasing dendrimers as antibacterial/anti-biofilm 
agents was demonstrated through the systematic study of killing efficiency as a function 
of NO-releasing dendrimer hydrophobicity and dendrimer size (i.e., dendrimer 
generation). The hydrophobicity of, in particular, dendrimer surface groups were found to 
significantly influence dendrimer association with Gram-negative bacteria, the efficiency 
of intracellular NO delivery, the extent of bacteria membrane disruption, and the 
cytotoxicity to mammalian cells. Optimal anti-biofilm activity with minimal toxicity 
toward mammalian cells was achieved by modifying the dendrimer exterior with a 
mixture of hydrophilic (PO) and hydrophobic (ED) functionalities. Roughly equal PO/ED 
modification amounts proved most effectively at eradicating P. aeruginosa biofilms at 
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minimally lethal concentrations to L929 mouse fibroblast cells. Future studies should 
include testing of these materials against polymicrobial biofilms, biofilms formed from 
clinically-isolated bacteria, and detailed pharmacological toxicity testing of the NO-
releasing dendrimers with human cells/tissues. 
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Chapter 4 
     Shape- and Nitric Oxide-Flux Dependent Bactericidal Activity of Nitric Oxide-
Releasing Silica Nanorods 
 
4.1 Introduction 
Nitric oxide (NO), a diatomic free radical produced endogenously by macrophages 
and other inflammatory cells, plays a key role in the natural immune response to 
pathogens.1-3 NO-releasing materials have been widely used in different biomedical 
applications. 4-9 Both NO and its reactive byproducts (e.g., peroxynitrite and dinitrogen 
trioxide) exert significant oxidative and nitrosative stress on bacterial cells to facilitate 
their killing.1-3 Nitrosative stress acts to nitrosate thiols influencing protein and DNA 
function, while lipid peroxidation via oxidative stress destroys the bacterial membrane 
integrity.3 Methods for delivering exogenous NO are thus actively being developed 
against both Gram–positive and Gram–negative bacteria.10-12 While gaseous NO from a 
cylinder and NO delivered from small molecule NO donors have proven to be 
antimicrobial,11, 13 macromolecular scaffolds are more potent due to their ability to 
deliver large localized concentrations of NO.11, 12  Indeed, we have previously reported 
the ability to achieve larger NO payloads and improved bactericidal efficacy using NO-
releasing dendrimers and silica particles, relative to small molecule NO donors.11, 14, 15 To 
date, the bacterial toxicity of NO-releasing particles has been shown to be dependent on 
chemical composition, NO-release kinetics and particle size.16 For example, the 
bactericidal activity of NO-releasing silica particles correlated directly with particle size, 
106 
 
with the smallest particles tested (i.e., 50 nm) exhibiting the greatest antibacterial 
efficacy.16 
Given the dependence of bactericidal efficacy on the physicochemical properties of 
NO-releasing particles, we hypothesized that particle shape might influence particle-
bacteria interactions and potentially the biocidal activity. Recent work on particle design 
for drug delivery to mammalian cells indicated the importance of particle shape on 
particle-cell adhesion strength, internalization rate, biodistribution, cytotoxicity, 
phagocytosis and circulation time. 17-31 In particular, rod-like nanoparticles have been 
shown to significantly influence mammalian cell internalization and circulation time 
compared to their spherical or cubic counterparts.23-27 Herein, we describe the synthesis 
and evaluation of the bactericidal efficacy of NO-releasing silica nanorods (SNRs) of ~1–
8 aspect ratios but similar size (e.g., particle volume) against Gram–negative and –
positive bacteria.  
4.2 Experimental section 
4.2.1 Materials.  
Tetraethyl orthosilicate (TEOS), N-(2-aminoethyl)-3-amino-isobutyl-dimethyl-
methoxysilane (AEAI), aminopropyldimethylethoxysilane (APDE) and 3-
aminopropyltrimethoxysilane (APTMS) were purchased from Gelest (Morrisville, PA). 
Cetyltrimethylammonium bromide (CTAB) was obtained from Acros Organics (Geel, 
Belgium). Rhodamine B isothiocyanate  (RITC), poly(ethylene glycol) methyl ether 
acrylate (average Mn = 480) (PEG), propidium iodide (PI), fetal bovine serum (FBS), 
Dulbecco's Modified Eagle's Medium (DMEM), phenazine methosulfate (PMS), 3-(4,5-
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dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
inner salt (MTS), trypsin, phosphate buffered saline (PBS) used for cell culture, and 
penicillin streptomycin (PS) were purchased from the Aldrich Chemical Company 
(Milwaukee, WI). Pseudomonas aeruginosa (ATCC #19143) and Staphylococcus aureus 
(ATCC# 29231) were obtained from the American Type Culture Collection (Manassas, 
VA). L929 mouse fibroblasts (ATCC #CCL-1) were purchased from the University of 
North Carolina Tissue Culture Facility (Chapel Hill, NC). Distilled water was purified 
with a Millipore Milli-Q Gradient A-10 water purification system (Bedford, MA). 4,5-
Diaminofluorescein diacetate (DAF-2 DA) was purchased from Calbiochem (San Diego, 
CA). Common laboratory salts and solvents were purchased from Fisher Scientific 
(Pittsburgh, PA). All materials were used as received without further purification unless 
noted otherwise.  
4.2.2 Surfactant-Templated Synthesis of Silica Nanorods.  
The silica nanorods (SNRs) were synthesized via a surfactant-templated method and 
tuning the aspect ratio by varying temperature, ammonia concentration, and solution 
volume (Table 4.1).  In a representative synthesis, 0.11 mL tetraethyl orthosilicate (TEOS) 
was added to a solution of 0.29 g cetyltrimethylammonium bromide (CTAB) in 50 mL of 
0.5 M ammonia at 50 oC. A subsequent addition of TEOS (0.60 mL) was added after 5 h 
of stirring, followed by aging for 24 h at 50 oC. The resulting SNRs were collected by 
centrifugation and washed twice with 50 mL of ethanol, recollected via centrifugation, 
and dried under vacuum at ambient temperature. To remove the CTAB templates, the 
SNRs were resuspended in a mixture of ethanol and concentrated HCl (9:1; v/v) and 
stirred at 60 oC for 24 h. Finally, the particles were re-collected by centrifugation and 
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washed twice with ethanol before drying under vacuum at ambient temperature. 
Complete removal of CTAB was confirmed by CHN elemental analysis. 
4.2.3 Preparation of Nitric Oxide-Releasing Silica Nanorods with Functionality c.  
A suspension of 50 mg SNRs and 0.5 mL AEAI in 10 mL anhydrous THF was 
refluxed under nitrogen overnight. The resulting amine-functionalized SNRs a were 
collected by centrifugation, washed twice with ethanol and dried under vacuum at 
ambient temperature. Elemental analysis (CHN) was performed to determine the amount 
of aminoalkoxysilane anchored onto the surface of the SNRs. To modify the SNRs for 
NO release, 15 mg AEAI-functionalized SNRs (a) were resuspended in a mixture of 2.7 
mL anhydrous DMF and 0.3 mL methanol and 50 µL of 5.4M NaOMe/MeOH. The 
suspension was added to vials in a Parr hydrogenation vessel, purged rapidly (5–10 s) 
with argon three times, and then three longer cycles (10 min) of argon purges to remove 
residual oxygen from the solution. The Parr hydrogenation vessel was then filled with 10 
atm of NO gas purified over KOH pellets to remove any impurities (NO degradation 
products) and maintained at 10 atm for 3 d. The same argon purging protocol was 
performed to remove unbound NO prior to removing the vials from the vessel. The SNRs 
were recollected by centrifugation, washed twice with anhydrous ethanol, dried under 
vacuum and stored at -20 oC until future use. 
4.2.4 Preparation of Nitric Oxide-Releasing Nanosilica Rods with Functionality d.  
Aminopropyldimethylethoxysilane (APDE)-functionalized SNRs were synthesized as 
described previously for SNRs a by simply replacing AEAI with APDE. Subsequently, 
poly(ethylene glycol) methyl ether acrylate (PEG) was added to a suspension of APDE-
functionalized SNRs in ethanol with equimolar PEG corresponding to the amine content 
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of the SNRs. After stirring at room temperature for 2 d, the PEG-modified SNRs (b) were 
collected by centrifugation, washed twice with anhydrous ethanol and dried at ambient 
temperature. The resulting secondary-amine functionalized SNRs b were modified with 
NO in the same manner described above. 
4.2.5 Characterization of Functionalized Nanosilica Rods.  
Scanning electron micrographs were recorded with a Hitachi S-4700 scanning 
electron microscope (Pleasanton, CA) to determine size and aspect ratios of the SNRs. 
Elemental (CHN) analysis was performed using a PerkinElmer CHN/S O Elemental 
Analyzer Series 2400 (Waltham, MA) instrument to quantify the amine content of each 
SNR, that would be proportional to the aminosilane surface coverage. The zeta potential 
of the silica particles was determined using a Zetasizer Nano ZS (Malvern, U.K.). 
Samples (~1 mg/mL) were prepared in phosphate buffer (10 mM, pH = 7.4) and 
immediately injected into a folded capillary cell for zeta potential analysis. Nitric oxide 
release was measured using a Sievers 280i Chemiluminescence Nitric Oxide Analyzer 
(Boulder, CO) by adding NO-releasing SNRs to deoxygenated PBS (pH = 7.4 and 37 oC).  
Nitrogen was purged through the solution to carry liberated NO to the analyzer at a flow 
rate of 70 mL/min. Additional nitrogen flow was supplied to match the collection rate of 
the analyzer at 200 mL/min. Real-time NO release profiles were recorded, allowing for 
the determination of NO release totals (t[NO]), half-lives (t1/2), and maximum NO fluxes 
([NO]max). For surface area measurement, N2 adsorption-desorption isotherms were 
obtained on a Micromeritics Tristar II analyzer. The BET model was applied to evaluate 
the specific surface areas and the Barret-Joyner-Halenda (BJH) method was used to 
calculate the pore volume. 
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4.2.6 Bactericidal Assays.  
Cultures of P. aeruginosa and S. aureus were prepared as described previously.6 
Briefly, bacterial cultures were grown from a frozen (-80 oC) stock overnight in TSB at 
37 oC. A 100 μL aliquot of the resulting suspension was added into 5 mL fresh TSB and 
incubated at 37 oC for ~2 h until the concentration reached 1×108 colony forming units 
(CFU)/mL, as confirmed by the OD600 and replicate plating and enumeration on nutrient 
agar. A working bacterial stock was prepared by plating the bacterial suspension on TSA 
and incubating at 37 oC overnight. The TSA bacterial stocks were prepared weekly and 
stored at 4 oC. For bactericidal assays, colonies of P. aeruginosa and S. aureus were 
taken from the TSA plate and dispersed in 3 mL TSB and then incubation at 37 oC 
overnight. A 100 μL aliquot of culture was added to 5 mL fresh TSB and incubated to a 
concentration of ~1×108 CFU/mL. The bacteria was collected by centrifugation and 
resuspended in 3 mL PBS or 1% (v/v) tryptic soy broth (TSB)-supplemented PBS. The 
resulting suspension was diluted 100-fold in PBS or 1% TSB-supplemented PBS to 
obtain a final concentration of 1×106 CFU/mL. The bactericidal efficacy of NO-releasing 
SNRs against the bacteria was evaluated after 4 h incubation over a range of 
concentrations. Bacteria suspensions in PBS or 1% (v/v) TSB-supplemented PBS were 
added to premeasured NO-releasing silica nanorods and incubated at 37 oC for 4 h. 
Following incubation, 100 μL aliquots of the bacteria suspensions were removed, diluted 
10-fold in PBS, deposited on TSA plates, and incubated overnight at 37 oC. The 
minimum concentration of NO-releasing SNRs that resulted in a 3-log reduction of 
bacterial viability after 4 h exposure was defined as the minimum bactericidal 
concentration (MBC). 
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4.2.7 In Vitro Toxicity.  
L929 mouse fibroblasts were grown in DMEM supplemented with 10% (v/v) fetal 
bovine serum (FBS) and 1 wt% penicillin/streptomycin, and incubated in 5% (v/v) CO2 
under humidified conditions at 37 oC. After reaching 80% confluency, the cells were 
trypsinized, seeded onto tissue-culture treated polystyrene 96-well plates at a density of 
3×104 cells/mL and incubated at 37 oC for 48 h. The supernatant was then aspirated prior 
to adding 200 μL fresh DMEM and 50 μL of a NO-releasing SNR suspension in PBS to 
each well. After incubation at 37 oC for 24 h, the supernatant was aspirated and 120 μL 
mixture of DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well. The absorbance 
of the resulting colored solution after 1.5 h incubation at 37 oC was quantified at 490 nm 
using a Thermoscientific Multiskan EX plate reader. The mixture of DMEM/MTS/PMS 
and untreated cells were used as blank and control, respectively. The cell viability was 
calculated by equation 4.1. 
Cell Viability ൌ  ሺ Absorbance୲୰ୣୟ୲ୣୢ ୡୣ୪୪ െ Absorbanceୠ୪ୟ୬୩ሻሺ Absorbance୳୬୲୰ୣୟ୲ୣୢ ୡୣ୪୪ െ Absorbanceୠ୪ୟ୬୩ሻ                  Eq. 4.1 
4.2.8  Confocal Microscopy for Detection of Intracellular Nitric Oxide.  
Bacteria (P. aeruginosa and S. aureus) were cultured in TSB to a concentration of 1 × 
108 CFU/mL, collected via centrifugation (3645  g for 10 min), resuspended in sterile 
PBS, and adjusted to 1 × 106 CFU/mL in PBS supplemented with 10 μM DAF-2 DA and 
30 μM PI. The bacteria solution (2.5 mL) was incubated in a glass bottom confocal dish 
for 45 min at 37 °C. A Zeiss 510 Meta inverted laser scanning confocal microscope with 
a 488 nm Ar excitation laser (2.0%) and a BP 505–530 nm filter was used to obtain DAF-
2 (green) fluorescence images. Red fluorescence images for PI were obtained using a 543 
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nm HeNe excitation laser (25.3%) with a BP 560–615 nm filter. The bright field and 
fluorescence images were collected using a N.A. 1.2 C-apochromat water immersion lens 
with a 40× objective. Suspensions (1.5 mL) of AR1-c or AR8-c NO-releasing silica 
nanorods (44 µg/mL) in PBS (supplemented with 10 μM DAF-2 DA and 30 μM PI) were 
added to the bacteria solution (1.5 mL) in the glass confocal dish. Images were collected 
every 5 min to observe intracellular NO concentrations and cell death. 
4.2.9 Synthesis of Fluorescently Labeled Silica Nanorods.  
Rhodamine B isothiocyanate (RITC, 1.52 mg) and 3-aminopropyltrimethoxysilane 
(ATPMS, 0.5 mL) were dissolved in 0.5 mL ethanol and stirred for 2 d to form RITC-
APTMS. A mixture of TEOS and RITC-APTMS (100:1) was used in a typical surfactant-
templated synthesis to form RITC-modified SNRs. The resulting fluorescently labeled 
SNRs were subjected to the same washing and CTAB removal protocols as non-labeled 
SNRs. 
4.2.10 Confocal Microscopy for Association of Particles with Bacteria Cells.  
P. aeruginosa was cultured in TSB to a concentration of 1 × 108 CFU/mL, collected 
via centrifugation (3645  g for 10 min), resuspended in sterile PBS, and adjusted to 1 × 
106 CFU/mL. Aliquots of the bacteria solution were incubated in a glass bottom confocal 
dish for 2 h at 37 °C. A Zeiss 510 Meta inverted laser scanning confocal microscope with 
a 543 nm HeNe excitation laser (80% intensity) and a LP 585 nm filter was used to 
obtain fluorescence images of the RITC-modified dendrimers. The bright field and 
fluorescence images were collected using a N.A. 1.2 C-apochromat water immersion lens 
with a 20× objective. Solutions of RITC-labeled NO-releasing (200 μg/mL) particles in 
PBS (1.5 mL) were added to the bacteria solution (1.5 mL) in the glass confocal dish to 
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achieve a final concentration of 100 μg/mL. Images were collected every 2 min to 
monitor association of the particles with P. aerugionsa temporally. 
4.3 Results and Discussion 
Surfactant-templated synthesis of silica materials were first developed by Mobil Oil 
Corporation.32 To date, both acidic33, 34 and alkaline32, 35, 36 routes have been used to 
synthesize these silica materials.37-41 According to a mechanism proposed by Stucky and 
coworkers,33, 34, 42 mesophase formation arises from the multidentate binding of silicate 
species to surfactant micelle interfaces via electrostatic interactions. The resulting liquid 
crystal phases self-assemble by charge density matching across the interface and 
continuously grow end to end or side to side through accretion into well-formed 
particles.43 Ozin suggested that any defects in the liquid crystal seeds direct the formation 
of specific particle morphologies (e.g., spirals, toroids, discoids or worm-like particles).44 
In addition, reaction conditions may be tuned to purposefully induce different particle 
morphology.43 For example, Sokolov demonstrated control over the aspect ratio of 
micron-sized silica rods synthesized under acidic condition by adjusting silane 
concentration and pH.43 Following the above reports, we synthesized silica rods with 
different aspect ratios (1.1–9.4) under alkaline conditions by varying the temperature and 
concentration of ammonia and silane.  
4.3.1 Aspect Ratios (AR) and Sizes Control of Silica Particles.  
As reported by Sokolov and coworkers, the aspect ratio of our silica rods also 
increased with reaction temperature.43 As shown in Figure 4.1 and Table 4.1, the 
observed particle morphology revealed a positive correlation between reaction 
temperature and SNR aspect ratio. For example, synthesis at 20 oC yielded particles with 
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a AR of ~4.5 (SNR A) while 30 and 50 oC resulted in particles with increased AR of ~8.0 
(SNR B) and ~9.4 (SNR C), respectively. Temperature also proved to affect the 
morphology of the SNRs. In contrast to SNR A and B, SNR C exhibited more twisted 
and curved morphology that has been previously attributed to defects in the liquid crystal 
seeds.44 The thermal energy available at increased reaction temperature likely allows for 
greater defect stabilization in the liquid crystal, leading to the formation of twisted and 
curved silica rods. 
Although the aspect ratio of the silica rods proved tunable via reaction 
temperature, the aspect ratio of the resulting particles was large (e.g., >4) for silane and 
ammonia concentrations of 64.0 mM and 0.5 M, respectively. To further adjust the aspect 
ratio, we also evaluated the role of pH and total silane concentration on particle 
morphology. Due to the influence of electrostatic interactions between the surfactant 
molecules and the silica species on silica rod formation,45 we hypothesized varying the 
reaction pH would alter rod morphology. Indeed, the use of more ammonia (1 M) 
resulted in SNRs with an aspect ratio of ~1.23 (SNR D), attributable to the cooperative 
assembly of surfactant and silica species. At high pH, the formation of silica oligomers 
that vary in degree of polymerization and charge represent more efficient multidentate 
ligands for the cationic surfactant molecules, and thus result in stronger interaction 
between the two species.45 The ensuing multidentate binding contributes to preferential 
side-to-side growth of liquid crystals and a lower aspect ratio.  
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Table 4.1 Influence of reaction temperature, pH, and concentration of silane on the size 
and aspect ratio of silica nanorods. 
 
 
 
 
 
 
 
 
Rod T (oC) 
TEOS 
(mM) 
CTAB 
(mM) 
Ammonia 
(M) 
Length 
(nm) 
Width 
(nm) AR 
SNR A 20 64.0 16.0 0.5 757 ± 42 168 ± 36 4.5 ± 0.9 
SNR B 30 64.0 16.0 0.5 1120 ± 69 140 ± 34 8.0 ± 1.0 
SNR C 50 64.0 16.0 0.5 1077 ± 105 115 ± 15 9.4 ± 0.7 
SNR D 20 64.0 16.0 1.0 671 ± 102 543 ± 106 1.2 ± 0.5 
SNR E 20 32.0 8.0 1.0 302 ± 35 280 ± 26 1.1 ± 0.1 
SNR F 50 42.7 10.7 0.5 241 ± 32 78 ± 6 3.1 ± 0.3 
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Figure 4.1 Scanning electron microscopy (SEM) images of silica nanorods with different 
morphologies. Aspect ratios of these particles were 4.5 ± 0.9 (A), 8.0 ± 1.0 (B), 9.4 ± 0.7 
(C), 1.2 ± 0.5 (D), 1.1 ± 0.1 (E), and 3.1 ± 0.3 (F), respectively. 
 
 
A B
C D
E F
1 µm 1 µm
1 µm 1 µm
1 µm 1 µm
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Both the size and aspect ratio of SNRs were also adjustable as a function of silane 
concentration. Decreasing the silane concentration from 64.0 mM (SNR D) to 32.0 mM 
yielded particles (SNR E) of smaller size (~0.02 μm3) and aspect ratio (1.10). 
A similar trend also observed between SNR C (aspect ratio of 9.4) and SNR F 
(aspect ratio of 3.1). Collectively, SNRs of a wide range of aspect ratios (~1–10) and 
volumes (~0.02 and 0.19 μm3) were synthesized by tuning temperature, pH, and silane 
concentration. SNRs E, A, and B were selected to study the role of aspect ratio on 
bactericidal activity due to their similar particle size (e.g., particle volume ~0.02 μm3), 
yet distinct aspect ratios (i.e., 1.1, 4.5, and 8.0). 
4.3.2 Synthesis of Diazeniumdiolate-Functionalized Silica Nanorods.  
Following SNR synthesis, the materials were functionalized with polyamine ligands 
to enable subsequent NO donor formation (Scheme 4.1). The environment surrounding 
N-diazeniumdiolate NO donors can greatly influence NO-release kinetics particularly if 
manipulating water uptake and local pH.15 Two distinct secondary amine functionalities 
were employed in this work to allow study of SNR NO-release kinetics on bactericidal 
activity. Monoalkoxysilanes (i.e., N-(2-aminoethyl)-3-amino-isobutyl-dimethyl-
methoxysilane (AEAI) and aminopropyldimethylethoxysilane (APDE) ) were anchored 
onto the surface of SNR E, A, and B, denoted as AR1, AR4, and AR8, following a 
previously published modification procedure.46 Aminopropyldimethylethoxysilane 
(APDE)-functionalized rods containing only primary amines were further functionalized 
with acrylate-functionalized PEG, resulting in the formation of secondary amines 
(Scheme 4.1).15 Varied NO-release kinetics were expected from these two functionalities, 
as the degradation of N-diazeniumdiolate NO donors is related to the protonation of the 
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polyamine that binds the NO. We hypothesized that more rapid water uptake/hydration 
by hydrophilic PEG chains on the surface of APDE-PEG functionalized SNRs would 
lead to faster N-diazeniumdiolate decomposition and NO release (i.e., higher [NO]max and 
shorter t1/2).15 Elemental analysis (Table 4.2) was used to determine the secondary amine 
content for AR1-a, AR4-a, AR8-a, AR4-b.  
As shown in Scheme 4.1, AR1-a, AR4-a, AR8-a, AR4-b were reacted or “charged” 
with NO at high pressures in methanol under basic conditions to form N-
diazeniumdiolate-functionalized nanorods (i.e., AR1-c, AR4-c, AR8-c, AR4-d). Next, 
chemiluminescence was used to characterize the NO storage and release properties of the 
N-diazeniumdiolate-modified SNRs (i.e., AR1-c, AR4-c, AR8-c, AR4-d) in PBS (pH 7.4, 
37 °C).  As shown in Table 4.3, the NO release totals and half-lives for AR1-c, AR4-c, 
and AR8-c were analogous (~0.70 μmol/mg and ~0.70 h, respectively) even though the 
porosity was different for these three particles (e.g., the pore volume for AR1-c, AR4-c 
and AR8-c was 3.3×10-3, 4.3×10-3, and 1.4×10-1 cm3/g, respectively). In contrast, AR4-d 
had lower NO storage and a shorter half-life due to less secondary amine content (See 
Table 4.2). Nevertheless, the secondary amine-to-diazeniumdiolate conversion efficiency 
was similar (~20%) regardless of precursor concentration. Similar NO donor conversion 
values were previously reported for N-diazeniumdiolated-modified dendrimers.15 The NO 
release profile of AR4-d showed the greatest initial flux (i.e., [NO]max ~14000 ppb/mg) 
and fastest decay (i.e., t1/2=0.16 h), due to greater water uptake facilitated by the 
hydrophilic PEG groups. The distinct NO-release kinetics between AR4-c and AR4-d 
SNRs could thus be used to study NO flux-dependent bactericidal activity in addition to 
nanorod aspect ratio. 
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Scheme 4.1 Synthesis of secondary amine- (functionalities a and b) control and N-
diazeniumdiolate-functionalized (functionalities c and d) silica nanorods.  
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Table 4.2 Elemental analysis and zeta potential characterization of the secondary amine-
functionalized silica nanorods. 
 C (%) 
H 
(%) 
N 
(%) 
2o-amine content 
(μmol/mg) 
Zeta Potential 
( mV ) 
AR1-a 23.99 ± 1.41 5.38 ± 0.27 6.07 ± 0.18 2.19 ± 0.06 34.1 ± 1.6 
AR4-a 23.16 ± 3.38 5.22 ± 1.20 5.77 ± 1.40 1.74 ± 0.42 35.2 ± 3.6 
AR8-a 25.23 ± 5.50 5.47 ± 1.07 6.21 ± 1.22 2.43 ± 0.47 38.4 ± 1.2 
AR4-b 18.80 ± 1.24  4.04 ± 0.45 2.14 ± 0.22 1.53 ± 0.16 -8.1 ± 0.9 
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Table 4.3 Nitric oxide-release properties and surface charge (i.e., zeta potential) of N-
diazeniumdiolate NO donor-functionalized SNRs. 
[a] total NO storage per milligram particles. [b] total NO released after 4 h per milligram particles. 
 
 
 
 
 
 
 
 
 t[NO]
a 
(μmol/mg) 
t[NO]b 
(μmol/mg) 
[NO]max 
(ppb/mg) 
t1/2 
(h) 
Zeta Potential 
( mV ) 
AR1-c 0.76 ± 0.12 0.63 ± 0.07 5400 ± 1100 0.77 ± 0.10 -18.9 ± 0.7 
AR4-c 0.69 ± 0.09 0.59 ± 0.07 5000 ± 800 0.70 ± 0.09 -17.1 ± 0.9 
AR8-c 0.77 ± 0.13 0.64 ± 0.09 5380 ± 700 0.76 ± 0.10 -15.3 ± 0.4 
AR4-d 0.36 ± 0.04 0.27 ± 0.03 14000 ± 1200 0.16 ± 0.01 -20.8 ± 0.6 
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4.3.3 Bactericidal Activity as a function of SNR Aspect Ratio.  
Since the porosity of AR1-c, AR4-c, and AR8-c did not affect the NO-release 
kinetics of the nanorods, the direct comparison of AR1-c, AR4-c, and AR8-c allows for 
the study of how particle aspect ratio affects bactericidal activity. Bacteria killing assays 
were evaluated in nutrient-free (“static”) solutions with P. aeruginosa, a Gram–negative 
pathogen involved in burn and chronic wound infections.47-49 The minimum bactericidal 
concentration (MBC) reported represents the lowest dose of NO-releasing SNRs resulting 
in a 3 log reduction in bacteria viability after 4 h exposure. The corresponding dose of 
NO released from the SNRs over the 4 h is provided in Figure 4.2B.  
As shown in Figure 4.2, particles of higher aspect ratio killed bacteria at lower 
concentrations than lower-aspect ratio particles. For example, the MBCs for AR1-c, 
AR4-c, and AR8-c were 500, 250, and 150 μg/mL, respectively. The NO dose required to 
achieve a 3 log reduction in bacteria viability for AR8-c was ~0.10 μmol/mL, lower than 
that of AR1-c (~0.32 μmol/mL) or AR4-c (~0.15 μmol/mL).  Given that NO-releasing 
silica particles associate with bacteria (Figure 4.3), the enhanced activity of AR8-c 
against P. aeruginosa may be attributed to greater contact area between the particle and 
the bacteria membrane, resulting in a greater NO dose delivered to the membrane.11 
Confocal microscopy was used to confirm the greater NO delivery by AR8-c to the 
bacteria using 4,5-diaminofluorescein diacetate (DAF-2 DA), an intracellular NO 
sensitive dye. Briefly, the membrane-permeable DAF2-DA is hydrolyzed to the 
impermeable form, 4,5-diaminofluorescein (DAF-2), by intracellular esterases. In the 
presence of oxygen and NO, DAF-2 is converted to the green fluorescent derivative, 
triazolofluorescein.11 
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Figure 4.2 P. aeruginosa viability (in PBS) as a function of particle (A) and bactericidal 
NO (B) doses using the NO-releasing (solid symbols) SNRs. Control particles (open 
symbols) did not impact bacteria viability at SNR concentrations up to 1000 µg/mL, the 
maximum concentration tested. 
 
 
 
0 200 400 600 800 1000 1200
104
105
106
B
ac
te
ri
al
 V
ia
bi
lit
y 
(C
FU
/m
L)
Concentration (g/mL)
 AR1-c
 AR4-c
 AR4-d
 AR8-c
 AR1-a
 AR4-a
 AR4-b
 AR8-a
A
AR1-c AR4-c AR4-d AR8-c
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
B
ac
te
ri
ci
da
l N
O
 D
os
e 
(m
o
l/m
L)
B
124 
 
As shown in Figure 4.4, the intracellular NO delivered from AR8-c was observed at 
95 min via DAF-2 fluorescence (Figure 4.4E), ~25 min earlier than bacteria incubated 
with AR1-c (Figure 4.4B). At 125 min, a greater number of bacteria incubated with AR8-
c exhibited DAF-2 fluorescence compared to those incubated with AR1-c (Figure 4.5). 
When bacteria were incubated with AR8-c for 125 min, over half of the bacteria 
exhibited green DAF-2 fluorescence indicating the presence of intracellular NO. The NO 
delivered from AR8-c also resulted in cell death at 125 min. However, only one 
bacterium exhibited green fluorescence from intracellular NO after exposure to AR1-c 
and cell death was not observed. The greater fluorescence intensity from bacteria 
incubated with AR8-c indicated larger intracellular NO concentrations (Figure 4.4F). As 
described previously by Fang,3 some of NO’s antibacterial action is the result of NO 
reacting with superoxide, a product of bacteria respiration, to form peroxynitrite, a potent 
oxidative species that induces lipid peroxidation. The delivery of larger NO payloads to 
bacteria (e.g., by AR8-c) would accordingly lead to increased bactericidal activity. As 
expected, the corresponding secondary amine-functionalized control particles (AR1-a, 
AR4-a, AR8-a depleted of NO) exhibited no killing of P. aeruginosa at the MBCs of 
their NO-releasing counterparts (e.g., AR1-c, AR4-c, AR8-c).  
4.3.4 Influence of Nitric Oxide-Release Kinetics.  
In addition to studying shape-dependence, we sought to understand the influence of 
SNR NO-release kinetics on bactericidal activity. AR4-d and AR4-c SNRs with distinct 
NO-release profiles were thus exposed to P. aeruginosa. As shown in Figure 4.6, AR4-d 
displayed greater initial NO flux ([NO]max ~14000 ppb/mg) and faster decay (t1/2 =0.16 h) 
due to the PEG modification and faster N-diazeniumdiolate breakdown. 
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Figure 4.3 Association of fluorescently-labeled particles with bacteria. (A) AR1 with P. 
aeruginosa; (B) AR8 with P. aeruginosa; (C) AR1 with S. aureus; (D) AR8 with S. 
aureus. 
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Figure 4.4 Intracellular DAF-2 fluorescence from P. aeruginosa bacterial cells incubated 
with 22 µg/mL AR1-c (Bright field (A), 120 min (B), 125 min (C)) and AR8-c (Bright 
field (D), 95 min (E), 100 min (F)) and from S. aureus bacterial cells incubated with 
AR1-c (Bright field (G), 135 min (H), 155 min (I)) AR8-c (Bright field (J), 100 min (K), 
130 min (L)). Intensity of DAF-2 fluorescence indicates the intracellular concentration of 
NO and reactive nitrogen species. 
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Figure 4.5 Bright field (A, C) and overlay images of intracellular DAF-2 (green) and PI 
(red) fluorescence from P. aeruginosa cells incubated with 22 µg/mL AR8-c (B) and 
AR1-c (D) for 125 min. DAF-2 fluorescence indicates the presence of NO and reactive 
nitrogen species, while PI fluorescence indicates membrane destruction and cell death. 
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Bacteria killing assays against P. aeruginosa indicated that the bactericidal NO dose 
for AR4-d was approximately half that for AR4-c (~0.07 vs ~0.15 μmol/ml, respectively), 
suggesting that greater initial NO flux is favorable for killing P. aeruginosa. However, 
the total NO storage (e.g., t[NO]) for AR4-c was also greater than AR4-d. To rule out 
possible influence of NO release total, SNRs with similar t[NO] to AR4-d were prepared 
but with different [NO]max, denoted as AR4-c*. As reported by Carpenter et al.,16 the total 
NO storage from a N-diazeniumdiolate macromolecule scaffold is easily tuned by 
altering the concentration of sodium methoxide. In this study, reduced amounts of sodium 
methoxide (25 μL of 5.4 M sodium methoxide in methanol per 15 mg AR4-a particles) 
were used to prepare AR4-c*, thus matching the total NO storage of AR4-d (~0.27 
μmol/mg). 
Since the resulting [NO]max for AR4-c* (~2000 ppb/mg) was substantially lower than 
that of AR4-d (~14000 ppb/mg), the comparison between AR4-d and AR4-c* revealed 
the effect of NO flux on killing efficacy. As expected, the MBC for AR4-c* in a 4 h 
bacteria killing assay against P. aeruginosa was 4 mg/mL, substantially greater than that 
for AR4-d (0.25 mg/mL), illustrating the significance of a large initial NO flux (e.g., 
[NO]max) for killing this bacterium.  
4.3.5 Bactericidal Assays Against S. aureus.  
In contrast to P. aeruginosa, S. aureus is a Gram–positive bacteria with a thicker 
peptidoglycan layer and spherical morphology.50 Privett et al. previously reported that 
NO produced from small molecule NO donors (e.g., 1-[2-(carboxylato)pyrrolidin-1-
yl]diazen-1-ium-1,2-diolate (PROLI/NO)) was less effective at killing S. aureus 
compared to P. aeruginosa.12 
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Figure 4.6 Nitric oxide-release profiles for AEAI (c)- and APDE-PEG (d)-functionalized 
AR4 silica nanorods. Inset: total NO release of AR4-c, AR4-c* and AR4-d as a function 
of time. 
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A working hypothesis describing this phenomenon involves the thicker peptidoglycan 
layer decreasing NO diffusion to the inside of the bacterium. In this regard, high-aspect 
ratio SNRs may improve the bactericidal activity of the silica-based NO-releasing 
scaffolds against S. aureus by delivering NO more efficiently due to their shape. 
As shown in Figure 4.7, the MBCs for AR1-c, AR4-c, and AR8-c against S. aureus 
were 2000, 1000, and 300 μg/mL, respectively, greater than that against P. aeruginosa. 
We hypothesize that this behavior may be the result of decreased NO diffusion into the 
bacterium due to the more substantial (i.e., thicker) peptidoglycan layer for S. aureus. 
Confocal microscopy was used to characterize the NO diffusion to the inside of P. 
aeruginosa and S. aureus cells by monitoring the intracellular NO concentration as a 
function of time. As shown in Figure 4.4, intracellular NO was observed more quickly for 
P. aeruginosa (Figure 4.4E) than S. aureus (Figure 4.4K). Furthermore, the intracellular 
NO levels for S. aureus did not change between 110 (Figure 4.4K) and 130 min (Figure 
4.4L) indicating slower NO diffusion.  
Analogous to P. aeruginosa, AR8-c also delivered NO into the S. aureus cells 
more rapidly than AR1-c. As shown in Figure 4.4, DAF-2 fluorescence appeared at 110 
min (Figure 4.4K) compared to 135 min for AR1-c (Figure 4.4H). As such, the AR8-c 
exhibited the greatest bactericidal activity. Overall, a more dramatic shape dependence of 
MBCs was observed against S. aureus, illustrating the influence of greater NO doses 
from high-aspect ratio particles (Figure 4.4). As expected, the comparison between AR4-
c and AR4-d again reinforced the benefits of greater initial NO flux on bactericidal 
activity. Compared to PROLI/NO,12 each of the NO-releasing SNRs studied exhibited 
enhanced bactericidal activity against S. aureus. The bactericidal NO doses against S. 
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aureus for AR1-c and AR4-c were 1.264 and 0.586 μmol/mL, respectively, roughly four 
times greater than that against P. aeruginosa. For AR8-c and AR4-d, the bactericidal NO 
doses against S. aureus were 0.191 and 0.134 μmol/mL, only twice that against P. 
aeruginosa. These results suggest that the more effective NO delivery (e.g., greater NO 
dose and flux) to the bacterium from NO-releasing SNRs may compensate for the lower 
bactericidal action of NO against Gram–positive S. aureus.  
4.3.6 Bactericidal Assays in Protein (Nutrient)-Containing Medium.  
To confirm the efficacy of the NO-releasing silica rods in a protein-containing media, 
P. aeruginosa killing assays were conducted in PBS supplemented with 1% (v/v) trypsin 
soy broth (TSB) nutrient-containing medium.51 After 4 h incubation, the bacteria viability 
in 1% (v/v) TSB supplemented PBS in the absence of silica rods was ~106 CFU/mL. In 
contrast, the MBCs for AR1-c and AR8-c were 250 and 750 µg/mL, respectively, 
demonstrating the shape-dependent bactericidal action of NO-releasing silica rods in the 
protein- and nutrient-containing medium. Of note, greater concentrations of particles (e.g., 
AR1-c and AR8-c) were required to achieve 3-log killing under nutrient-supplemented 
condition (e.g., 1% v/v TSB supplemented PBS). As we reported previously, this 
behavior is attributed to NO scavenging by proteins.11 
4.3.7 Mammalian Cell Cytotoxicity of Nitric Oxide.  
MTS assays were performed against L929 mouse fibroblasts over 24 h to evaluate the 
toxicity of the NO-releasing SNRs at the MBCs from the bactericidal assays. Particle 
concentrations were selected from 150 to 2000 μg/mL to encompass the bactericidal 
concentrations of the NO-releasing SNRs in PBS. 
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Figure 4.7 S. aureus viability (in PBS) as a function of particle (A) and bactericidal NO 
(B) doses using the NO-releasing (solid symbols) SNRs. Control particles (open symbols) 
did not impact bacteria viability at SNR concentrations up to 2000 µg/mL, the maximum 
concentration tested. 
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The normalized cell viabilities after 24 h as a function of particle concentration are 
shown in Figure 4.8. Nitric oxide-releasing SNRs (i.e., AR1-c, AR4-c, AR8-c, AR4-d) 
were not toxic at concentrations < 500 μg/mL, while toxicity was observed at 1000 and 
2000 μg/mL. Further inspection of the cytotoxicity and bactericidal assay results revealed 
that AR8-c and AR4-d were nontoxic at the MBCs against both P. aeruginosa and S. 
aureus. Although AR1-c and AR4-c were also nontoxic at the P. aeruginosa MBCs, 
reduced L929 cell viability was observed at the S. aureus MBCs. MTS assays were also 
used to assess the cytotoxicity of secondary-amine functionalized control particles. As 
shown in Figure 4.8B, control particles also exhibited cytotoxicity at 1000 and 2000 
μg/mL, explaining the toxicity of the NO-releasing SNRs. Collectively, the cytotoxicity 
results reinforce the advantage of AR4-d (e.g., high initial NO flux) and AR8-c (e.g., 
large aspect ratio) as antibacterial agents relative to AR4-c and AR1-c SNRs. 
4.4 Conclusions 
The bactericidal activity of NO-releasing silica nanorods against Gram–negative (P. 
aeruginosa) and –positive (S. aureus) bacteria appear to depend on both the NO flux and 
particle morphology. For example, we found that significantly less NO is required to kill 
bacteria from NO-releasing silica nanorods with higher aspect ratio or greater NO flux 
due to more efficient NO delivery to the bacterium. Regardless of morphology or NO 
flux, the NO-releasing silica nanorods were nontoxic to L929 mouse fibroblast cells at 
bactericidal concentration against P. aeruginosa. In contrast, high aspect ratio (e.g., 8) 
NO-releasing SNRs were necessary to eradicate S. aureus at non-cytotoxic 
concentrations to L929 fibroblasts, demonstrating the variance in bactericidal efficacy 
and toxicity. 
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Figure 4.8 Cytotoxicity of NO-releasing (A) and control (B) SNRs to L929 mouse 
fibroblasts. 
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Of note, effective killing was nevertheless achievable at nontoxic (mammalian cells) 
concentrations. Future studies will evaluate the antibacterial efficacy of these particles in 
different biological media as NO scavenging by proteins and cells may require more NO 
delivery to achieve similar results. Antibiofilm efficacy studies should also be carried out 
as >99% of all bacteria live in biofilm communities that offer protection against 
antimicrobial agents.52  
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Chapter 5 
     Nitric Oxide-Releasing Chitosan Oligosaccharides as Anti-biofilm Agents 
 
5.1 Introduction 
Bacteria in nature exist in two states – free-floating planktonic bacteria and bacterial 
biofilms.1 While many antimicrobial agents have proved effective against planktonic 
bacteria, medically relevant infections including the infections associated with medical 
implants, non-healing wounds, diabetic mellitus, and cystic fibrosis are often caused by 
bacterial biofilms.2-5 Biofilms are communities of microorganisms adhered to a surface 
and surrounded by a self-produced extracellular polysaccharide (EPS) matrix that 
impedes immune response.6-7 Compared to planktonic bacteria, biofilm-based bacteria 
are more resistant to antibiotics due to several specific defense mechanisms including 
inefficient penetration of antimicrobial agents cross EPS.8-9 For example, the antibiotic 
dose to kill bacteria in biofilms may be 1000 times the dose required to kill planktonic 
bacteria.10 As such, new antimicrobial agents capable of eradicating mature biofilms are 
urgently needed.  
Nitric oxide (NO), a diatomic free radical produced endogenously, plays a key role in 
the mammalian immune response to pathogens.11-13 The bactericidal properties of NO are 
attributed to the nitrosative and oxidative stress exerted by its reactive byproducts such as 
dinitrogen trioxide and peroxynitrite, ultimately leading to the disruption of bacteria 
membrane.13 Nitric oxide-releasing materials have been widely developed for the use in a 
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number of different biomedical applications, many related to pathogen killing.14-17 Recent 
research has demonstrated the antimicrobial efficacy of small molecule (e.g., 1-[2-
(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO)) and macromolecular 
(e.g., silica nanoparticles and dendrimers) NO-releasing vehicles against both Gram–
positive and Gram–negative bacteria, including methicillin-resistant Staphylococcus 
aureus (MRSA).18-23 Nitric oxide-releasing macromolecular scaffolds (e.g., silica 
nanoparticles and dendrimers) are particularly attractive due to enhanced bactericidal 
activity against planktonic bacteria and biofilms compared to small molecule NO donors 
(e.g., PROLI/NO).20-23 Although NO-releasing silica particles proved effective at 
eradicating established biofilms, the lack of biodegradability greatly hinders the clinical 
utility of silica-based NO-releasing vehicles as antimicrobial agents. 
Biodegradable NO-releasing materials have been developed as implant coatings (e.g., 
poly(diol citrate) elastomers24 and polyesters25-27) to inhibit biofilm formation rather than 
eradicate established biofilms. To enable more efficient killing of biofilms, the design of 
new scaffolds is necessary to allow efficient EPS penetration and NO delivery to the 
bacteria embedded in the biofilms. Chitosan, the second most abundant natural 
biopolymer, has been widely used for biomedical applications including tissue 
engineering, drug delivery, and antimicrobial agents due to its biocompatibility, 
biodegradability and cationic composition.28-31 The use of chitosan derivatives as NO-
releasing scaffolds has also been investigated since these materials contain large 
concentrations of primary amines, necessary for N-diazeniumdiolate NO donor 
formation.32-34 Unfortunately, previously reported N-diazeniumdiolate-functionalized 
chitosan polysaccharides have been characterized by low N-diazeniumdiolate conversion 
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efficiency and NO storage (~0.2 µmol/mg), likely the result of chitosan insolubility under 
the basic conditions required for N-diazeniumdiolate formation.32-34 Additionally, the 
effectiveness of chitosan polysaccharides is a concern due to insolubility under 
physiological conditions.35,36 To obtain N-diazeniumdiolate-functionalized chitosan 
derivatives with greater NO storage, we synthesized chitosan oligosaccharides that are 
soluble under both neutral and basic conditions and highly effective  against 
Pseudomonas aeruginosa biofilms. 
5.2 EXPERIMENTAL 
5.2.1 Materials and Methods.  
Medium molecular weight chitosan, 2-methyl aziridine (MAz), rhodamine B 
isothiocyanate  (RITC), poly(ethylene glycol) methyl ether acrylate (average Mn = 480) 
(PEG), fetal bovine serum (FBS), Dulbecco's Modified Eagle's Medium (DMEM), 
phenazine methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), trypsin, 
phosphate buffered saline (PBS), and penicillin streptomycin (PS) were purchased from 
the Aldrich Chemical Company (Milwaukee, WI). Pseudomonas aeruginosa (ATCC 
#19143) was obtained from the American Type Culture Collection (Manassas, VA). 
Trypic soy broth (TSB) and Tryptic soy agar (TSA) are purchased from Becton, 
Dickinson, and Company (Franklin Lakes, NJ). L929 mouse fibroblasts (ATCC #CCL-1) 
were obtained from the University of North Carolina Tissue Culture Facility (Chapel Hill, 
NC). Distilled water was purified with a Millipore Milli-Q Gradient A-10 water 
purification system (Bedford, MA). Syto 9 green fluorescent nucleic acid stain was 
purchased from Life Technologies (Grand Island, NY). Common laboratory salts and 
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solvents were purchased from Fisher Scientific (Pittsburgh, PA). All materials were used 
as received without further purification unless noted otherwise. Nuclear magnetic 
resonance (NMR) spectra were recorded on a 400 MHz Bruker instrument. Elemental 
(carbon, hydrogen, and nitrogen or CHN) analysis was performed using a PerkinElmer 
Elemental Analyzer Series 2400 instrument (Waltham, MA). 
5.2.2 Synthesis of Chitosan Oligosaccharides.  
Chitosan oligosaccharides were prepared by oxidative degradation using hydrogen 
peroxide. Medium molecular weight chitosan (2.5 g) was suspended in a hydrogen 
peroxide solution (15 or 30 wt%) under stirring for 1 h at 65–85 oC. Following the 
removal of undissolved chitosan by filtration, chitosan oligosaccharides were precipitated 
from solution by adding acetone to the filtrate. The precipitate was collected by 
centrifugation, washed twice with ethanol, and dried under vacuum at room temperature. 
The viscosity of the chitosan oligosaccharides was measured in a solution of NaCl (0.20 
M) and CH3COOH (0.10 M) at 25 oC using an Ubbleohde capillary viscometer. 
Oligosaccharide molecular weight was determined using the classic Mark-Houwink 
equation (i.e., [η]=1.81×10−3 M0.93).39 
5.2.3 Synthesis of Secondary Amine-Functionalized Chitosan Oligosaccharides.  
2-methyl aziridine (MAz) grafted chitosan oligosaccharides were synthesized 
following a previously reported procedure.40 Briefly, a mixture of concentrated HCl (11 
µL), water (100 µL) and MAz with a 1:1 (Chitosan 1) or 2:1 (Chitosan 2) molar ratio to 
primary amines on the chitosan oligosaccharides was added dropwise to a solution of 
chitosan oligosaccharides (100 mg) in deionized water (5 mL). The resulting solution was 
stirred at room temperature for 5 d, and then at 75 oC for 24 h. The product was purified 
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by dialysis and collected by lyophilization. Any high molecular weight poly(2-methyl 
aziridine) in the product was removed by washing with methanol, and the resulting 
material was dried under vaccum at room temperature. Chitosan 2 was then dissolved in 
water at pH 10.0. The primary amine on the chitosan oligosaccharides was functionalized 
by adding poly(ethylene glycol) methyl ether acrylate to generate Chitosan 3. The 
resulting PEG-functionalized chitosan oligosaccharide derivative was purified by dialysis 
and collected by lyophilization. 
1H NMR data of Chitosan 1 and Chitosan 2 (400 MHz, CD3OD, δ): 0.8–1.1 
(NH2CH(CH3)CH2NH), 1.9 (C7: CHNHCOCH3),  2.3–2.7 (NH2CH(CH3)CH2NHCH, C2: 
NH2CH(CH3)CH2NHCH), 3.3–4.0 (C3, C4, C5, C6: OHCH, OCHCH(OH)CH(NH2)CH, 
OHCH2CH, OHCH2CH), 4.4 (C1: OCH(CHNH2)O). 1H NMR data of  Chitosan 3 (400 
MHz, CD3OD, δ): 0.8–1.1 (NH2CH(CH3)CH2NH), 1.9 (C7: CHNHCOCH3),  2.3–2.7 
(NH2CH(CH3)CH2NHCH, C2: NH2CH(CH3)CH2NHCH), 3.2 (OCH2CH2OCH3), 3.3–4.0 
(OCH2CH2O and C3, C4, C5, C6: OHCH, OCHCH(OH)CH(NH2)CH, OHCH2CH, 
OHCH2CH), 4.4 (C1: OCH(CHNH2)O). 
5.2.4 Synthesis of N-Diazeniumdiolate-Functionalized Chitosan Oligosaccharides.  
Secondary amine-functionalized chitosan oligosaccharides (Chitosan 1, Chitosan 2, 
and Chitosan 3) and 5.4 mM sodium methoxide (75 µL) were added to a methanol/water 
mixture (2 mL) of different v/v ratios (e.g., 10:0, 9:1, 8:2, 7:3, 6:4). The suspension was 
added to vials in a Parr hydrogenation vessel, which was purged rapidly (5–10 s) with 
argon three times followed by three longer argon purge cycles (10 min) to remove 
residual oxygen from the solution. The Parr hydrogenation vessel was then pressurized to 
10 atm with NO gas purified over KOH pellets (to remove NO degradation products) and 
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maintained at 10 atm for 3 d. The same argon purging protocol was performed to remove 
unreacted NO and degradation products from the solution prior to removing the vials 
from the vessel. 
5.2.5 Characterization of NO Storage and Release.  
N-diazeniumdiolate-functionalized chitosan oligosaccharides (1 mg) (Chitosan 1/NO, 
Chitosan 2/NO, Chitosan 3/NO) in the water/methanol mixture were added into a 
sample vessel containing 30 mL deoxygenated phosphate buffered saline (PBS) (10 mM, 
pH = 7.4) at 37 °C, which initiated NO release. To quantify the NO released, the solution 
was purged with nitrogen at a flow rate of 70 mL/min to carry the liberated NO to the 
analyzer. Additional nitrogen flow was supplied to the vessel to match the collection rate 
of the instrument (200 mL/min). The analysis of NO was terminated when the NO release 
levels fell to below 10 ppb NO/mg chitosan oligosaccharides. Chemiluminescence data 
for the NO-releasing chitosan oligosaccharides were represented as: 1) total amount of 
NO release (t[NO], µmol NO/mg of secondary amine-functionalized chitosan 
oligosaccharides); 2) the maximum flux of NO release ([NO]max, ppb/mg of secondary 
amine-functionalized chitosan oligosaccharides); and 3) the half-life of NO release (t1/2). 
5.2.6 Synthesis of Fluorescently-Labeled Chitosan Oligosaccharides.  
Fluorescently-labeled chitosan oligosaccharides were prepared following a previously 
reported procedure.41 Briefly, chitosan oligosaccharides (50 mg) were dissolved in water 
(2 mL) at pH 9.0. Rhodamine B isothiocyanate (RITC) was added to the solution in a 
1:100 molar ratio to the primary amine of the chitosan oligosaccharides prior to the 
grafting of 2-methyl aziridine. The solution was stirred at room temperature for 3 d in the 
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dark. Subsequent dialysis and lyophilization yielded the RITC-labeled chitosan 
oligosaccharides. 
5.2.7 Bactericidal Assays Under Static Conditions.  
P. aeruginosa bacterial cultures were grown from a frozen (-80 oC) stock overnight in 
TSB at 37 oC. A 500 μL aliquot of the resulting suspension was added into 50 mL fresh 
TSB and incubated at 37 oC for ~2 h until the concentration reached ~1×108 colony 
forming units (CFU)/mL, as confirmed by the OD600, replicate plating and enumeration 
on nutrient agar. A working bacterial stock was generated by plating the bacterial 
suspension on TSA and incubating at 37 oC overnight. The TSA bacterial stocks were 
prepared weekly and stored at 4 oC. For bactericidal assays, colonies of P. aeruginosa 
were taken from the TSA plate, dispersed in 3 mL TSB, and incubated at 37 oC overnight. 
A 500 μL aliquot of culture was added to 50 mL fresh TSB and incubated to a 
concentration of ~1×108 CFU/mL. The bacteria was collected by centrifugation, 
resuspended in PBS, and diluted to ~1×106 CFU/mL. The bactericidal efficacy of NO-
releasing chitosan oligosaccharides against P. aeruginosa was evaluated by incubating 
the bacteria suspension with NO-releasing chitosan oligosaccharides at 37 oC. At 4 h, 100 
μL aliquots of the bacterial suspensions were removed, diluted 10-fold in PBS, plated on 
TSA, and incubated overnight at 37 oC. The minimum concentration of NO-releasing 
chitosan oligosaccharides that resulted in a 3-log reduction of bacterial viability was 
defined as the minimum bactericidal concentration (MBC) for planktonic studies. 
5.2.8 Growth of P. aeruginosa Biofilms.  
A CDC bioreactor (Biosurface Technologies, Bozeman, MT) was used to grow P. 
aeruginosa biofilms over a 48 h period. Briefly, medical grade silicone rubber substrates 
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were mounted in coupon holders prior to assembling the reactor. The assembled reactor 
was then autoclaved. The reactor effluent line was clamped, and 1% (v/v) sterile TSB 
(500 mL) was added aseptically. P. aeruginosa was then cultured in TSB to 108 CFU/mL. 
The reactor was inoculated with an aliquot (1 mL) of this bacterial suspension at a final 
concentration ~2 × 105 CFU/mL. The reactor was incubated at 37 °C for 24 h with slow 
stirring (150 rpm). Following this “batch phase” growth, the reactor media was refreshed 
continuously with 0.33% (v/v) TSB at 6 mL/min for another 24 h through the effluent 
line.   
5.2.9 Treatment of P. aeruginosa Biofilms with NO-releasing Chitosan 
Oligosaccharides.  
 
 P. aeruginosa biofilms grown on silicone rubber substrates were exposed to chitosan 
oligosaccharide in PBS with slight agitation (37 °C, 24 h) to determine the minimum 
bactericidal concentration (MBC) necessary to elicit a 5-log reduction in viability. At 24 
h, samples were then sonicated and vortexed to disrupt the biofilm. Aliquots (100 µL) of 
the bacteria/chitosan suspensions were diluted and plated on TSA. After incubating the 
TSA plates overnight at 37 oC, bacteria viability was determined by counting observed 
colonies. Of note, the limit of detection for this selected plate counting method is 2.5 × 
103 CFU/mL. As such, biofilm growth conditions were selected to accurately represent a 
5-log reduction in viability for biofilms. 
5.2.10 Confocal Microscopy. 
 P. aeruginosa was cultured in TSB to a concentration of ~1 × 108 CFU/mL, collected 
via centrifugation (3645  g for 10 min), resuspended in sterile PBS, and adjusted to ~1 × 
106 CFU/mL. Aliquots of the bacteria solution were incubated in a glass bottom confocal 
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dish for 1.5 h at 37 °C. A Zeiss 510 Meta inverted laser scanning confocal microscope 
with a 543 nm HeNe excitation laser and a LP 585 nm filter was used to obtain 
fluorescence images of the rhodamine B isothiocyanate (RITC)-modified chitosan 
oligosaccharides. The bright field and fluorescence images were collected by a N.A. 1.2 
C-apochromat water immersion lens with a 40x objective. Solutions of RITC-labeled 
NO-releasing chitosan oligosaccharides in PBS (1.5 mL) were added to the bacteria 
solution (1.5 mL) in the glass confocal dish to achieve a final concentration of 150 μg/mL. 
Images were collected every 2 min to characterize the association, if any, of the chitosan 
oligosaccharides with P. aeruginosa temporally. To observe the association of chitosan 
oligosaccharides with bacteria within biofilms, Established biofilms stained with syto 9 
(10 µM) were incubated with RITC-labeled chitosan oligosaccharides (150 μg/mL in 
PBS) for 2.5 h. Prior to imaging, samples were rinsed with PBS (3x). A Zeiss 510 Meta 
inverted laser scanning confocal microscope with 488 nm Ar and 543 nm HeNe 
excitation lasers, and a BP 505–530 nm and LP 585 nm filters, respectively, was used to 
obtain all confocal images. Fluorescence images were collected with a 20x objective. 
5.2.11 In Vitro Cytotoxicity Testing of NO-releasing Chitosan Oligosaccharides.  
L929 mouse fibroblasts were grown in DMEM supplemented with 10% v/v fetal 
bovine serum (FBS) and 1 wt% penicillin/streptomycin, and incubated in 5% v/v CO2 
under humidified conditions at 37 oC. After reaching confluency (80%), the cells were 
trypsinized, seeded onto tissue-culture treated polystyrene 96-well plates at a density of 
3×104 cells/mL, and incubated at 37 oC for 48 h. The supernatant was then aspirated prior 
to adding fresh DMEM (200 μL) and the NO-releasing chitosan oligosaccharides solution 
in PBS (50 μL) to each well. After incubation at 37 oC for 24 h, the supernatant was 
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aspirated and a mixture of DMEM/MTS/PMS (105/20/1, v/v/v) (120 μL) was added to 
each well. The absorbance of the resulting colored solution after 1.5 h incubation at 37 oC 
was quantified using a Thermoscientific Multiskan EX plate reader at 490 nm. The 
mixture of DMEM/MTS/PMS and untreated cells were used as a blank and control, 
respectively. Cell viability was calculated as follows (Eq. 5.1). 
Cell Viability ൌ  ሺ Absorbance୲୰ୣୟ୲ୣୢ ୡୣ୪୪ െ Absorbanceୠ୪ୟ୬୩ሻሺ Absorbance୳୬୲୰ୣୟ୲ୣୢ ୡୣ୪୪ െ Absorbanceୠ୪ୟ୬୩ሻ                  Eq. 5.1 
5.3 Results and Discussion 
Chitosan has been widely used in antitumor, antimicrobial, and wound healing 
applications due to favorable biocompatibility and the ability to slowly degrade into 
nontoxic byproducts.40-43 This polymer has also been modified to store and release NO by 
functionalizing the primary amines with NO to form N-diazeniumdiolates. 32-34 
Unfortunately, the NO storage is rather modest (~0.2 µmol/mg) due to poor solubility of 
polysaccharides in basic solutions necessary for NO donor formation.32-34 To synthesize 
N-diazeniumdiolate-functionalized chitosan derivatives with improved NO storage, we 
prepared water-soluble chitosan oligosaccharides by the degradation of chitosan 
polysaccharides in hydrogen peroxide. An additional benefit of the low-molecular weight 
(MW < 8000) chitosan oligosaccharides involves their ability to more easily penetrate 
biofilms.39, 44 In this regard, we predict that low-molecular weight N-diazeniumdiolate-
modified chitosan oligosaccharides would have even greater bactericidal activity 
compared to the polysaccharides. 
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5.3.1 Synthesis of Secondary Amine-Functionalized Chitosan Oligosaccharides.  
A number of strategies have been reported for degrading chitosan into oligomer 
derivatives.38, 45 Rather than use enzymatic degradation requiring costly enzymes (e.g., 
chitosanase), we adapted an oxidative degradation strategy using hydrogen peroxide to 
synthesize chitosan oligosaccharides.38 Control of the molecular weight (Mw) was 
achieved by varying the concentration of hydrogen peroxide and degradation temperature. 
The viscosity of the chitosan oligosaccharides was determined in a solution of sodium 
chloride (0.20 M) and acetic acid (0.10 M) using an Ubbleohde capillary viscometer.37 In 
combination with the Mark-Houwink equation (i.e., [η] = 1.81×10−3 M0.93), molecular 
weights were determined as a function of processing conditions. Collectively, larger 
concentrations of hydrogen peroxide and elevated degradation temperatures led to lower 
molecular weight chitosan. As shown in Table 5.1, chitosan oligosaccharides of ~10 kD 
molecular weight were prepared in 15 wt% hydrogen peroxide at 65 oC for 1 h. 
Increasing the degradation temperature to 85 oC resulted in significantly smaller size 
(MW ~5 kD). When both a larger concentration of hydrogen peroxide (i.e., 30 wt%) and 
elevated temperature (i.e., 85 oC) were adopted, the molecular weight of chitosan 
oligosaccharides decreased further (~ 2.5 kD) were achieved. As shown in Table 5.2, the 
CHN elemental analysis of the oligosaccharides indicated an overall nitrogen content of 
6.3 wt%.  
To enhance NO storage (secondary amines are more readily converted to NO form 
due to their increased basicity22, 46-47), the primary amines on the synthesized chitosan 
oligosaccharides were thus modified by a cationic ring opening of MAz to produce 
secondary amine functionalities (Scheme 5.1A). 
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Table 5.1 Degradation conditions and elemental analysis of chitosan 
oligosaccharides of different molecular weights. 
Chitosan oligosaccharides Mva T (oC) [H2O2] (wt%) 
2.5 k 2657 85 30 
5 k 5370 85 15 
10 k 10142 65 15 
                 
 
 
 
 
 
 
 
a viscosity average molecular weight as determined by classic Mark-Houwink 
equation (i.e., [η] = 1.81×10−3 M0.93).  
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Table 5.2 Elemental (CHN) analysis of chitosan oligosaccharides and secondary amine-
functionalized derivatives. 
Materials C (%) H (%) N (%) 
Chitosan oligosaccharidesa 42.2 ± 1.6 6.8 ± 0.1 6.3 ± 0.2 
Chitosan 1-5k 43.5 ± 1.2 7.7 ± 0.3 8.9 ± 0.1 
Chitosan 2-5k 44.7 ± 1.8 8.4 ± 0.2 10.8 ± 0.8 
Chitosan 3-5k 51.0 ± 0.2  9.0 ± 0.2 3.1 ± 0.1 
Chitosan 2-2.5k 43.7 ± 0.7 8.5 ± 0.2 10.9 ± 0.1 
Chitosan 2-10k 44.7 ± 1.8 8.4 ± 0.2 10.8 ± 0.8 
       a chitosan oligosaccharides before the grafting of 2-methyl aziridine. 
    Each parameter was analyzed with multiple replicates (n=3). 
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By tuning the ratio of MAz and primary amine (e.g., 1:1 Chitosan 1, 2:1 Chitosan 2), 
the number of MAz repeating units grafted onto the chitosan oligosaccharides proved 
tunable (as verified by NMR), leading to a range of secondary amine concentrations and 
NO storage. To investigate how the local environment surrounding the N-
diazeniumdiolate NO donors affected the NO-release kinetics,22 acrylate-functionalized 
PEG chains were conjugated to the primary amines on Chitosan 2 by the Michael 
addition reaction to yield PEG-modified scaffolds (e.g., Chitosan 3, Scheme 5.1B). 
Grafting of 2-methyl aziridine to the oligosaccharides increased the corresponding 
nitrogen content from 6.3 to 8.9 and 10.8 wt% for Chitosan 1 and Chitosan 2, 
respectively. As expected, the PEGylation of Chitosan 2 led to a corresponding decrease 
in nitrogen content (3.1 wt%) (Chitosan 3). 
5.3.2 Synthesis of NO-releasing Chitosan Oligosaccharides.  
Reaction of the secondary amine-functionalized chitosan oligosaccharides (Chitosan 
1, Chitosan 2, and Chitosan 3) with NO (10 atm under basic conditions) yielded N-
diazeniumdiolate NO donor-functionalized chitosan oligosaccharides (Chitosan 1/NO, 
Chitosan 2/NO, and Chitosan 3/NO). The NO conjugation (“charging”) solvent dictates 
the charging efficiency and thus total NO storage.22 Aqueous solutions were necessary in 
order to adequately dissolve the chitosan oligosaccharides. Despite the high pH that 
should inhibit NO donor breakdown,47 NO donor formation due to the presence of water 
was a concern. To examine the influence of water concentration on N-diazeniumdiolate 
conversion efficiency, mixtures of methanol (a common charging solvent)22, 48 and water 
were prepared (10:0, 9:1, 8:2, 7:3, and 6:4 v/v) and the pH was adjusted to above 10 by 
adding sodium methoxide.  
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Scheme 5.1 Synthesis of secondary amine- and N-diazeniumdiolate-functionalized 
chitosan oligosaccharide derivatives. (A) grafting of 2-methyl aziridine onto primary 
amines of chitosan oligosaccharides (Chitosan 1 and 2) and N-diazeniumdiolation of the 
resulting materials (Chitosan 1 and 2-NO); (B) PEGylation of 2-methyl aziridine-
grafted-chitosan oligosaccharide (Chitosan 3) and the N-diazeniumdiolation of the 
resulting material (Chitosan 3-NO). 
 
 
 
 
 
 
 
A
B
Chitosan 1 x=1
Chitosan 2 x=2
Chitosan 1/NO x=1
Chitosan 2/NO x=2
Chitosan 3 x=2 Chitosan 3/NO x=2
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Chitosan 2/NO-5k was used as a representative oligosaccharide for these studies 
with the assumption that lower and greater MW chitosan oligosaccharides would behave 
similarly. The NO release profile for Chitosan 2/NO-5k as a function of the charging 
solvent are shown in Figure 5.1. Specific NO-release parameters (e.g., total NO release, 
maximum flux, and half-life) were extracted from these profiles and are provided in 
Table 5.3. The NO storage increased with increasing water/methanol ratios up to 7:3. The 
maximum NO storage (using the 7:3 methanol/water charging solvent ratio) was 0.87 
µmol/mg, roughly 4x larger than that for previously reported chitosan polysaccharides 
(~0.2 µmol/mg).37-39 The improved NO storage may be attributed to the enhanced 
solubility of Chitosan 2-5k in the charging solvents (e.g., methanol/water 9:1, 8:2, 7:3) 
relative to methanol. In charging solvent where Chitosan 2-5k was essentially insoluble 
(e.g., methanol), only secondary amines on the exterior of the Chitosan 2-5k precipitate 
were accessible to NO, leading to a lower NO donor formation efficiency. In contrast, 
complete dissolution exposes a significantly greater proportion of secondary amines to 
the base and NO. At larger water concentrations (i.e., methanol/water 6:4 v/v or 40% 
water), the NO storage decreased slightly (~0.76 µmol/mg), suggesting destabilization of 
the N-diazeniumdiolate NO donor by water. Chitosan 2/NO-5k exhibited similar NO-
release kinetics (e.g., half-life of ~2 h) regardless of the charging solvent, indicating that 
while the chemical structure (e.g., the local environment surrounding N-
diazeniumdiolates) of the NO-releasing scaffolds dictates NO-release kinetics, variation 
in charging solvent only affects the total NO storage. Overall, the NO-release data 
revealed that the optimal charging solvent was methanol/water 7:3 (v/v).  
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Table 5.3 Influence of charging solvent on nitric oxide-release properties for secondary 
amine-functionalized chitosan oligosaccharides (Chitosan 2/NO-5k) in PBS (pH = 7.4, 
37 °C) as measured using a chemiluminescence NO analyzer. 
MeOH/H2O 10:0 9:1 8:2 7:3 6:4 
t[NO]a (μmol/mg)  0.58 ± 0.09 0.74 ± 0.12 0.81 ± 0.14 0.87 ± 0.16 0.75 ± 0.18 
[NO]max (ppb/mg)  2648 ± 120 4150 ± 70 4350 ± 484 5500 ± 414 5000 ± 572 
Half-life (h)  2.40 ± 0.13 2.25 ± 0.02 2.05 ± 0.07 2.20 ± 0.14 2.05 ± 0.25 
a total NO storage per mg chitosan. Each parameter was analyzed with multiple replicates (n=3). 
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Figure 5.1 Nitric oxide release profiles of Chitosan 2/NO-5k in methanol (solid square), 
methanol/water 9:1 (solid circle), 8:2 (open triangle), 7:3 (solid triangle), and 6:4 v/v 
(open square). 
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This solvent composition was used for the functionalization of the other secondary 
amine-functionalized chitosan oligosaccharides (Chitosan 1-5k and Chitosan 3-5k). 
The antibacterial efficacy of NO-releasing materials has been reported to be 
dependent on both NO storage (i.e., payload) and release kinetics.49 2-methyl aziridine 
(MAz) was grafted onto the chitosan oligosaccharides at different feed ratios (i.e., 2:1 and 
1:1) to alter the secondary amine functionalization and NO storage. As expected, 
increasing the feed ratio of 2-methyl aziridine to primary amines from 1:1 (Chitosan 1-
5k) to 2:1 (Chitosan 2-5k) resulted in greater NO storage (e.g., ~0.30 to 0.87 µmol/mg, 
respectively). As shown in Figure 5.2, the NO flux and storage of Chitosan 1/NO-5k 
were lower than Chitosan 2/NO-5k, a result that is attributable to the smaller amine 
concentration of Chitosan 1-5k (~8.9 wt%) compared to Chitosan 2-5k (~10.8 wt%). 
To tune the NO-release kinetics of chitosan oligosaccharides further, Chitosan 2-5k 
was modified with acrylate-functionalized PEG chains (Chitosan 3-5k). As expected, 
hydrophilic functionalization of the oligosaccharides with PEG facilitated a more 
aqueous local environment and result in both larger initial NO flux (~12600 ppb/mg) and 
faster overall NO release (half-life ~0.15 h) relative to Chitosan 2-5k (Figure 5.2).22 The 
PEGylation of primary amines on Chitosan 2-5k also affected its ionic characteristics by 
shielding the amine moieties, a key factor influencing the association of chitosan-based 
materials with bacteria.36 The distinct NO-release kinetics and ionic characteristics of the 
resulting NO-releasing chitosan oligosaccharides allowed for the study of how surface 
charge and NO release affect anti-biofilm activity. 
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Table 5.4 Nitric oxide-release properties of different N-diazeniumdiolate NO donor-
functionalized chitosan oligosaccharides in PBS (pH = 7.4, 37 °C) as measured using a 
chemiluminescence NO analyzer. 
Material t[NO]
a 
(μmol/mg) 
t[NO]b  
(μmol/mg)
[NO]max 
(ppb/mg) 
t1/2 
(h) 
Chitosan 1/NO-5 k  0.30 ± 0.04 0.16 ± 0.03  1600 ± 215 3.60 ± 0.13 
Chitosan 2/NO-5 k  0.87 ± 0.16 0.52 ±  0.15  5500 ± 414 2.20 ± 0.14 
Chitosan 3/NO-5 k  0.35 ± 0.02 0.29 ± 0.01  12600 ± 2121 0.15 ± 0.01 
Chitosan 2/NO-2.5 k 0.84 ± 0.04  0.49 ± 0.02  7500 ± 550 2.06 ± 0.10 
Chitosan 2/NO-10 k 0.81 ± 0.05  0.47 ± 0.03  7350 ± 672 2.04 ± 0.05 
a total NO released and b NO released over 24 and 4 h (μmol) per milligram of secondary amine-
functionalized PPI. Each parameter was analyzed with multiple replicates (n=3). 
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Figure 5.2  Real-time NO release profiles (A) and plot of t[NO] vs time (B) for NO-
releasing chitosan oligosaccharides (e.g., Chitosan 1-5k (solid line), Chitosan 2-5k (dot 
line), and Chitosan 3-5k (dash dot line)). 
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5.3.3 Bactericidal Studies: Planktonic Bacteria. 
Control and NO-releasing chitosan oligosaccharides (e.g., Chitosan 1/NO -5k, 
Chitosan 2/NO-5k, Chitosan 3/NO -5k) were exposed to Gram–negative P. aeruginosa, 
a pathogen involved in infections associated with burn wounds and cystic fibrosis, to 
evaluate their ability to kill bacteria.5, 50 Bacterial viability assays were performed under 
static conditions to determine the concentration of chitosan required to reduce bacteria 
viability by 3 logs (i.e., 99.9% killing), which hereafter will be referred to as the 
minimum bactericidal concentration or MBC. The amount of NO delivered from NO-
releasing chitosan oligosaccharides (Table 5.4) over the time of the assay (4 h) was also 
examined to quantitatively assess the NO dose necessary for 99.9% bacterial killing. Both 
MBCs and the bactericidal NO doses required for the chitosan oligosaccharides are 
provided in Table 5.5. Each of the NO-releasing chitosan oligosaccharides studied 
(Chitosan 1/NO-5k, Chitosan 2/NO-5k and Chitosan 3/NO-5k) resulted in ≥99.9% 
killing of P. aeruginosa. At equivalent concentrations, the control (non-NO-releasing) 
chitosan did not lead to a significant reduction in bacterial viability, indicating NO as the 
bactericidal agent (data not shown). Further inspection of the bactericidal NO doses in 
Table 5.5 reveals that greater NO levels were required from Chitosan 3/NO-5k 
compared to Chitosan 1/NO-5k and Chitosan 2/NO-5k to kill P. aeruginosa. This 
behavior may be attributed to decreased interaction between the chitosan 
oligosaccharides and bacteria membrane. Sun et al. previously reported that positively 
charged dendrimers associated more readily with bacteria than neutral dendrimers. 
enhanced bactericidal action was the result of such interactions.23 The less effective 
bacteria killing observed for Chitosan 3/NO-5k could stem from the ability of the neutral 
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PEG chains to shield the amine moieties. In contrast, Chitosan 1/NO-5k and Chitosan 
2/NO-5k have positively charged primary amines at pH 7.4 on their exterior that enhance 
their association with the bacteria and facilitate more localized NO delivery. 
To further confirm that the lessened antibacterial activity of Chitosan 3/NO-5k was 
the result of decreased interactions with the bacteria membrane, confocal microscopy was 
utilized to compare the association kinetics of Chitosan 3/NO-5k and Chitosan 2/NO-
5k with bacteria. Rhodamine B isothiocyanate (RITC)-labeled Chitosan 2/NO-5k and 
Chitosan 3/NO-5k were synthesized as previously reported.39 The potential impact of 
RITC on chitosan-bacteria association was minimized by using small concentration of 
RITC (i.e., in 1:100 molar ratio to total primary amines). The degree of association of the 
NO-releasing chitosan oligosaccharides with bacteria was then followed by measuring 
red fluorescence surrounding the bacteria. As expected, Chitosan 2/NO-5k associated 
with the bacteria more rapidly (within 24 min) than Chitosan 3/NO-5k (86 min) (Figure 
5.3).  The fluorescence from Chitosan 2/NO-5k at 42 min was significantly greater than 
that of Chitosan 3/NO-5k at 110 min, further demonstrating that Chitosan 3/NO-5k 
associated with the bacteria at a much slower rate due to the PEG (neutral) modification. 
Further inspection of Chitosan 2/NO-5k and Chitosan 3/NO-5k association with P. 
aeruginosa revealed enhanced bacteria association for Chitosan 2/NO-5k (Figure 5.3-G, 
H), confirming the benefits of the cationic/positive properties of Chitosan 2/NO-5k over 
Chitosan 3/NO-5k.  
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Table 5.5  Minimum bactericidal concentration (MBC) and NO 
doses of NO-releasing chitosan oligosaccharides for 3-log 
reduction in planktonic P. aeruginosa viability. 
Chitosans MBC  (µg/mL)  NO dose (µmol/mL)  
Chitosan 1/NO-5k 2000 0.32 
Chitosan 2/NO-5k 200 0.10 
Chitosan 3/NO-5k 1500 0.45 
Chitosan 2/NO-2.5k 250 0.12
Chitosan 2/NO-10k 250 0.12
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Figure 5.3 Bright field and fluorescent images of RITC-modified Chitosan 2/NO-5k at A) 
24, B) 28, C) 42 min and Chitosan 3/NO-5k at D) 82, E) 86, F) 110, H) 120 min (150 μg 
mL-1) association with P. aeruginosa. Overlay images of P. aeruginosa incubated with G) 
Chitosan 2/NO-5k at 44 min and H) Chitosan 2/NO-5k at 120 min. 
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In addition to charge effect, we sought to study the role of molecular weight in P. 
aeruginosa killing. Chitosan oligosaccharides of ~2.5, 5, and 10 kD were synthesized and 
functionalized with NO (Chitosan 2/NO-2.5 k, Chitosan 2/NO-5 k, Chitosan 2/NO-10 
k). As expected, these materials exhibited similar NO-release kinetics (Table 5.4) due to 
the similar nitrogen content, allowing for the study of how molecular weight impacts 
bactericidal efficacy. Regardless of size (i.e., molecular weight), each of the NO-
releasing chitosan oligosaccharides (Chitosan 2/NO-2.5 k, Chitosan 2/NO-5 k, 
Chitosan 2/NO-10 k) exhibited similar bactericidal NO concentrations (i.e., ~10 µmol 
NO/mL) for 3-log killing (Table 5.5). 
5.3.4 Bactericidal Studies: Biofilms Eradication. 
As previously reported, NO-releasing scaffolds have proven effective against both 
planktonic and biofilm bacteria.20, 23, 51-52 For example, Barraud et al.  reported that 
exposing established biofilms to NO (from small molecule NO donors) greatly enhanced 
the anti-biofilm efficacy of antimicrobial compounds including tobramycin, hydrogen 
peroxide, and sodium dodecyl sulfate.52 Hetrick et al. demonstrated the use of 
macromolecular NO-releasing scaffolds (e.g., N-diazeniumdiolate-modified silica 
particles) to eradicate a broad-spectrum of biofilms with comparable or reduced toxicity 
(~80% viability reduction) against mammalian cells versus currently administered 
antiseptics (e.g., povidone iodine or chlorhexidine).51 Based on these prior studies, we 
expected the NO-releasing chitosan oligosaccharides to also be effective against biofilms 
with perhaps less toxicity against mammalian cells than other scaffolds (e.g., silica, 
dendrimers).53. 
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To evaluate the anti-biofilm activity of NO-releasing chitosan oligosaccharides (e.g., 
Chitosan 1/NO-5k, Chitosan 2/NO-5k, Chitosan 3/NO-5k), P. aeruginosa biofilms 
were exposed to 0.2–1.3 mg/mL NO-releasing chitosan oligosaccharides for 24 h 
(corresponding to ~0.17–0.46 µmol NO/mL). After treatment, the biofilms were removed 
from the silicone rubber substrates by vortexing and sonication to enable viability 
quantification.52 Control experiments were performed to confirm the growth of P. 
aeruginosa biofilms using the selected protocol. As shown in Figure 5.4, the viability of 
P. aeruginosa in the biofilm was ~2×108 CFU when exposed only to PBS. The chitosan 
concentrations for 5-log reduction of biofilm bacteria viability (MBC) were 400, 700, and 
1000 µg/mL for Chitosan 2/NO-5k, Chitosan 1/NO-5k, and Chitosan 3/NO-5k, 
respectively. Chitosan 2/NO-5k exhibited the greatest anti-biofilm efficacy, a likely 
result due to both increased NO storage/release and rapid association with the negatively 
charged bacteria. Although Chitosan 1/NO-5k and Chitosan 3/NO-5k stored similar 
levels of NO (~0.3 µmol/mg), Chitosan 1/NO-5k was more effective at eradicating the 
biofilm bacteria (MBC 700 µg/mL) compared to Chitosan 3/NO-5k (MBC 1000 µg/mL). 
The decreased antibiofilm efficacy for Chitosan 3/NO-5k may result from the shielding 
of the amine moieties by the neutral PEG chains, thus impeding association with the 
negatively charged exterior of the bacteria. To confirm this hypothesis, the association of 
Chitosan 2/NO-5k and Chitosan 3/NO-5k with P. aeruginosa biofilm was evaluated 
using confocal microscope. As shown in Figure 5.5, biofilms exposed to Chitosan 2/NO-
5k exhibited more intense red fluorescence compared to Chitosan 3/NO-5k, again 
confirming the enhanced association of the positively charged Chitosan 2/NO-5k with 
the bacteria.  
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Figure 5.4  Anti-biofilm efficacy of NO-releasing (solid symbols) and control (open 
symbols) chitosan oligosaccharides (Chitosan 1-5k (sphere), Chitosan 2-5k (square), 
and Chitosan 3-5k (triangle)) against established P. aeruginosa biofilms. Control 
chitosan oligosaccharides resulted in no significant reduction in bacteria viability. 
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Figure 5.5 Confocal fluorescence images of RITC-labeled chitosan oligosaccharide 
association with P. aeruginosa in biofilms (A. Chitosan 2/NO-5k, B. Chitosan 3/NO-5k, 
C. Chitosan 2-10k) and images of syto 9 labeled biofilms incubated with D) Chitosan 
2/NO-5k, E) Chitosan 3/NO-5k and F) Chitosan 2/NO-10k. Green fluorescence of syto 
9 indicates the P. aeruginosa bacteria embedded in the biofilms. Red fluorescence of 
RITC indicates the association of RITC-labeled chitosan oligosaccharides with P. 
aeruginosa in biofilms. Scale bar: 40 µm. 
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The efficient association of chitosan oligosaccharides with bacteria in biofilms is a great 
advantage over previously reported NO-releasing polysaccharides which are not expected to 
penetrate the exopolysaccharides matrix due to their insolubility under physiological conditions. 
Although chitosan molecular weight was not observed to play a significant role in 
planktonic killing, less effective bacteria killing was observed when using Chitosan 
2/NO-10k, the largest chitosan oligosaccharides (600 µg/mL vs. 400 µg/mL for 
Chitosan 2/NO-10k and Chitosan 2/NO-2.5k) against biofilms. The exopolysaccharides 
matrix is likely slowing the diffusion of the largest chitosan structure. Takenaka et al., 
previously reported less efficient EPS penetration of high (vs low)-molecular weight 
dextran,53 further supporting this hypothesis that the impeded diffusion of Chitosan 
2/NO-10k led to slow association with bacteria within the biofilms (Figure 5.5). Control 
chitosan oligosaccharides (e.g., Chitosan 1, Chitosan 2, and Chitosan 3) did not lead to 
a significant reduction in bacterial viability at the same concentrations as their NO-
releasing counterparts, indicating that the observed bacterial killing was due to NO from 
the N-diazeniumdiolate-functionalized chitosan oligosaccharides rather than the chitosan 
scaffolds themselves. 
5.3.5 Cytotoxicity of NO-releasing Chitosan Oligosaccharides to Mammalian 
Fibroblasts.  
 
The benefit of utilizing chitosan as NO-releasing vehicles includes its non-toxic 
nature to mammalian cells. The cytotoxicity of control and NO-releasing chitosan 
oligosaccharides were compared by exposing mouse fibroblast cells to the 
oligosaccharides at the MBCs against P. aerugionsa biofilms noted above.  The 
normalized cell viabilities of control and NO-releasing chitosan oligosaccharides after 24 
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h incubation are shown in Figure 5.6. Regardless of size (i.e., molecular weight), the 
control and NO-releasing chitosan oligosaccharides were non-toxic against mouse 
fibroblast cells at the MBCs for the NO-releasing scaffolds, indicating an advantage of 
these materials as anti-biofilm agents compared to other antibacterial agents.51 Of note, 
the NO-releasing chitosan oligosaccharides exhibited lower cytotoxicity than the chitosan 
controls, corroborating previous reports that certain levels of NO may promote cell 
proliferation.54-55 Indeed, treatment of mouse lung endothelial cells and human aortic 
endothelial cells with small molecule NO donors such as S-nitroso-L-glutathione (GSNO), 
S-nitroso-N-acetylpenicillamine (SNAP), N-diazeniumdiolated-diethyltriamine 
(DETA/NO) has been shown to promote proliferation.56-57 Collectively, the antimicrobial 
activity against planktonic and biofilm bacterial and the lack of toxicity of NO-releasing 
chitosan oligosaccharides suggests that NO-releasing chitosan oligosaccharides may 
serve as ideal antimicrobial agents for applications including wound healing and cystic 
fibrosis. 
5.4 Conclusions 
Chronic infections associated with diabetic mellitus and cystic fibrosis pose great 
medical challenges and cost billions of dollars annually.58 Nitric oxide-releasing 
materials hold great potential as antimicrobial therapeutics due to their biocidal efficacy 
against medically relevant and antibiotic-resistant bacteria and non-systemic risk.23, 48 
This chapter focused on the synthesis of N-diazeniumdiolate-modified chitosan 
oligosaccharides with controlled NO storage (e.g., four times greater than prior NO-
releasing chitosan polysaccharides) and tunable NO-release kinetics by tailoring the 
number of secondary amines and the hydrophobicity of the local environment 
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Figure 5.6  Viability of L929 mouse fibroblasts exposed to control and NO-releasing 
chitosan oligosaccharides at concentration for 5-log bacteria viability reduction (MBC) 
against P. aeruginosa biofilms. Each parameter was analyzed with multiple replicates 
(n=3). 
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surrounding the N-diazeniumdiolates, respectively.The water solubility of chitosan 
oligosaccharides allows for both beneficial diffusion into biofilms and subsequent 
association with bacteria, resulting in efficient eradication of biofilm bacteria at 
concentrations eliciting minimal toxicity against L929 mouse fibroblast cells. This study 
demonstrates the potential of NO-releasing chitosan oligosaccharides as antimicrobial 
agents. Experiments are underway to evaluate the biocidal efficacy of these materials 
against a broad spectrum of bacteria strains including methicillin-resistant 
Staphylococcus aureus and cystic fibrosis-related P. aeruginosa strains (e.g., 
mucoid/alginate-producing strains). Future work should also focus on evaluating their 
anti-biofilm efficacy in vivo and more detailed pharmacological toxicity testing of the 
NO-releasing chitosan oligosaccharides with human cells. 
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Chaper 6 
      Summary and Future Directions 
 
6.1 Summary 
In recent years, nitric oxide-releasing scaffolds have been used as antimicrobial 
agents and have been proved effective at inhibiting bacterial growth and also bacteria 
killing.1-3 N-diazeniumdiolate-modified silica particles and dendrimer exhibited enhanced 
bactericidal efficacy compared to small molecule NO donors due to the association of 
such (macromolecular) scaffolds with bacteria.1, 4 Size- and NO release-dependent 
bacteria killing of NO-releasing silica particles and dendrimers have also been observed 
with smaller scaffolds and high NO flux more effective.4-5 Clearly, the scaffold for NO 
delivery plays an important role in the delivery efficiency and the subsequent bactericidal 
efficacy. My research has focused on the development of NO-releasing silica particles, 
dendrimers, and chitosans for enhanced bactericidal efficacy and reduced toxicity to 
mammalian cells. 
Chapter 2 presented the synthesis of structurally diverse secondary amine-
functionalized poly(propylene imine) (PPI) dendrimers capable of tunable nitric oxide 
(NO) release using ring-opening or conjugate-addition reactions with propylene oxide 
(PO), styrene oxide (SO), acrylonitrile (ACN), poly(ethylene glycol) methyl ether 
acrylate (average Mn = 480) (PEG) or 1,2-epoxy-9-decene (ED). N-Diazeniumdiolate 
nitric oxide donors were formed on the resulting secondary amine-functionalized G2-G5 
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PPI dendrimers by reaction with NO gas in basic solution. The NO storage and release 
kinetics for the resulting dendritic scaffolds were diverse (0.9-3.8 µmol NO/mg totals and 
0.3 to 4.9 h half lives), illustrating the importance of the exterior chemical modification 
(e.g., steric environments, hydrophobicity, etc.) on diazeniumdiolate 
stability/decomposition. Even more tunable NO release was demonstrated by combining 
two NO donor systems on the exterior of one macromolecular scaffold. The approaches 
described in this chapter extend the range and scope of NO-releasing macromolecular 
scaffolds by unlocking a series of materials for use as dopants in biomedical polymers or 
stand-alone therapeutics depending on the exterior modification. 
In Chapter 3, a series of amphiphilic nitric oxide (NO)-releasing poly(amidoamine) 
(PAMAM) dendrimers with different exterior hydrophobicities were synthesized by a 
ring-opening reaction between primary amines of the dendrimers and propylene oxide 
(PO), 1,2-epoxy-9-decene (ED), or a ratio of the two, followed by reaction with NO at 10 
atm to produce N-diazeniumdiolate-modified scaffolds with a total storage of ~1 
µmol/mg to study how the hydrophobiciy affects their NO delivery efficiency, 
penetration of extracellular polysaccharides, and bactericidal efficacy. The 
hydrophobicity of the exterior functionality was tuned by varying the ratio of PO and ED 
grafted onto the dendrimers. The bactericidal efficacy of these NO-releasing vehicles was 
then evaluated as a function of dendrimer exterior hydrophobicity (i.e., ratio of PO/ED), 
size (i.e., generation), and NO release against established Gram-negative Pseudomonas 
aeruginosa biofilms. Both the size and the exterior functionalization of dendrimer proved 
important for dendrimer association with bacteria, the efficiency of NO delivery, bacteria 
membrane disruption, migration within the biofilm, and toxicity to mammalian cells. 
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Although enhanced bactericidal efficacy was observed for the hydrophobic chains (e.g., 
ED), toxicity to L929 mouse fibroblast cells was also noted at the concentrations 
necessary to reduce bacterial viability by 5-logs (99.999% killing). The optimal PO to ED 
ratios for biofilm eradication with minimal toxicity against L929 mouse fibroblast cells 
were 7:3 and 5:5. This study demonstrates the importance of both dendrimer size and 
exterior properties in determining ultimate therapeutic utility (i.e., efficacy against 
established biofilms without compromising biocompatibility to mammalian cells). 
The synthesis of silica nanorods (SNRs) was decribed in Chapter 4 
Aminoalkoxysilanes were used to modify the surface of the rods to prepare a new class of 
nitric oxide (NO)-releasing materials. Both the aspect ratio and size of the SNRs were 
tuned by varying the temperature, pH, and silane concentration used during the 
surfactant-templated synthesis. N-Diazeniumdiolates nitric oxide (NO) donors were 
formed on the secondary amine-functionalized SNRs by reaction with NO gas under 
basic conditions. Particle surface modification by hydrophilic poly(ethylene glycol) was 
employed to yield rapid NO-release kinetics. The diverse morphology (i.e., aspect ratio 
~1–8), NO-release kinetics (2000–14000 ppb NO/mg particle) and similar size (i.e., 
particle volume ~0.02 μm3) of the resulting NO-releasing SNRs facilitated further study 
of how particle shape and NO flux impacts bactericidal activity against Gram–positive 
Staphylococcus aureus (S. aureus) and Gram–negative Pseudomonas aeruginosa (P. 
aeruginosa) bacteria. The biocidal action of these materials improved with increasing 
particle aspect ratio and initial NO flux. Both chemical (i.e., NO-release kinetics) and 
physical (i.e., morphology) properties greatly influenced the bactericidal activity of these 
materials. 
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In Chapter 5, I described the synthesis of secondary amine-functionalized chitosan 
oligosaccharides of different molecular weights (i.e., ~2500, 5000, 10000) by grafting 2-
methyl aziridine onto the primary amines on chitosan oligosaccharides. The amines were 
then reacted with nitric oxide (NO) gas under basic conditions to yield N-
diazeniumdiolate NO donors. The total NO storage (e.g., 0.30–0.87 µmol/mg) and 
maximum NO flux (e.g., 1600–12600 ppb/mg) of the resulting NO-releasing chitosan 
oligosaccharides were controlled by the molar ratio of 2-methyl aziridine to primary 
amines (e.g., 1:1, 2:1) and the functional group surrounding the N-diazeniumdiolates (e.g., 
polyethylene glycol (PEG) chains), respectively. Compared to previous chitosan-based 
materials, significantly greater NO storage was achieved through increased solubility of 
the chitosan oligosaccharides in the basic conditions necessary for N-diazeniumdiolate 
formation. In addition, the water-solublibility of the chitosan oligosaccharides facilitated 
their diffusion into Pseudomonas aeruginosa biofilms and association with embedded 
bacteria. The resulting biofilm eradication of these chitosan oligosaccharides was shown 
to depend on both the molecular weight and ionic characteristics. Low molecular weight 
(i.e., ~2500 and 5000) and cationic chitosan oligosaccharides exhibited rapid diffusion 
into biofilms and association with bacteria, leading to enhanced biofilm killing. At 
concentrations resulting in 5-log killing (≥ 99.999%), the NO-releasing and control 
chitosan oligosaccharides elicited no cytotoxicity to mouse fibroblast L929 cells in vitro. 
Conversely, antiseptics such as povidone iodine and chlorhexidine reduce mouse 
fibroblast L929 cells viability by ~90%. The water soluble NO-releasing chitosan 
oligosaccharides presented in this chapter effectively eradicated bacterial biofilms with 
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no cytotoxicity to mammalian cells, thus demonstrating their potential as anti-biofilm 
agents. 
6.2 Future Directions  
The work presented in this thesis indicates the potential of NO-releasing amphiphilic 
dendrimers, silica nanorods, and chitosan oligosaccharides as antimicrobial agents. To 
fully explore their therapeutic effect, the bactericidal efficacy against a broader spectrum 
of bacteria should be undertaken, along with in animal models need to be evaluated. The 
development of materials with enhanced NO storage and NO delivery efficiency should 
also continue to further improve the therapeutic potential of NO release. 
6.2.1 NO-Releasing Mesoporous Silica Nanorods with Enhanced NO Storage 
The synthesis of NO-releasing mesoporous silica particles was presented in Chapter 3 
by anchoring aminosilanes on the particle surface, followed by the reaction with NO gas 
to form N-diazeniudmiolate NO donors.  The resulting particles were characterized by a 
NO storage of ~0.8 µmol/mg. To increase the NO storage, the synthesis of mesoporous 
silica particles consisting of aminosilanes throughout the particle should be investigated. 
Suteewong et al. reported the synthesis of mesoporous silica particles containing >50% 3-
aminopropyltrimethoxysilane (APTES) via co-condensation of tetraethyoxysilane (TEOS) 
and APTES.6 The highly aminated particles were prepared via base-catalyzed sol-gel 
silica reactions using hexadecyltrimethyl ammonium bromide (CTAB), TEOS, and large 
molar amounts of APTES in the presence of ethyl acetate. Significant amine content in 
these particles is reflected by a strongly positive zeta potential of the acid-extracted 
particles in water (i.e., 42 ± 5 mV). Following this procedure, hybrid particles via the co-
condensation of TEOS and secondary amine-containing silanes (e.g., N-(6-
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Aminohexyl)aminopropyltrimethoxysilane or AHAP) should be achievable and expected 
to have greater NO storage compared to aminosilane-grafted particles. 
Another strategy of enhancing the total NO storage might be growing amine-
containing polymer brushes from the surface of silica particles. As depicted in Scheme 
6.1, an aminosilane is anchored onto the silica particle surface, following by the growth 
of the poly(2-methyl aziridine) “brushes” from the surface of the particles via the ring 
opening of 2-methyl aziridine.7 Tunable NO storage could be yielded by controlling the 
molecular weight of the poly(2-methyl aziridine). The NO-release kinetics of the 
resulting particles may be adjusted by conjugating liphiphilic groups of varied 
hydrophobicity to the primary amines at the end of poly(2-methyl aziridine) brushes, as 
discussed in Chapter 5. 
6.2.2 Nitric Oxide-Releasing Chitosan Oligosaccharides for Cystic Fibrosis 
Cystic fibrosis (CF) is an inherited disease caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene,8 resulting in the malfunction of 
CFTR gene and ultimately interfering with mucociliary clearance of inhaled 
microorganisms.9 In healthy individuals, the cilia of epithelial cells in the upper airway 
efficiently remove microbes and particles that are trapped in the thin fluidic mucus (a 
process termed mucociliary clearance). In patients with CF, the cilia cannot clear the 
viscous and dehydrated mucus layer efficiently, which results in colonization by bacteria 
and chronic infection.9 P. aeruginosa in the chronically infected lung leads to immune 
complex-mediated inflammation, dominated by polymorphonuclear leukocytes (PMNs), 
often resulting in lung tissue damage and decreased lung function, in addition to the 
damage that is actively caused by the bacteria.10 
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Scheme 6.1 Synthesis of NO-releasing silica particles with surface-grafted N-
diazenimdiolate-modified polyamines. A) grafting of aminosilane on the particles surface; 
B) polymerization of 2-methyl aziridine on the particle surface; C) Diazeniumdiolation of 
secondary amines on the poly(2-methyl aziridine) chains. 
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Intensive treatment with antibiotics has extended the mean expected lifetime of CF 
patients dramatically,11 but the heavy use of antibiotics in CF clinics has led to the 
development of antibiotic-resistant bacteria. For example, P. aeruginosa isolates from CF 
patients are commonly found to be resistant to all clinically relevant classes of 
antibiotics.12 As such, the urgent need for a new class of antimicrobial agents for CF 
treatment is urgent. 
Nebulization is one common method of pulmonary drug administration that has been 
used for many years to treat CF.13 We hypothesize that water soluble NO-releasing 
chitosan oligosaccharides can be dissolved in water and nebulized for effective delivery 
of NO to the lungs. The diffusion of NO-releasing chitosan oliogsaccharides as a function 
of molecular weight in the mucus should be studied by monitoring the migration of 
fluorescently labeled chitosans using confocal microscopy.  The bactericidal efficacy of 
these materials against CF bacterial strains should be evaluated in vitro and in vivo 
against clinically relevant planktonic and biofilm bacteria. 
6.2.3 Nitric Oxide-Releasing Chitosan Nanoparticles for Cystic Fibrosis 
Chitosan nanoparticles have been widely used as drug carriers due to their ability to 
pass through biological barriers in vivo (e.g., the blood/brain barrier) and deliver drugs to 
a lesion site to enhance efficacy.14 In addition, chitosan nanoparticles also exhibit 
enhanced bactericidal activity against a wide range of bacterial strains.15 One approach to 
prepare chitosan nanoparticles is ionic gelation of chitosan using a polyanionic molecule 
(e.g., sodium tripolyphosphate or TPP) under acidic condition. S-nitrosothiol NO donors 
can be encapsulated using this technique due to the stability of S-nitrosothiols under the 
same condition. In prior work, chitosan in diluted acetic acid has been added to the 
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solution of TPP dropwise under vigorous stirring and ionic cross-linking is generated by 
auto-aggregation between chitosan and TPP to form nanosized particles.16 Of note, this 
method has been widely used to encapsulate proteins and gene drugs.17 Similarly, NO-
releasing chitosan nanoparticles could be synthesized by the encapsulation of S-
nitrosothiol small molecules within chitosan/TPP particles. The NO payloads would be 
controlled by the concentration of S-nitrosothiol donors in the reaction solution. The 
gelation process would need to be conducted at low temperatures to avoid NO loss by 
thermal degradation. The performance of these particles as therapeutics for cystic fibrosis 
could be evaluated in terms of pulmonary delivery efficiency, diffusion within the mucus, 
and biofilm eradication in vivo.  
6.3 Conclusions 
A range of nitric oxide-releasing macromolecular scaffolds including silica nanorods, 
dendrimers, and chitosan oligosaccharides were synthesized and shown to possess 
enhanced bactericidal activity against problematic bacteria in vitro. The reduced toxicity 
of these scaffolds as presented in this thesis demonstrates their great potential as 
antimicrobial agents. The true ability to treat infections associated with different diseases 
(e.g., diabetic ulcers, cystic fibrosis) should now be evaluated in appropriate animal 
models to truly comprehend their therapeutic potential. The approaches described in the 
preceding chapters allow for the control of physical (e.g., size, shape, and molecular 
weight) and chemical (e.g., ionic characteristics, hydrophobicity) properties, thus greatly 
impacting the future development of NO-releasing materials.  
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